<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Signal Transduct Target Ther</journal-id><journal-id journal-id-type="iso-abbrev">Signal Transduct Target Ther</journal-id><journal-id journal-id-type="pmc-domain-id">3308</journal-id><journal-id journal-id-type="pmc-domain">sigtrans</journal-id><journal-title-group><journal-title>Signal Transduction and Targeted Therapy</journal-title></journal-title-group><issn pub-type="ppub">2095-9907</issn><issn pub-type="epub">2059-3635</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10560686</article-id><article-id pub-id-type="pmcid-ver">PMC10560686.1</article-id><article-id pub-id-type="pmcaid">10560686</article-id><article-id pub-id-type="pmcaiid">10560686</article-id><article-id pub-id-type="pmid">37806986</article-id><article-id pub-id-type="doi">10.1038/s41392-023-01619-w</article-id><article-id pub-id-type="publisher-id">1619</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Drug-microbiota interactions: an emerging priority for precision medicine</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="Q">Qing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Y">Yao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="W">Weihua</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="H">Honghao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6190-3129</contrib-id><name name-style="western"><surname>Zhang</surname><given-names initials="W">Wei</given-names></name><address><email>csuzhangwei@csu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Department of Clinical Pharmacology, Xiangya Hospital, </institution><institution>Central South University, </institution></institution-wrap>87 Xiangya Road, Changsha, 410008 PR China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Institute of Clinical Pharmacology, </institution><institution>Central South University, Hunan Key Laboratory of Pharmacogenetics, </institution></institution-wrap>110 Xiangya Road, Changsha, 410078 PR China </aff><aff id="Aff3"><label>3</label>Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha, 410078 PR China </aff><aff id="Aff4"><label>4</label>National Clinical Research Center for Geriatric Disorders, 87 Xiangya Road, Changsha, 410008 PR China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02bnz8785</institution-id><institution-id institution-id-type="GRID">grid.412614.4</institution-id><institution>The First Affiliated Hospital of Shantou University Medical College, </institution></institution-wrap>Shantou, 515041 PR China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02gr42472</institution-id><institution-id institution-id-type="GRID">grid.477976.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 4014</institution-id><institution>The First Affiliated Hospital of Guangdong Pharmaceutical University, </institution></institution-wrap>Guangzhou, 510080 PR China </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Central Laboratory of Hunan Cancer Hospital, </institution><institution>Central South University, </institution></institution-wrap>283 Tongzipo Road, Changsha, 410013 PR China </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>8</volume><issue-id pub-id-type="pmc-issue-id">424931</issue-id><elocation-id>386</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2022</year></date><date date-type="rev-recd"><day>20</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>24</day><month>8</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>10</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>10</day><month>10</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-08 03:25:25.663"><day>08</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41392_2023_Article_1619.pdf"/><abstract id="Abs1"><p id="Par1">Individual variability in drug response (IVDR) can be a major cause of adverse drug reactions (ADRs) and prolonged therapy, resulting in a substantial health and economic burden. Despite extensive research in pharmacogenomics regarding the impact of individual genetic background on pharmacokinetics (PK) and pharmacodynamics (PD), genetic diversity explains only a limited proportion of IVDR. The role of gut microbiota, also known as the second genome, and its metabolites in modulating therapeutic outcomes in human diseases have been highlighted by recent studies. Consequently, the burgeoning field of pharmacomicrobiomics aims to explore the correlation between microbiota variation and IVDR or ADRs. This review presents an up-to-date overview of the intricate interactions between gut microbiota and classical therapeutic agents for human systemic diseases, including cancer, cardiovascular diseases (CVDs), endocrine diseases, and others. We summarise how microbiota, directly and indirectly, modify the absorption, distribution, metabolism, and excretion (ADME) of drugs. Conversely, drugs can also modulate the composition and function of gut microbiota, leading to changes in microbial metabolism and immune response. We also discuss the practical challenges, strategies, and opportunities in this field, emphasizing the critical need to develop an innovative approach to multi-omics, integrate various data types, including human and microbiota genomic data, as well as translate lab data into clinical practice. To sum up, pharmacomicrobiomics represents a promising avenue to address IVDR and improve patient outcomes, and further research in this field is imperative to unlock its full potential for precision medicine.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Molecular medicine</kwd><kwd>Microbiology</kwd><kwd>Genetics research</kwd><kwd>Drug delivery</kwd><kwd>Molecular biology</kwd></kwd-group><funding-group><award-group><funding-source><institution>the National Key Research and Development Program (No. 2021YFA1301200), the National Scientific Foundation of China (No. 82073945, 81874329, and 81974513).</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>the Fundamental Research Funds of Central South University (2020zzts276)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>the Natural Science Foundation of Hunan Province (grant 2022JJ80113, 2022JJ80097).</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; West China Hospital, Sichuan University 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Why does a drug with a well-response for one patient, but not for the next, or in some cases, lead to serious adverse drug reactions (ADRs), namely individual variability in drug response (IVDR)? The answers are complicated and multi-faceted. First of all, therapeutic response rates of different drugs caused by IVDR differ. According to a survey, cyclooxygenase-2 (COX-2) inhibitors exhibit the most remarkable response rate (80%) among drugs used to treat various diseases, while tumor chemotherapy displays the lowest response rate (25%).<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Furthermore, the response rates for various other medications varied from 50&#8211;75%, indicating that a significant proportion of patients did not benefit from these treatments.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Secondly, the rate of ADRs caused by IVDR is not the same thing. ADRs are the joint occurrence and can have a substantial impact on morbidity, mortality, and healthcare costs.<sup><xref ref-type="bibr" rid="CR2">2</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref></sup> For example, ADRs accounted for approximately 4.93% of emergency hospitalizations in China, with a majority of them being preventable (around 73.7%).<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> However, IVDR makes the prevention of ADRs tricky. These facts underscore the urgent need to better understand IVDR to meet the highly effective drug or prevent ADRs.</p><p id="Par3">Precision medicine aims to develop tailored medical interventions on the basis of an individual&#8217;s genetic, environmental, and lifestyle elements.<sup><xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref></sup> However, IVDR is a major barrier to the implementation of precision medicine, as it poses a challenge to predict drug efficacy and identify patients who are at risk for ADRs.<sup><xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref></sup> Consequently, it is crucial to develop improved biomarkers that can predict drug efficacy and toxicity in order to successfully implement precision medicine.</p><p id="Par4">Pharmacogenetics focuses on identifying genetic variants that influence drug metabolism, transport, pharmacodynamics (PD), and others.<sup><xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref></sup> Pharmacogenomics is a broader field that considers whole genome and its impact on drug response.<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref></sup> Despite the progress made in pharmacogenetics and pharmacogenomics, studies to determine IVDR have shown that human genome contributes anywhere between 20% and 95% of the variability (this percentage may vary depending on the disease model).<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> Hence, genetic factors alone are insufficient to explain IVDR, and additional factors (such as diversity in gut microbiota spectrum) may also be important.<sup><xref ref-type="bibr" rid="CR28">28</xref>&#8211;<xref ref-type="bibr" rid="CR34">34</xref></sup></p><p id="Par5">Gut microbiota, which is a bifunctional and heterogeneous ecosystem, often described as a &#8216;metabolic organ&#8217;, contains over 100 trillion microbes and 5 million genes, making it much larger than human gene count (~150 times).<sup><xref ref-type="bibr" rid="CR35">35</xref>&#8211;<xref ref-type="bibr" rid="CR45">45</xref></sup> Due to various host-related factors, gut microbiota composition and structure vary greatly between individuals and over time as well as external factors (e.g., drugs, diet, and environment).<sup><xref ref-type="bibr" rid="CR46">46</xref>&#8211;<xref ref-type="bibr" rid="CR52">52</xref></sup> Studies conducted on both mice and humans have demonstrated that drug intake has significant effects on the structure of gut microbiota.<sup><xref ref-type="bibr" rid="CR53">53</xref>&#8211;<xref ref-type="bibr" rid="CR55">55</xref></sup> In recent years, gut microbiota has also been mandated for IVDR, gut microbiota can alter drug PD and pharmacokinetics (PK) by direct transforming the drug or modulating the metabolism or immune system of the host.<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR54">54</xref>,<xref ref-type="bibr" rid="CR56">56</xref>&#8211;<xref ref-type="bibr" rid="CR58">58</xref></sup></p><p id="Par6">The term pharmacomicrobiomics has been coined to describe the interactions between gut microbiota and drug response that can alter PK (i.e., changes in drug absorption, distribution, metabolism, excretion, and its plasma drug concentration dynamics) or PD (i.e., changes in drug targets or biological pathways resulting in differential susceptibility of the organism to pharmacological effects).<sup><xref ref-type="bibr" rid="CR59">59</xref>&#8211;<xref ref-type="bibr" rid="CR65">65</xref></sup> Understanding this interaction can help develop microbiota-targeted approaches to enhance drug efficacy and reduce ADRs.<sup><xref ref-type="bibr" rid="CR66">66</xref>&#8211;<xref ref-type="bibr" rid="CR68">68</xref></sup> Clearly, pharmacomicrobiomics is becoming an integral part of the advances in precision medicine, and modifying gut microbiota could be a highly appealing option for managing the efficiency and safety of drugs at an individualistic level.<sup><xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR61">61</xref></sup> This review outlines pharmacomicrobiomics advances in human diseases to better understand the impact of IVDR in future precision medicine.</p></sec><sec id="Sec2"><title>Background</title><sec id="Sec3"><title>Causes of the individual variability in drug response (IVDR)</title><p id="Par7">IVDR is a complex and multifactorial phenomenon that can result from a combination of factors, as shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>, including (1) Genetics: Variations in individual genes encoding drug-metabolizing enzymes, transporters, and targets can affect their metabolism and response to drugs, leading to IVDR.<sup><xref ref-type="bibr" rid="CR69">69</xref>&#8211;<xref ref-type="bibr" rid="CR73">73</xref></sup> (2) Age: Younger and older patients may experience different drug responses due to differences in their physiological function, such as changes in liver and kidney function, body composition, and hormone levels.<sup><xref ref-type="bibr" rid="CR74">74</xref>&#8211;<xref ref-type="bibr" rid="CR78">78</xref></sup> For example, elderly patients may have reduced renal function and hepatic metabolism, leading to altered PK.<sup><xref ref-type="bibr" rid="CR79">79</xref>&#8211;<xref ref-type="bibr" rid="CR81">81</xref></sup> (3) Gender: Biological dissimilarities between men and women can influence drug response.<sup><xref ref-type="bibr" rid="CR82">82</xref>&#8211;<xref ref-type="bibr" rid="CR87">87</xref></sup> Women may have higher drug concentrations due to disparities in body composition and hormone levels, which will affect drug metabolism and clearance.<sup><xref ref-type="bibr" rid="CR88">88</xref>&#8211;<xref ref-type="bibr" rid="CR91">91</xref></sup> (4) Lifestyle: Factors such as diet, exercise, smoking, and alcohol intake can affect drug response by changing the way drugs are metabolized and eliminated from the body.<sup><xref ref-type="bibr" rid="CR92">92</xref>&#8211;<xref ref-type="bibr" rid="CR95">95</xref></sup> (5) Disease state: Patients with certain diseases or conditions may experience IVDR due to changes in organ function, altered drug metabolism, or altered drug receptor expression.<sup><xref ref-type="bibr" rid="CR96">96</xref>&#8211;<xref ref-type="bibr" rid="CR99">99</xref></sup> For example, drug metabolism may be reduced in patients with liver diseases and drug clearance may be reduced in patients with kidney diseases.<sup><xref ref-type="bibr" rid="CR100">100</xref>&#8211;<xref ref-type="bibr" rid="CR103">103</xref></sup> (6) Drug-drug interactions: Concomitant use of multiple medications may result in drug-drug interactions that alter drug absorption, distribution, metabolism, and excretion (ADME).<sup><xref ref-type="bibr" rid="CR104">104</xref>&#8211;<xref ref-type="bibr" rid="CR107">107</xref></sup> (7) Environmental factors: Exposure to environmental toxins and pollutants can affect drug metabolism and clearance, potentially leading to IVDR.<sup><xref ref-type="bibr" rid="CR108">108</xref>&#8211;<xref ref-type="bibr" rid="CR112">112</xref></sup> (8) Gut microbiota: Gut microbiota may also affect drug PK and PD, and variations in the composition of gut microbiota between individuals contribute to IVDR.<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR66">66</xref>,<xref ref-type="bibr" rid="CR113">113</xref>&#8211;<xref ref-type="bibr" rid="CR115">115</xref></sup> Overall, understanding these factors is critical to optimizing drug therapy and minimising the risk of ADRs.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Causes of the individual variability in drug response (IVDR)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e476" position="float" orientation="portrait" xlink:href="41392_2023_1619_Fig1_HTML.jpg"/></fig></p><sec id="Sec4"><title>Heterogeneity of the human genome profile in IVDR</title><p id="Par8">In the early 1900s, Archibald Garrod, a renowned physiologist from England, proposed that genetic factors may contribute to inborn errors in drug metabolism and IVDR.<sup><xref ref-type="bibr" rid="CR116">116</xref>,<xref ref-type="bibr" rid="CR117">117</xref></sup> Since then, numerous studies have demonstrated that genetic factors can explain as much as 95% of the inter-individual variability in drug PK and PD for specific drugs or drug classes<sup><xref ref-type="bibr" rid="CR118">118</xref>&#8211;<xref ref-type="bibr" rid="CR121">121</xref></sup> (Table <xref rid="Tab1" ref-type="table">1</xref>). In the late 1950s, it was discovered that inherited glucose-6-phosphate dehydrogenase deficiency could lead to serious hemolysis in patients administered primaquine, an anti-malarial drug, primarily in African-Americans and minimally in Caucasians of North, West, and East European heritage.<sup><xref ref-type="bibr" rid="CR122">122</xref>&#8211;<xref ref-type="bibr" rid="CR124">124</xref></sup> Subsequently, in 1959, Vogel introduced the term pharmacogenetics to define IVDR.<sup><xref ref-type="bibr" rid="CR125">125</xref></sup> The evolution (from genetics to genomics) and application of genome-wide strategies has led to the emergence of the term pharmacogenomics, with the potential to target specific drug therapies to genetically defined patient subpopulations and to establish novel diseases and therapeutic classifications at the molecular and phenotypic level.<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR126">126</xref>&#8211;<xref ref-type="bibr" rid="CR128">128</xref></sup><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Comparison of pharmacogenomics and pharmacomicrobiomics in IVDR</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Individual variability</th><th colspan="1" rowspan="1">Pharmacogenomics</th><th colspan="1" rowspan="1">Pharmacomicrobiomics</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Dependent variables</td><td colspan="2" rowspan="1">Pharmacokinetic (PK) and pharmacodynamic (PD) outcomes.</td></tr><tr><td colspan="1" rowspan="1">Independent variables</td><td colspan="1" rowspan="1">Variations in the human genome that are inherited from generation to generation.</td><td colspan="1" rowspan="1">Composition and structure of gut microbiota, and its genomic, metabolomic, transcriptomic, and proteomic variations.</td></tr><tr><td colspan="1" rowspan="1">Intra-individual variations</td><td colspan="1" rowspan="1">The human genome is a relatively stable entity, with only rare mutations emerging during an individual&#8217;s lifetime.</td><td colspan="1" rowspan="1">Human microbiota is a dynamic and mobile entity, similar to a cloud, whose composition and structure are constantly changing under the influence of intra-individual variations (e.g., hormones in vivo), leading to subtle and constant changes in physiology.</td></tr><tr><td colspan="1" rowspan="1">Inter-individual variations</td><td colspan="1" rowspan="1">Pharmacogenetics and pharmacogenomics are the study of genetic and genomic variations that influence drug response inter-individuals IVDR. Allelic variations in drug-metabolizing enzymes, such as cytochromes, are among the most commonly studied. Other allelic variations that may affect drug action include transporters, and target molecules or receptors.</td><td colspan="1" rowspan="1">Increasing attention has been focused on functional rather than microbiota profile-based classifications of inter-individual variations. By this means, different functional clusters or metabolic phenotypes have been identified between individuals, which can provide valuable information for insight into the underlying mechanisms of health and disease. The potential of single biomarkers (e.g., <italic toggle="yes">Bifidobacterium</italic>) as tools to assess health and disease between individuals.</td></tr></tbody></table></table-wrap></p><p id="Par9">IVDR poses a serious challenge in clinical management, and genetic polymorphisms play a vital role in this variability.<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup> Genetic variations in genes associated with drug transport, metabolism, and targets can change the individual&#8217;s sensitivity to treatment, resulting in variable drug response.<sup><xref ref-type="bibr" rid="CR121">121</xref>,<xref ref-type="bibr" rid="CR129">129</xref>&#8211;<xref ref-type="bibr" rid="CR137">137</xref></sup> The function of transporters in controlling the transfer of drugs and their metabolites into and out of cells is critical to drug efficacy and toxicity.<sup><xref ref-type="bibr" rid="CR138">138</xref>,<xref ref-type="bibr" rid="CR139">139</xref></sup> In the case of pro-drugs, metabolism is essential to prevent ADRs caused by elevated plasma drug levels in some patients. However, environmental factors can also influence drug metabolism, efficacy, and toxicity, leading to IVDR.<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR140">140</xref></sup> Despite the important influences of genetic variation on drug response, the complexity of environment and microbiota may also constrain the prediction of drug response on the basis of genomic diversity alone.<sup><xref ref-type="bibr" rid="CR141">141</xref></sup> Hence, it is crucial to have a comprehensive comprehension of the intricate interaction between genetic and external factors to develop precision medicine strategies that optimize drug therapy for individual patients.</p><p id="Par10">IVDR can also be attributed to the presence of variant alleles of drug-metabolizing enzymes, transporters, and targets in different populations.<sup><xref ref-type="bibr" rid="CR142">142</xref>&#8211;<xref ref-type="bibr" rid="CR144">144</xref></sup> Allelic variation of target genes in the study population is essential for the advancement of personalized tumor treatment.<sup><xref ref-type="bibr" rid="CR145">145</xref>&#8211;<xref ref-type="bibr" rid="CR150">150</xref></sup> However, the frequency of unique variant alleles can vary significantly between races, making it difficult to incorporate pedigree into clinical decision-making because it confounds drug response.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> In addition, PK differences between drug-metabolizing enzyme and transporter populations can affect IVDR and raise the risk of ADRs (e.g., thiopurines, allopurinol, and carbamazepine).<sup><xref ref-type="bibr" rid="CR143">143</xref>,<xref ref-type="bibr" rid="CR151">151</xref></sup> A lot of ADRs are linked to specific phenotypes of drug metabolites, such as hypersensitivity reactions triggered by sulfonamides.<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR152">152</xref>&#8211;<xref ref-type="bibr" rid="CR154">154</xref></sup> A more in-depth mechanistic and phenotypic study of drug metabolism and individual differences between patients may help to guide treatment based on unique characteristics and the application of predictive models to avoid ADRs.<sup><xref ref-type="bibr" rid="CR25">25</xref></sup></p></sec><sec id="Sec5"><title>Diversity of microbiota spectrum in IVDR</title><p id="Par11">The Human Genome Project (HGP) was concluded in 2003, but human genome contains fewer coding genes, and variations in genetic, epigenetic, and regulators are insufficient to describe IVDR in the phenotype, with limited utility for precision medicine<sup><xref ref-type="bibr" rid="CR155">155</xref></sup> (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). The focus has shifted to gut microbiota to study its composition, variation, and function in understanding the spectrum of human phenotypic variation, including its impact on well-being, immune system, and drug response. In comparison to human genome, gut microbiota is remarkably adaptive and mobile, similar to a cloud whose components and genetic pool are unclear at every moment in time and space<sup><xref ref-type="bibr" rid="CR156">156</xref></sup> (Table <xref rid="Tab1" ref-type="table">1</xref>). It can be partially or completely swapped out and is exposed to various factors that influence its evolution, including immune responses, phage attacks, diet, toxins, anti-biotics, and others.<sup><xref ref-type="bibr" rid="CR157">157</xref>,<xref ref-type="bibr" rid="CR158">158</xref></sup> Because of the abilities of gut microbiota to influence drug response and disease progression, targeted manipulation of gut microbiota may improve drug efficacy and reduce drug-drug interactions.<sup><xref ref-type="bibr" rid="CR141">141</xref></sup> Mobility of gut microbiota is not limited to movement within inter-individuals, but can also occur within intra-individuals due to factors such as spatial, transient, seasonal, hormonal, and nutritional changes or the presence of multiple drugs.<sup><xref ref-type="bibr" rid="CR159">159</xref></sup> The diversity of gut microbiota gives it a remarkable metabolic capacity that exceeds even that of the host.<sup><xref ref-type="bibr" rid="CR160">160</xref>&#8211;<xref ref-type="bibr" rid="CR162">162</xref></sup> Specifically, gut microbiota can produce a range of metabolic responses to drugs and xenobiotics, resulting in both direct effects on drug metabolism and toxicity, and indirect effects on host metabolic enzymes/transporters/immune system, these responses can ultimately affect IVDR.<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR163">163</xref></sup> Gut microbiota can directly affect drug metabolism in several manners, including generating enzymes that degrade or catalyze a drug molecule, competing with drug molecules for a metabolic enzyme, altering the metabolic levels of drugs in the host, or generating enzymes that stimulate metabolites originally derived from the diet.<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR164">164</xref></sup> The presence of microbiota-encoded enzymes represents a potentially valuable intermediate target for PK modification that may ultimately improve clinical response.<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> In turn, drug administration may also affect microbiota metabolism or growth, leading to variations in the structure and function of microbiota.<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> Changes in a pathological state, metabolic enzyme expression, and drug transporter expression may result in gut microbiota producing compounds that affect drug PK and PD.<sup><xref ref-type="bibr" rid="CR165">165</xref></sup><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Timeline of the historical milestone for the development of pharmacomicrobiomics in the past eight decades</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e727" position="float" orientation="portrait" xlink:href="41392_2023_1619_Fig2_HTML.jpg"/></fig></p><p id="Par12">In addition, human genome and gut microbiota work in tandem to influence personal metabolism and contribute to IVDR.<sup><xref ref-type="bibr" rid="CR59">59</xref></sup> Through anatomical and physiological linkages (e.g., the intestinal barrier), they exchange metabolically active molecules and beneficial host-immune interactions.<sup><xref ref-type="bibr" rid="CR164">164</xref>,<xref ref-type="bibr" rid="CR166">166</xref></sup> This metabolic axis of gut microbiota links human genome to microbiota ecosystem as a genetic or epigenetic basis for up-keeping human immune and nutrition functions.<sup><xref ref-type="bibr" rid="CR166">166</xref>&#8211;<xref ref-type="bibr" rid="CR169">169</xref></sup> Interactions between human genome and the diversity of gut microbiota genomes lead to the synthesis of compounds benefiting human healthcare, e.g., amino acids (AAs), short-chain fatty acids (SCFAs), and bile acids (BAs).<sup><xref ref-type="bibr" rid="CR165">165</xref>,<xref ref-type="bibr" rid="CR170">170</xref></sup> Genes encoded by gut microbiota greatly enhance the metabolic potential of human, contributing as much as 36% of small molecule metabolism in human blood.<sup><xref ref-type="bibr" rid="CR59">59</xref></sup> Therefore, the measurement of large numbers of metabolites is necessary to better report and manage the multitude of diseases and treatment efficacy issues.<sup><xref ref-type="bibr" rid="CR171">171</xref></sup></p><p id="Par13">In summary, understanding the influence of human genome heterogeneity and gut microbiota spectrum diversity on IVDR is a key component in developing and improving precision medicine while minimizing ADRs.<sup><xref ref-type="bibr" rid="CR59">59</xref></sup> In addition, modeling changes in gut microbiota will help to understand xenobiotic metabolism, thereby accurately predicting drug responses by taking into account genetic diversity and metabolic interactions between host and pertinent microorganisms.<sup><xref ref-type="bibr" rid="CR59">59</xref></sup></p></sec></sec><sec id="Sec6"><title>Human microbiome exploration in IVDR</title><p id="Par14">The microbiome encompasses the genetic material of various microorganisms, such as bacteria, fungi, protozoa, and viruses, that inhabit both the external and internal regions of the host.<sup><xref ref-type="bibr" rid="CR172">172</xref>&#8211;<xref ref-type="bibr" rid="CR174">174</xref></sup> The term microbiome can denote the genetic make-up of the microbiota or the entire genome of all its members.<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR175">175</xref>,<xref ref-type="bibr" rid="CR176">176</xref></sup> Microbiome can also refer to the total environment that microorganisms inhabit.<sup><xref ref-type="bibr" rid="CR177">177</xref></sup> Meanwhile, microbiomics is a scientific discipline that utilizes high-throughput molecular approaches to study microbial communities.<sup><xref ref-type="bibr" rid="CR178">178</xref>&#8211;<xref ref-type="bibr" rid="CR180">180</xref></sup></p><p id="Par15">The Human Microbiome Project (HMP) is a collaborative program initiated by the National Institutes of Health (NIH) in 2007 to explore in depth the diversity and functional of the human microbiota<sup><xref ref-type="bibr" rid="CR181">181</xref></sup> (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). The project aims to apply high-throughput sequence techniques to characterize microbiota from multiple body sites in human, to investigate the importance of microbiota in IVDR, and to initiate novel research tools and resources for the scientific community. The HMP involved a consortium of more than 200 researchers across multiple institutions, whose findings greatly enhance our knowledge of microbiota and its impact on human health and IVDR. The project was completed in 2012, and its data and resources continue to be used in ongoing microbiota research. The second phase of the HMP started in 2014 and is still in progress.<sup><xref ref-type="bibr" rid="CR182">182</xref></sup> With the support of the HMP, numerous revolutionary findings have significantly enhanced our understanding of microbiota-associated disorders. The discovery of these results has led researchers to reevaluate the origin and development of human diseases and utilize the unique capabilities of the microbiota to create innovative diagnostic methods and more accurate treatments. Furthermore, numerous projects such as the Earth Microbiome Project (EMP), Integrative Human Microbiome Plan (iHMP), and Metagenomics of the Human Intestinal Gut (MetaHIT) have been initiated to further analyze the composition and functions of microbiota, resulting in the accumulation of extensive microbiota data represented as phylogenetic or functional composition profiles.<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR183">183</xref>&#8211;<xref ref-type="bibr" rid="CR185">185</xref></sup> Meanwhile, it has also facilitated the emergence and development of new microbiota-related fields of discipline.</p></sec></sec><sec id="Sec7"><title>Emerging of pharmacomicrobiomics in IVDR</title><p id="Par16">Recently, the research of drug-microbiota interactions has become a systematically developed field, due to the increasing fascination with the variation of gut microbiota.<sup><xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR186">186</xref>&#8211;<xref ref-type="bibr" rid="CR189">189</xref></sup> This field has given rise to various sub-disciplines, including pharmacomicrobiomics, pharmacometabonomics, and pharmacometagenomics.<sup><xref ref-type="bibr" rid="CR159">159</xref>,<xref ref-type="bibr" rid="CR190">190</xref>&#8211;<xref ref-type="bibr" rid="CR193">193</xref></sup> These sub-disciplines aim to study the effect of microbiota on PK and PD, and to explore how microbiota variation affects IVDR in human diseases<sup><xref ref-type="bibr" rid="CR194">194</xref>&#8211;<xref ref-type="bibr" rid="CR197">197</xref></sup> (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). In addition, these areas explore systems-level studies of microbial metabolites and their diagnostic and implications for pharmacological properties of drugs.<sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR198">198</xref>,<xref ref-type="bibr" rid="CR199">199</xref></sup><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>An overview of pharmacomicrobiomics is a rapidly growing field that seeks to understand the complex interactions between drugs, microbiota, and host physiology</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e875" position="float" orientation="portrait" xlink:href="41392_2023_1619_Fig3_HTML.jpg"/></fig></p><p id="Par17">In fact, during the 1930s, several research teams reported that prontosil had a beneficial effect on mice infections of various strains. But the outcomes were considered atypical regarding the lack of anti-bacterial activity of prontosil in vitro<sup><xref ref-type="bibr" rid="CR200">200</xref></sup> (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Nevertheless, sulfanilamide, a metabolite of prontosil, exhibited potent anti-bacterial effects in vivo, suggesting that the anti-bacterial properties of prontosil stemmed from this derivative.<sup><xref ref-type="bibr" rid="CR200">200</xref>,<xref ref-type="bibr" rid="CR201">201</xref></sup> Subsequently, numerous sulfonamide compounds have been synthesized and used to treat bacterial infections, and many studies of drug-microbiota interactions have sprouted among them. Until 2010 when it was first proposed, the term &#8216;pharmacomicrobiomics&#8217; was used to describe the effects of alterations in microbiota composition and function on IVDR and host genetic<sup><xref ref-type="bibr" rid="CR190">190</xref></sup> (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). While the interactions between drugs and individual microbiota have been studied for some time, advanced and accurate meta-omics technologies, including <italic toggle="yes">16</italic>&#8201;<italic toggle="yes">S</italic> ribosomal RNA (rRNA) amplicon, <italic toggle="yes">18</italic>&#8201;<italic toggle="yes">S</italic> rRNA amplicon, <italic toggle="yes">ITS</italic>, <italic toggle="yes">MiSeq</italic>, <italic toggle="yes">HiSeq</italic>, and whole-metagenome shotgun sequencing have facilitated a deeper exploration into the phylogeny, interactions, and functions of microbiota species.<sup><xref ref-type="bibr" rid="CR202">202</xref>&#8211;<xref ref-type="bibr" rid="CR206">206</xref></sup> By using these technologies, the development of pharmacomicrobiomics has made significant progress, providing a comprehensive analysis of the connection between drugs and the microbiota.</p><p id="Par18">To study the effects of gut microbiota on drugs, terms such as pharmacometabolomics and pharmacometabonomics can be used in addition to pharmacomicrobiomics.<sup><xref ref-type="bibr" rid="CR141">141</xref>,<xref ref-type="bibr" rid="CR191">191</xref>,<xref ref-type="bibr" rid="CR207">207</xref>,<xref ref-type="bibr" rid="CR208">208</xref></sup> These fields focus on the systems-level study of metabolites from microbiota, integrating genomics and metabolomics.<sup><xref ref-type="bibr" rid="CR198">198</xref>,<xref ref-type="bibr" rid="CR209">209</xref>&#8211;<xref ref-type="bibr" rid="CR212">212</xref></sup> While primarily concerned with microbiota variation, these fields also study the ultimate metabolic products of host-microbiota interactions, namely the metabolites that are generated as a result of drug metabolizing in humans and with its co-occurring microbiota.<sup><xref ref-type="bibr" rid="CR208">208</xref>,<xref ref-type="bibr" rid="CR213">213</xref></sup></p><p id="Par19">Pharmacometagenomics is another term used to study IVDR by integrating the analysis of microbiota genomes and human genetics.<sup><xref ref-type="bibr" rid="CR193">193</xref></sup> While metagenomics studies the species and gene pool of ecosystems, pharmacometagenomics specifically examines shotgun sequencing or chance microbiota genome analysis, and it needs to be distinguished from amplicon analysis, which merely determines the phylogenetic tree of the living beings. What characterizes pharmacometagenomics is that it integrates microbiota composition (by <italic toggle="yes">16</italic>&#8201;<italic toggle="yes">S</italic> or <italic toggle="yes">18</italic>&#8201;<italic toggle="yes">S</italic> amplicon sequencing) and potential function (by metagenomics, metaproteomics, metatranscriptomics, and metabolomics), all elements of microbiomics. The integration of multi-omic approaches is essential, as it can be difficult to solely predict function from microbiota.<sup><xref ref-type="bibr" rid="CR214">214</xref></sup></p><p id="Par20">The emerging field connecting the composition and activity of microbiota to prevalent diseases and drugs has spawned numerous promising discoveries in recent years. Association studies have revealed bidirectional effects between various drugs and gut microbiota in patients with gastrointestinal disorders (e.g., inflammatory bowel diseases and colorectal cancer) and other system diseases (e.g., cardiovascular and metabolism disorders, autoimmunity diseases, and psychiatric disorders). These findings have important implications for understanding IVDR and developing precision medicine approaches tailored to individual microbiota composition and function. We will discuss these findings in greater detail below (Fig. <xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Examples of drug-microbiota interactions with well-defined mechanisms. Created with BioRender.com</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e993" position="float" orientation="portrait" xlink:href="41392_2023_1619_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec8"><title>Pharmacomicrobiomics of IVDR in human diseases</title><sec id="Sec9"><title>Pharmacomicrobiomics in cancers</title><p id="Par21">In the context of cancer, gut microbiota is known to be critical for the pathogenesis, progression and IVDR of several types of cancers.<sup><xref ref-type="bibr" rid="CR215">215</xref>,<xref ref-type="bibr" rid="CR216">216</xref></sup> Numerous studies have investigated the potential of pharmacomicrobiomics to improve tumor treatment outcomes (Table <xref rid="Tab2" ref-type="table">2</xref>). Here, we describe the mechanisms by which several representative drugs and gut microbiota interact in cancer patients.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Examples of immunotherapies and chemotherapies interactions with the gut microbiota</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="1">Drugs</th><th colspan="1" rowspan="1">Involved bacteria</th><th colspan="1" rowspan="1">Mechanisms of interaction with microbiota</th><th colspan="1" rowspan="1">Animal Models</th><th colspan="1" rowspan="1">PMID</th></tr></thead><tbody><tr><td rowspan="14" colspan="1">Chemotherapies</td><td rowspan="4" colspan="1">Cyclophosphamide (CTX)</td><td colspan="1" rowspan="1"><italic toggle="yes">Escherichia coli, Enterobacteraceae, Pseudomonas</italic>, and <italic toggle="yes">Enterococci</italic></td><td colspan="1" rowspan="1">Increased intestinal permeability due to decreased function of tight junctions and adhesive junctions.</td><td colspan="1" rowspan="1">Male Balb/c mice.</td><td colspan="1" rowspan="1">23791611</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Bacteroides acidifaciencs</italic> and <italic toggle="yes">Streptococcaceae</italic></td><td colspan="1" rowspan="1">Increased bacteria.</td><td colspan="1" rowspan="1">C57/BL6 mice.</td><td colspan="1" rowspan="1">25553830</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Lactobacillus johnsonii</italic> and <italic toggle="yes">Enterococcus hirae</italic></td><td colspan="1" rowspan="1">Increased Th17-mediated IL-17 secretion. From the gut to the secondary lymphatic organs is essential for the differentiation of CD4<sup>+</sup> T cells.</td><td colspan="1" rowspan="1">B16F10 melanoma mouse.</td><td colspan="1" rowspan="1">24264990</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Enterococcus hirae</italic> and <italic toggle="yes">Barnesiella intestinihominis</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">E. hirae</italic> increased the CD8<sup>+</sup> T/Treg cells ratio within tumors, <italic toggle="yes">B. intestinihominis</italic> promoted the infiltration of IFN-&#947;-producing &#947;&#948;T cells into tumors.</td><td colspan="1" rowspan="1">MCA205 sarcoma mice.</td><td colspan="1" rowspan="1">27717798</td></tr><tr><td rowspan="3" colspan="1">Irinotecan (CPT-11)</td><td colspan="1" rowspan="1"><italic toggle="yes">Escherichia coli, Staphylococcus</italic>, and <italic toggle="yes">Clostridium</italic></td><td colspan="1" rowspan="1">Express high levels of &#946;-glucuronidase, a microbial enzyme that eliminates SN-38-G.</td><td colspan="1" rowspan="1">Rats.</td><td colspan="1" rowspan="1">18927500</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Lactobacillus</italic> and <italic toggle="yes">Bifidobacterium</italic></td><td colspan="1" rowspan="1">Reducing &#946;-glucuronidase activity and diarrhea.</td><td colspan="1" rowspan="1">C57/BL6 mice.</td><td colspan="1" rowspan="1">33298215</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Enterococcus faecium</italic></td><td colspan="1" rowspan="1">Reducing &#946;-glucuronidase activity and diarrhea.</td><td colspan="1" rowspan="1">Rats.</td><td colspan="1" rowspan="1">8706020</td></tr><tr><td rowspan="2" colspan="1">5-Fluorouracil (5-FU)</td><td colspan="1" rowspan="1"><italic toggle="yes">Fusobacterium nucleatum</italic></td><td colspan="1" rowspan="1">Targeting the TLR4-MYD88 pathway and activating the autophagy pathway.</td><td colspan="1" rowspan="1">HCT116 xenograft mouse.</td><td colspan="1" rowspan="1">28753429</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Bacteroides (B. vulgatus, B. thetaiotaomicron, B. fragilis, B. uniformis</italic>, and <italic toggle="yes">B. eggerthii)</italic></td><td colspan="1" rowspan="1">Produces uracil metabolites that inactivate dihydropyrimidine dehydrogenase and cause toxicity.</td><td colspan="1" rowspan="1">Male SD rats.</td><td colspan="1" rowspan="1">9110360</td></tr><tr><td rowspan="2" colspan="1">Gemcitabine</td><td colspan="1" rowspan="1"><italic toggle="yes">&#947;-proteobacteria</italic></td><td colspan="1" rowspan="1">Bacterial long isoform cytidine deaminase metabolism gemcitabine into inactivated form 2&#8242;,2&#8242;-difluorodeoxyuridine.</td><td colspan="1" rowspan="1">MC-26 xenograft mouse.</td><td colspan="1" rowspan="1">28912244</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Mycoplasma hyorhinis</italic></td><td colspan="1" rowspan="1">Encoded cytidine deaminase.</td><td colspan="1" rowspan="1">Human breast carcinoma MDA-MB-231 cells and MCF-7.</td><td colspan="1" rowspan="1">26322268</td></tr><tr><td rowspan="3" colspan="1">Oxaliplatin &amp; Cisplatin</td><td colspan="1" rowspan="1">Gram-negative bacteria</td><td colspan="1" rowspan="1">Regulate the TLR4-dependent pathway to prepare myeloid cells for ROS release.</td><td colspan="1" rowspan="1">EL4, MC38, and B16 xenograft mouse.</td><td colspan="1" rowspan="1">24264989</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Bacteroides fragilis</italic> and <italic toggle="yes">Erysipelotrichaceae</italic></td><td colspan="1" rowspan="1">Induce migrating DCs to transduce IL-1&#946; and IL-12 responses to follicular Th cells.</td><td colspan="1" rowspan="1">MC38 and CT26 xenograft mouse.</td><td colspan="1" rowspan="1">32451498</td></tr><tr><td colspan="1" rowspan="1">Butyrate-producing bacteria</td><td colspan="1" rowspan="1">Butyrate activated CD8<sup>+</sup> T cells via ID2-dependent IL-12.</td><td colspan="1" rowspan="1">Male Wistar rats.</td><td colspan="1" rowspan="1">33761313</td></tr><tr><td rowspan="7" colspan="1">Immunotherapies</td><td rowspan="3" colspan="1">Anti-CTLA-4 mAbs</td><td colspan="1" rowspan="1"><italic toggle="yes">Bacteroides fragilis, Bacteroides thetaiotaomicron</italic>, and <italic toggle="yes">Burkholderia cepacia</italic></td><td colspan="1" rowspan="1">Stimulating CD11b<sup>+</sup> DCs improves IL-12-dependent Th1 immunity.</td><td colspan="1" rowspan="1">MCA205 sarcoma mice.</td><td colspan="1" rowspan="1">26541610</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Bifidobacterium</italic></td><td colspan="1" rowspan="1">Enhanced functions of intestinal Treg cells.</td><td colspan="1" rowspan="1">MCA205 sarcoma mice.</td><td colspan="1" rowspan="1">33077598</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Bifidobacterium pseudolongum, Lactobacillus johnsonii</italic>, and <italic toggle="yes">Olsenella species</italic></td><td colspan="1" rowspan="1">Enhanced immune response through producing inosine.</td><td colspan="1" rowspan="1">C57BL/6 and Foxp3-DTR mice.</td><td colspan="1" rowspan="1">32792462</td></tr><tr><td rowspan="4" colspan="1">Anti-PD-1/PD-L1 mAbs</td><td colspan="1" rowspan="1"><italic toggle="yes">Bifidobacterium</italic></td><td colspan="1" rowspan="1">Promoting the role of DCs and activating cytotoxic CD8<sup>+</sup> T cells.</td><td colspan="1" rowspan="1">B16.SIY melanoma mouse.</td><td colspan="1" rowspan="1">26541606</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Bifidobacterium</italic></td><td colspan="1" rowspan="1">Increased gut permeability leading to intratumor localization, enhanced NK cell functions.</td><td colspan="1" rowspan="1">B16F10 and LLC melanoma mouse.</td><td colspan="1" rowspan="1">34516769</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Bifidobacterium breve</italic></td><td colspan="1" rowspan="1">Bacterial antigens affect the T cells.</td><td colspan="1" rowspan="1">SIY melanoma mouse.</td><td colspan="1" rowspan="1">32324171</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Lactobacillus rhamnosus</italic> GG</td><td colspan="1" rowspan="1">Stimulatiing cGAS/STING/TANK binding kinase 1/interferon regulatory factor 7 axis in DCs.</td><td colspan="1" rowspan="1">MC38 and B16F10 xenograft mouse.</td><td colspan="1" rowspan="1">33685966</td></tr></tbody></table></table-wrap></p><sec id="Sec10"><title>Cyclophosphamide (CTX)</title><p id="Par22">CTX is a pro-drug that needs activation, with its primary active ingredient being phosphoramide mustard, which creates crosslinks in inter and intra-strand deoxyribonucleic acid (DNA).<sup><xref ref-type="bibr" rid="CR217">217</xref>&#8211;<xref ref-type="bibr" rid="CR220">220</xref></sup> T cells, particularly cytotoxic T cells, play a crucial role in targeting tumor cells in various cancers, and increased T cell infiltration into tumors has been linked to better patient outcomes.<sup><xref ref-type="bibr" rid="CR221">221</xref>&#8211;<xref ref-type="bibr" rid="CR224">224</xref></sup> Previous microbiota studies have identified specific microbiota associated with improved anti-tumor T cell responses following tumor therapy.<sup><xref ref-type="bibr" rid="CR225">225</xref></sup> CTX activates anti-tumor immune response, thereby boosting the differentiation of anti-tumor T helper (Th)-1 and Th17 cells, exhausting pro-tumor regulatory T (Treg) cell populations, stimulating the secretion of various cytokines, and increasing the death of immunogenic tumor cells.<sup><xref ref-type="bibr" rid="CR226">226</xref>&#8211;<xref ref-type="bibr" rid="CR233">233</xref></sup> Saxman et al. compared the efficacy of combined CTX with CTX alone and showed IVDR of 18.8% in the combined group compared with 6% in the other group.<sup><xref ref-type="bibr" rid="CR234">234</xref></sup> It is worth noting that CTX treatment results in increased intestinal permeability due to decreased function of tight junctions and adhesive junctions.<sup><xref ref-type="bibr" rid="CR235">235</xref>,<xref ref-type="bibr" rid="CR236">236</xref></sup> This increased permeability is associated with higher levels of pathogenic strains, e.g., <italic toggle="yes">Escherichia coli</italic> (<italic toggle="yes">E. coli</italic>)<italic toggle="yes">, Enterobacteraceae, Pseudomonas</italic>, and <italic toggle="yes">Enterococci</italic> in the gut.<sup><xref ref-type="bibr" rid="CR236">236</xref></sup> Furthermore, CTX treatment reduces fecal microbiota diversity and increases the <italic toggle="yes">Firmicutes</italic>-to-<italic toggle="yes">Bacteroidetes</italic> ratio.<sup><xref ref-type="bibr" rid="CR237">237</xref></sup> Several species and families were found in CTX-treated samples but not in untreated samples, e.g., <italic toggle="yes">Bacteroides acidifaciencs</italic> and <italic toggle="yes">Streptococcaceae</italic>, even though the implications of this are not well known.<sup><xref ref-type="bibr" rid="CR237">237</xref></sup></p><p id="Par23">A study conducted in 2013 discovered that germ-free (GF) and antibiotic-treated mice had a noticeably decrease anti-tumor response to CTX treatment.<sup><xref ref-type="bibr" rid="CR235">235</xref></sup> In particular, CTX treatment resulted in increased Th17-mediated pro-inflammatory interleukin (IL) -17 secretion in specific pathogen-free (SPF) mice, but not in GF or antibiotic-treated mice. This research further revealed that the CTX-mediated translocation of gram-positive bacteria, e.g., <italic toggle="yes">Lactobacillus johnsonii</italic> and <italic toggle="yes">Enterococcus hirae</italic> (<italic toggle="yes">E. hirae</italic>), from the gut to the secondary lymphatic organs is vital to differentiation of CD4<sup>+</sup> T cells.<sup><xref ref-type="bibr" rid="CR235">235</xref></sup> Co-administration of CTX and vancomycin had worse total anti-tumor activity than CTX monotherapy, emphasizing how essential elements of the microbiota influence the action of CTX.<sup><xref ref-type="bibr" rid="CR235">235</xref></sup> Further research has identified <italic toggle="yes">E. hirae</italic>, when translocated from the gut to the secondary lymphatic organs, increased the CD8<sup>+</sup> T/Treg cells ratio within tumors.<sup><xref ref-type="bibr" rid="CR238">238</xref></sup> On the other hand, <italic toggle="yes">Barnesiella intestinihominis</italic> does not translocate but accumulates in the colon, stimulating CD8<sup>+</sup> T cells and Th1 cells, thus enhancing the infiltration of interferon (IFN)-&#947;-producing &#947;&#948;T cells into tumors.<sup><xref ref-type="bibr" rid="CR238">238</xref></sup> The interaction between IVDR of CTX and the microbiota is complex, as CTX affects the intestinal barrier integrity, resulting in the translocation of pathogenic species, while being affected by commensal bacteria for pharmacological immune-mediated efficacy. Such discoveries emphasize the significance of considering gut microbiota in the use of CTX and other chemotherapeutic agents.</p></sec><sec id="Sec11"><title>Irinotecan (CPT-11)</title><p id="Par24">Chemotherapeutic agents such as CPT-11 are commonly for treating several cancers, however, their use can be limited by the occurrence of severe diarrhea as ADRs.<sup><xref ref-type="bibr" rid="CR239">239</xref>&#8211;<xref ref-type="bibr" rid="CR242">242</xref></sup> This side effect can be attributed to the influence of gut microbiota, which can convert the less toxic SN-38-glucuronide (SN-38-G) metabolite back into the extremely toxic 7-ethyl-10-hydroxycamptothecin (SN-38), leading to intestinal damage.<sup><xref ref-type="bibr" rid="CR243">243</xref>,<xref ref-type="bibr" rid="CR244">244</xref></sup> Specifically, certain strains (e.g., <italic toggle="yes">E. coli, Staphylococcus</italic>, and <italic toggle="yes">Clostridium</italic>) that express high levels of &#946;-glucuronidase (GUSs), a microbial enzyme that eliminates SN-38-G, have been shown to exacerbate this problem.<sup><xref ref-type="bibr" rid="CR245">245</xref></sup> However, antibiotic administration to decrease the abundance of such strains has been investigated as a potential strategy to alleviate CPT-11-induced diarrhea.<sup><xref ref-type="bibr" rid="CR246">246</xref>,<xref ref-type="bibr" rid="CR247">247</xref></sup></p><p id="Par25">In clinical trials, the use of anti-biotics (e.g., levofloxacin, cholestyramine, and neomycin) has been evaluated in conjunction with CPT-11 treatment.<sup><xref ref-type="bibr" rid="CR246">246</xref>,<xref ref-type="bibr" rid="CR247">247</xref></sup> As a result, the overall incidence of IVDR was significantly decreased from the 40% reported in earlier studies.<sup><xref ref-type="bibr" rid="CR246">246</xref></sup> Administering neomycin alongside CPT-11 reduced or eliminated diarrhea in six out of seven volunteers, according to another study.<sup><xref ref-type="bibr" rid="CR247">247</xref></sup> Although co-administration of these drugs leads to a reduction or elimination of diarrhea, concerns have been raised about the possible consequences for gut microbiota and the emergence of antibiotic resistance.<sup><xref ref-type="bibr" rid="CR248">248</xref></sup> Additionally, selective inhibition of microbial GUSs has been investigated as an alternative strategy.<sup><xref ref-type="bibr" rid="CR249">249</xref>,<xref ref-type="bibr" rid="CR250">250</xref></sup> Repurposing existing drugs and designing new GUSs inhibitors have been explored, with promising results demonstrating effective reduction of diarrhea without compromising the anti-tumor effects of CPT-11.<sup><xref ref-type="bibr" rid="CR249">249</xref>,<xref ref-type="bibr" rid="CR251">251</xref>&#8211;<xref ref-type="bibr" rid="CR253">253</xref></sup></p><p id="Par26">The administration of probiotics another potential strategy for mitigating CPT-11-induced diarrhea has also been investigated. <italic toggle="yes">Enterococcus faecium</italic> (<italic toggle="yes">E. faecium</italic>) and multi-strain probiotics (e.g., <italic toggle="yes">Lactobacillus</italic> and <italic toggle="yes">Bifidobacterium</italic>) have shown effectiveness in reducing GUSs activity and diarrhea in clinical studies.<sup><xref ref-type="bibr" rid="CR254">254</xref>,<xref ref-type="bibr" rid="CR255">255</xref></sup> However, the potential risks and costs of probiotics must be carefully considered, particularly when administering them to immunocompromised individuals, as they could potentially increase the risk of superinfection.</p><p id="Par27">In conclusion, the intervention of gut microbiota has shown potential in mitigating the ADRs associated with CPT-11 treatment. While the use of anti-biotics and probiotics has proven effective in reducing diarrhea, their potential modulation of gut microbiota and the occurrence of anti-biotic resistance must be carefully considered. Selective inhibition of microbial GUSs offers a promising alternative strategy to mitigate CPT-11-induced diarrhea. More in-depth studies are warranted to assess the effects and risks of such measures in larger patient populations.</p></sec><sec id="Sec12"><title>Oxaliplatin and cisplatin</title><p id="Par28">Platinum-containing anti-neoplastic drugs, including oxaliplatin and cisplatin, have been used extensively to treat several cancers.<sup><xref ref-type="bibr" rid="CR256">256</xref>&#8211;<xref ref-type="bibr" rid="CR258">258</xref></sup> These drugs work by interfering with the DNA replication process in tumor cells, leading to their death.<sup><xref ref-type="bibr" rid="CR259">259</xref>&#8211;<xref ref-type="bibr" rid="CR261">261</xref></sup> However, the effectiveness of these drugs relies on the generation of reactive oxygen species (ROS), which cause oxidative injury to tumor cells. Interestingly, recent reports reveal that gut microbiota is crucial for the production of ROS and IVDR associated with these drugs.<sup><xref ref-type="bibr" rid="CR262">262</xref>,<xref ref-type="bibr" rid="CR263">263</xref></sup> Specifically, gut microbiota, particularly gram-negative bacteria, regulate the myeloid differentiation primary response 88 (MYD88) related pathway to prepare myeloid cells for ROS release in the tumor undergoing treatment with oxaliplatin.<sup><xref ref-type="bibr" rid="CR263">263</xref></sup> This means that the integrity of the microbiota is necessary for the early cytotoxic effects of these drugs. Moreover, gut microbiota also plays a significant role in the late immunomodulatory effects of oxaliplatin.</p><p id="Par29">For an effective anti-cancer immune response, immunogenic gut commensals are required, along with the antigenic properties of the apoptosis mediated by oxaliplatin. Immunogenic bacteria, such as non-enterotoxigenic <italic toggle="yes">Bacteroides fragilis</italic> and <italic toggle="yes">Erysipelotrichaceae</italic>, induce migrating dendritic cells (DCs) to transduce IL-1&#946; and IL-12 responses to follicular Th cells.<sup><xref ref-type="bibr" rid="CR264">264</xref></sup> This interaction leads to increased IgG2b reaction and increased anti-cancer effector CD8<sup>+</sup> T cells activity. It is important to mention that without immunogenic gut commensals, these immune responses are greatly diminished.</p><p id="Par30">Moreover, metabolites such as SCFAs can also help to the improvement of the immune response to oxaliplatin.<sup><xref ref-type="bibr" rid="CR265">265</xref></sup> SCFAs, especially butyrate, are able to block histone deacetylases (HDCA) to upregulate the DNA transcription modulator inhibitor of DNA binding 2 (ID2).<sup><xref ref-type="bibr" rid="CR266">266</xref></sup> This, in turn, enhances the cytotoxic activity of CD8<sup>+</sup> T cells through IL-12 signaling, promoting anti-tumor immunity generated by oxaliplatin. In conclusion, gut microbiota and their metabolites are major regulators of the anti-tumor immunity responses to platinum-based drugs.</p></sec><sec id="Sec13"><title>Immune checkpoint inhibitors (ICIs)</title><p id="Par31">ICIs have revolutionized tumor therapy by specifically modulating inhibitory receptors (e.g., CTLA-4, PD-1, LAG-3, and TIM-3) and ligands (PD-L1) presented on immune and tumor cells, ultimately stimulating anti-tumor IVDR.<sup><xref ref-type="bibr" rid="CR267">267</xref>&#8211;<xref ref-type="bibr" rid="CR269">269</xref></sup> Emerging preclinical evidence also emphasizes the role of gut microbiota in modulating the IVDR of ICIs treatment by influencing the immune response.<sup><xref ref-type="bibr" rid="CR235">235</xref>,<xref ref-type="bibr" rid="CR238">238</xref>,<xref ref-type="bibr" rid="CR263">263</xref></sup></p><p id="Par32">Studies using preclinical mouse models have shown that an effective anti-tumor response after anti-CTLA-4 antibody therapy requires intact commensal microbiota.<sup><xref ref-type="bibr" rid="CR270">270</xref></sup> Anti-biotic treatment or the absence of living microorganisms compromised the anti-tumor efficacy of anti-CTLA-4 antibodies.<sup><xref ref-type="bibr" rid="CR270">270</xref></sup> Recolonization experiments with specific strains isolates showed that the introduction of certain commensal bacteria (e.g., <italic toggle="yes">Bacteroides fragilis, Bacteroides thetaiotaomicron</italic>, and <italic toggle="yes">Burkholderia cepacia</italic>) was able to recover anti-tumor responses.<sup><xref ref-type="bibr" rid="CR270">270</xref></sup> Another study reported that <italic toggle="yes">Bifidobacterium</italic> was linked to improved anti-tumor efficacy of anti-PD-L1 antibodies, and that orally administered <italic toggle="yes">Bifidobacterium</italic> improved the anti-tumor efficacy of ICIs by promoting the role of DCs and activating cytotoxic CD8<sup>+</sup> T cells.<sup><xref ref-type="bibr" rid="CR271">271</xref></sup> These findings indicate that specific commensal bacteria may enhance the anti-tumor efficacy of ICIs.</p><p id="Par33">Further research aimed to identify specific strains in human microbiota that can enhance the effectiveness of anti-tumor treatment. Research on patients with metastatic melanoma, has shown that certain bacterial strains (e.g., <italic toggle="yes">Faecalibacterium prausnitzii</italic> and <italic toggle="yes">Gemmiger formicilis</italic>) are linked to a favorable reaction to anti-tumor antibodies, while other strains (e.g., <italic toggle="yes">Bacteroides</italic>) are linked to adverse linked to ADRs.<sup><xref ref-type="bibr" rid="CR272">272</xref></sup> In addition, a greater &#945;-diversity and the existence of particular bacterial (e.g., <italic toggle="yes">Ruminococcaceae</italic>) are also connected to a positive reaction to anti-PD-1 antibodies.<sup><xref ref-type="bibr" rid="CR273">273</xref></sup> In non-small cell lung cancer or urothelial tumor patients with clinically effective to ICIs, <italic toggle="yes">Akkermansia muciniphila</italic> (<italic toggle="yes">A. muciniphila</italic>) and <italic toggle="yes">E. hirae</italic> were found to be more abundant than normal.<sup><xref ref-type="bibr" rid="CR274">274</xref></sup> Despite the fact that <italic toggle="yes">Bifidobacterium longum, Collinsella aerofaciens</italic>, and <italic toggle="yes">E. faecium</italic> were enriched in melanoma patients who were responsive to anti-PD-1 antibodies, <italic toggle="yes">Ruminococcus obeum</italic> and <italic toggle="yes">Roseburia intestinalis</italic> were enriched in non-responders.<sup><xref ref-type="bibr" rid="CR275">275</xref></sup> The transfer of microbiota from tumor patients responsive to ICIs to GF- or antibiotic-pretreated mice resulted in enhanced anti-tumor efficacy.<sup><xref ref-type="bibr" rid="CR273">273</xref>&#8211;<xref ref-type="bibr" rid="CR275">275</xref></sup> In addition, co-administration of a mixture of 11 strains acquired by healthy volunteers was found to enhance the anti-tumor effects of ICIs in GF mice by vigorously inducing the production of IFN-&#947; by CD8<sup>+</sup> T cells.<sup><xref ref-type="bibr" rid="CR276">276</xref></sup> Although B cells have been considered to play a potential role in ICIs therapy, the relationship between B cells responses and gut microbiota has not been extensively studied.<sup><xref ref-type="bibr" rid="CR277">277</xref></sup></p><p id="Par34">Collectively, these studies indicate that the mouse and human gut microbiota may play a crucial role in regulating tumor IVDR on ICIs by modulating the host immune system. However, there is limited coherence in the key microbiota subgroups reported in these studies, which may be due to factors such as geographical and population differences, specific microbiota associations with certain tumor types, and other aspects of the microbiota that are currently understudied.<sup><xref ref-type="bibr" rid="CR278">278</xref>,<xref ref-type="bibr" rid="CR279">279</xref></sup> To further explore these associations, larger clinical studies and deeper sequencing analyses may be necessary.<sup><xref ref-type="bibr" rid="CR280">280</xref></sup></p><p id="Par35">Although targeting gut microbiota to enhance the effectiveness of ICIs efficacy is a relatively new strategy, recent progress has been made. Two early clinical studies using fecal microbiota transplant (FMT) showed the potential for improved responses to ICIs therapy.<sup><xref ref-type="bibr" rid="CR281">281</xref>,<xref ref-type="bibr" rid="CR282">282</xref></sup> In one trial, 10 individuals with anti-PD-1-resistant metastatic melanoma were administered FMT from a donor who had previously achieved complete remission with anti-PD-1 therapy.<sup><xref ref-type="bibr" rid="CR281">281</xref></sup> This trial revealed that FMT, along with anti-PD-1 reinduction therapy, is both secure and viable for certain patients, leading to heightened immune activity within the tumor. Different research involved the use of FMT derived from melanoma patients who had shown a long-term response to treat patients with anti-PD-1-resistant melanoma.<sup><xref ref-type="bibr" rid="CR282">282</xref></sup> Among the 15 patients, 3 achieved objective responses and 3 had long-lasting stable disease. These findings indicate that manipulating gut microbiota could potentially alter the tumor microenvironment and counteract resistance to ICIs treatment. However, larger patient cohorts are needed to identify the ideal composition of FMT and the microbiota profiles of patients that will improve ICIs efficacy.</p></sec></sec><sec id="Sec14"><title>Pharmacomicrobiomics in cardiovascular system</title><p id="Par36">Cardiovascular diseases (CVDs) are responsible for 31% of global mortality, causing over 17.7 million deaths worldwide.<sup><xref ref-type="bibr" rid="CR283">283</xref>&#8211;<xref ref-type="bibr" rid="CR286">286</xref></sup> Studies show that alterations in gut microbiota are linked to an increased risk of CVDs, e.g., hypertension, atherosclerosis (AS), and heart failure by affecting IVDR and inflammation.<sup><xref ref-type="bibr" rid="CR287">287</xref>&#8211;<xref ref-type="bibr" rid="CR291">291</xref></sup> Pharmacomicrobiomics holds promise for understanding how microbiota affects CVDs and how drugs can be developed to better target microbiota.<sup><xref ref-type="bibr" rid="CR292">292</xref></sup> However, more work is necessary to truly unlock the intricate interactions between microbiota, drugs, and CVDs. Next, we describe the mechanisms of drug-microbiota interactions for patients with CVDs (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>List of example drug-microbiota interactions with well-characterized mechanisms in eight human body systems</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Diseases</th><th colspan="1" rowspan="1">Drugs</th><th colspan="1" rowspan="1">Involved bacteria</th><th colspan="1" rowspan="1">Mechanisms of interaction with microbiota</th><th colspan="1" rowspan="1">PMID</th></tr></thead><tbody><tr><td rowspan="7" colspan="1">Cardiovascular system diseases</td><td rowspan="2" colspan="1">Warfarin</td><td colspan="1" rowspan="1"><italic toggle="yes">Bacteroides, Escherichia Shigella</italic>, and <italic toggle="yes">Klebsiella</italic></td><td colspan="1" rowspan="1">Weak response to the drug.</td><td colspan="1" rowspan="1">32505835</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Enterococcus</italic></td><td colspan="1" rowspan="1">High response to the drug.</td><td colspan="1" rowspan="1">32505835</td></tr><tr><td colspan="1" rowspan="1">Statins</td><td colspan="1" rowspan="1"><italic toggle="yes">Bacteroides, Butyricimonas</italic>, and <italic toggle="yes">Mucispirillum</italic></td><td colspan="1" rowspan="1">Anti-inflammatory and improves hyperglycemia.</td><td colspan="1" rowspan="1">31551944</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1"><italic toggle="yes">Eggerthella lenta</italic></td><td colspan="1" rowspan="1">Reduction of digoxin to its inactive metabolite and <italic toggle="yes">E. lenta</italic> is transcriptionally activated by digoxin.</td><td colspan="1" rowspan="1">23869020 6836275 32815419 10555354</td></tr><tr><td rowspan="2" colspan="1">Captopril</td><td colspan="1" rowspan="1"><italic toggle="yes">Parabacteroides, Mucispirillum</italic>, and <italic toggle="yes">Allobaculum</italic></td><td colspan="1" rowspan="1">Increased bacteria.</td><td colspan="1" rowspan="1">30755073</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Clostridiales (Dehalobacterium, Oscillospira, Roseburia</italic>, and <italic toggle="yes">Coprococcus)</italic></td><td colspan="1" rowspan="1">Increased bacteria.</td><td colspan="1" rowspan="1">26301638</td></tr><tr><td colspan="1" rowspan="1">Benazepril &amp; Enalapril</td><td colspan="1" rowspan="1">Gut dysbiosis</td><td colspan="1" rowspan="1">Enalapril has been shown to reduce blood trimethylamine N-oxide (TMAO) levels.</td><td colspan="1" rowspan="1">29290360 29236735</td></tr><tr><td rowspan="15" colspan="1">Endocrine system diseases</td><td rowspan="2" colspan="1">Metformin</td><td colspan="1" rowspan="1"><italic toggle="yes">Akkermentia muciniphila</italic></td><td colspan="1" rowspan="1">Contribute to the glucose-lowering effects of metformin.</td><td colspan="1" rowspan="1">28530702</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Bacteroides fragilis</italic></td><td colspan="1" rowspan="1"><italic toggle="yes">B. fragilis</italic>-glycoursodeoxycholic acid (GUDCA)-intestinal farnesoid X receptor (FXR) axis improves anti-hyperglycemic effect.</td><td colspan="1" rowspan="1">30397356</td></tr><tr><td rowspan="4" colspan="1">Acarbose</td><td colspan="1" rowspan="1"><italic toggle="yes">Prevotella, Lactobacillus</italic>, and <italic toggle="yes">Faecalibacterium</italic></td><td colspan="1" rowspan="1">Acarbose increases SCFAs-producing bacteria.</td><td colspan="1" rowspan="1">10198028</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Dialister</italic></td><td colspan="1" rowspan="1">Increased bacteria, had a negative correlation with Hemoglobin A1c (HbA1c).</td><td colspan="1" rowspan="1">28130771</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Bifidobacterium</italic> and <italic toggle="yes">Lactobacillus</italic></td><td colspan="1" rowspan="1">Increased bacteria.</td><td colspan="1" rowspan="1">25327485 7256727</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Bacteroidaceae, Enterobacteriaceae</italic>, and <italic toggle="yes">lecithinase positive Clostridium</italic></td><td colspan="1" rowspan="1">Decreased bacteria.</td><td colspan="1" rowspan="1">25327485 7256727</td></tr><tr><td rowspan="2" colspan="1">Miglitol</td><td colspan="1" rowspan="1"><italic toggle="yes">Erysipelotrichaceae</italic> and <italic toggle="yes">Coriobacteriaceae</italic></td><td colspan="1" rowspan="1">Decreasing harmful bacteria.</td><td colspan="1" rowspan="1">28349245</td></tr><tr><td colspan="1" rowspan="1">SCFAs-producing bacteria</td><td colspan="1" rowspan="1">Increased bacteria.</td><td colspan="1" rowspan="1">28349245</td></tr><tr><td colspan="1" rowspan="1">Liraglutide</td><td colspan="1" rowspan="1">SCFAs-producing bacteria, including <italic toggle="yes">Bacteroides</italic>, <italic toggle="yes">Lachnospiraceae</italic>, and <italic toggle="yes">Bifidobacterium</italic></td><td colspan="1" rowspan="1">Changed the composition of gut microbiota, increased the <italic toggle="yes">Bacteroidetes-</italic>to<italic toggle="yes">-Firmicutes</italic> ratio.</td><td colspan="1" rowspan="1">27633081 29171288</td></tr><tr><td rowspan="3" colspan="1">Sitagliptin</td><td colspan="1" rowspan="1"><italic toggle="yes">Bacteroidetes</italic></td><td colspan="1" rowspan="1">Decreased bacteria.</td><td colspan="1" rowspan="1">30922964</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Firmicutes</italic> and <italic toggle="yes">Tenericutes</italic></td><td colspan="1" rowspan="1">Increased bacteria.</td><td colspan="1" rowspan="1">30922964</td></tr><tr><td colspan="1" rowspan="1">SCFAs-producing bacteria</td><td colspan="1" rowspan="1">Sitagliptin partially corrected the dysbiosis of microbiota.</td><td colspan="1" rowspan="1">27631013</td></tr><tr><td rowspan="3" colspan="1">Vildagliptin</td><td colspan="1" rowspan="1"><italic toggle="yes">Lactobacilli spp</italic>.</td><td colspan="1" rowspan="1">Increased bacteria.</td><td colspan="1" rowspan="1">30186247</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Oscillibacter spp</italic>.</td><td colspan="1" rowspan="1">Decreased bacteria.</td><td colspan="1" rowspan="1">30186247</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Bacteroidetes</italic> and <italic toggle="yes">Firmicutes</italic></td><td colspan="1" rowspan="1">Decreased <italic toggle="yes">Firmicutes-to-Bacteroidetes</italic> ratio.</td><td colspan="1" rowspan="1">29036231</td></tr><tr><td rowspan="5" colspan="1">Digestive system diseases</td><td colspan="1" rowspan="1">Sulfasalazine (SAS)</td><td colspan="1" rowspan="1"><italic toggle="yes">Lactobacillus acidophilus L10, Bifidobacterium lactis B94</italic>, and <italic toggle="yes">Streptococcus salivarius K12</italic></td><td colspan="1" rowspan="1">Probiotics possessed azoreductase activity to metabolize sulfasalazine.</td><td colspan="1" rowspan="1">6129936</td></tr><tr><td rowspan="3" colspan="1">Proton pump inhibitors (PPIs)</td><td colspan="1" rowspan="1"><italic toggle="yes">Enterobacteriaceae, Enterococcaceae</italic>, and <italic toggle="yes">Lactobacillaceae; Rothia dentocariosa</italic> and <italic toggle="yes">Rothia mucilaginosa</italic>, the genus <italic toggle="yes">Actinomyces</italic> and the family <italic toggle="yes">Micrococcaceae</italic></td><td colspan="1" rowspan="1">Increased bacteria.</td><td rowspan="2" colspan="1">26719299 26657899 26164495</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Ruminococcaceae</italic> and <italic toggle="yes">Bifidobacteriaceae</italic></td><td colspan="1" rowspan="1">Decreased bacteria.</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Clostridium difficile, Campylobacter</italic>, and <italic toggle="yes">Salmonella</italic></td><td colspan="1" rowspan="1">Increase susceptibility to enteric infections.</td><td colspan="1" rowspan="1">25337874 24096337</td></tr><tr><td colspan="1" rowspan="1">Nonsteroidal anti-inflammatory drugs (NSAIDs)</td><td colspan="1" rowspan="1"><italic toggle="yes">Clostridium perfrengens</italic> and <italic toggle="yes">Escherichia coli</italic></td><td colspan="1" rowspan="1">Bacteria in the intestine produce &#946;-glucuronidases to de-glucuronidation of drugs leading to toxic metabolites.</td><td colspan="1" rowspan="1">30401818</td></tr><tr><td rowspan="3" colspan="1">Nervous system diseases</td><td rowspan="3" colspan="1">Levodopa, carbidopa, and entacapone</td><td colspan="1" rowspan="1"><italic toggle="yes">Enterococcus faecalis</italic> and <italic toggle="yes">Lactobacillus</italic></td><td colspan="1" rowspan="1">Bacterial contain tyrosine decarboxylases (tyrDCs) that can convert levodopa to dopamine.</td><td colspan="1" rowspan="1">30659181 31196984</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Eggerthella lenta</italic></td><td colspan="1" rowspan="1">Convert dopamine to m-tyramine, which can cause hypertensive crisis.</td><td colspan="1" rowspan="1">31196984</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Ruminococcus torques</italic></td><td colspan="1" rowspan="1">Metabolize entacapone 84% efficiency.</td><td colspan="1" rowspan="1">31158845 29555994</td></tr><tr><td rowspan="3" colspan="1">Locomotor system diseases</td><td rowspan="3" colspan="1">Methotrexate (MTX)</td><td colspan="1" rowspan="1"><italic toggle="yes">Enterobacterial</italic> group<italic toggle="yes">, Ruminococcaceae, Bacteroidetes</italic> phyla, and <italic toggle="yes">Bacteroides fragilis</italic></td><td colspan="1" rowspan="1">Decreased bacteria.</td><td colspan="1" rowspan="1">29351480 7601013 30049384</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Lachnospiraceae</italic> family</td><td colspan="1" rowspan="1">Increased bacteria.</td><td colspan="1" rowspan="1">29351480</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Prevotella maculosa</italic></td><td colspan="1" rowspan="1">Enhancement of the response to the treatment.</td><td colspan="1" rowspan="1">26214836</td></tr><tr><td rowspan="2" colspan="1">Genitourinary system diseases</td><td rowspan="2" colspan="1">Abiraterone acetate (ABI), enzalutamide (ENZ), and degarelix acetate (DEG)</td><td colspan="1" rowspan="1"><italic toggle="yes">Akkermansia muciniphila</italic> and <italic toggle="yes">Lachnospiraceae</italic></td><td colspan="1" rowspan="1">Depleted in patients treated with abiraterone acetate.</td><td colspan="1" rowspan="1">32973149</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Ruminococcaceae</italic> and <italic toggle="yes">Akkermansia muciniphila</italic></td><td colspan="1" rowspan="1">More abundant in the microbiota of men taking oral ATT.</td><td colspan="1" rowspan="1">29089606 34618567</td></tr><tr><td rowspan="4" colspan="1">Respiratory system diseases</td><td rowspan="4" colspan="1">Isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA)</td><td colspan="1" rowspan="1"><italic toggle="yes">Clostridiales</italic> and <italic toggle="yes">Lactobacillus</italic></td><td colspan="1" rowspan="1">Decreased bacteria.</td><td colspan="1" rowspan="1">28683818 29555994</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Porphyromonadaceae, Bacteroidetes, Proteobacteria, Gordonibacter</italic>, and <italic toggle="yes">Marvinbryantia</italic></td><td colspan="1" rowspan="1">Increased bacteria.</td><td colspan="1" rowspan="1">28683818 30910543</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Bacteroides</italic></td><td colspan="1" rowspan="1">Produce polysaccharides that increase Treg cell responses and mediate mucosal tolerance.</td><td colspan="1" rowspan="1">22999859</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Prevotella</italic></td><td colspan="1" rowspan="1">Increased Th17 cells-mediated inflammation.</td><td colspan="1" rowspan="1">28542929 21995674</td></tr></tbody></table></table-wrap></p><sec id="Sec15"><title>Warfarin</title><p id="Par37">Warfarin, a vitamin K antagonist, has become the mainline of oral anti-coagulant treatment for preventing and treating thromboembolic complications in 1954.<sup><xref ref-type="bibr" rid="CR293">293</xref>&#8211;<xref ref-type="bibr" rid="CR295">295</xref></sup> However, its narrow therapeutic window and apparent IVDR prompted many studies to identify genetic factors that influence treatment outcomes.<sup><xref ref-type="bibr" rid="CR296">296</xref>&#8211;<xref ref-type="bibr" rid="CR298">298</xref></sup> Through these studies, mutations predictive of therapeutic response have been identified in VKORC1 and CYP2C9, which encode metabolic enzymes associated with vitamin K and coumarin vitamin K antagonists, respectively.<sup><xref ref-type="bibr" rid="CR299">299</xref>,<xref ref-type="bibr" rid="CR300">300</xref></sup> Nonetheless, approximately 35% of individuals with a delay in responding to warfarin have not been explained by these genetic factors.<sup><xref ref-type="bibr" rid="CR301">301</xref></sup> Recently, researchers have investigated the possible impact of gut microbiota response to warfarin, given the known association between gut microbiota and vitamin K metabolism. A trial of 200 patients with varying degrees of reaction to warfarin showed that <italic toggle="yes">Bacteroides</italic>, <italic toggle="yes">Escherichia Shigella</italic>, and <italic toggle="yes">Klebsiella</italic> were prominent in the lower-responders. <italic toggle="yes">Escherichia Shigella</italic> has the necessary enzymes to produce vitamin K, which may account for the weak response. In contrast, <italic toggle="yes">Enterococcus</italic> was connected to an increased reaction to warfarin.<sup><xref ref-type="bibr" rid="CR302">302</xref></sup> This research is the initial one to establish a connection between gut microbiota and IVDR to warfarin, a medicinal compound that has a limited therapeutic window and can result in bleeding or inefficiency if not dosed appropriately. Although these findings show promise, additional research is required to confirm and refine the results. Determining the impact of gut microbiota in warfarin response has the potential to improve individualized dosing strategies and optimize treatment outcomes.</p></sec><sec id="Sec16"><title>Statins</title><p id="Par38">Statins are commonly utilized for the first and second-line management of CVDs by reduction of low-density lipoprotein cholesterol (LDL-C), the so-called &#8216;bad&#8217; cholesterol.<sup><xref ref-type="bibr" rid="CR303">303</xref>&#8211;<xref ref-type="bibr" rid="CR305">305</xref></sup> By inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), statins mainly reduce the de novo synthesis of cholesterol in the liver.<sup><xref ref-type="bibr" rid="CR306">306</xref></sup> However, studies in recent decades have shown that statins have a number of pleiotropic effects, including anti-inflammation, anti-thrombosis, and anti-oxidation, which may be involved in their cardiovascular protective properties.<sup><xref ref-type="bibr" rid="CR307">307</xref>,<xref ref-type="bibr" rid="CR308">308</xref></sup> Statins have been proven to inhibit the function of Rho kinase and Rac1 protein, which are associated with the progression of AS, a major risk factor for CVDs. Statins also activate peroxisome proliferator-activated receptor-gamma (PPAR-&#947;), a nuclear receptor that contributes to the regulation of inflammation, lipometabolism, and glycometabolism.<sup><xref ref-type="bibr" rid="CR308">308</xref></sup> However, the mechanisms underlying such effects of statins are poorly understood.</p><p id="Par39">Furthermore, recent research indicates that statins can modify the structure of gut microbiota, leading to changes in the proportion of certain species. One study found that statin treatment dramatically boosted the amount of certain anti-inflammation-related species (e.g., <italic toggle="yes">Bacteroides</italic>, <italic toggle="yes">Butyricimonas</italic>, and <italic toggle="yes">Mucispirillum</italic>), which may help to ameliorate hyperglycemia.<sup><xref ref-type="bibr" rid="CR309">309</xref></sup> Meanwhile, another research suggests that statins could cause gut dysregulation by altering the complexity of the BAs pool via a pregnancy X receptor (PXR) based mechanism,<sup><xref ref-type="bibr" rid="CR310">310</xref></sup> potentially leading to adverse health effects.<sup><xref ref-type="bibr" rid="CR311">311</xref></sup> BAs are synthesized from cholesterol in the liver and are important in the digestion and absorption of dietary fats. Direct inhibition of de novo cholesterol formation by statins could inhibit BAs synthesis in the liver, thereby altering the BAs pool in the human gut. Alterations in the number and structure of BAs in the gut may directly or indirectly induce considerable and complex physiological reactions by altering gut microbiota.</p><p id="Par40">Despite growing evidence that statins might be beneficial for gut microbiota, more studies are warranted to investigate the long-term effects of statin treatment on gut microbiota and whether these changes are consistently beneficial for CVDs. In addition, it is critical to evaluate the possible risks and benefits of statin treatment and IVDR when making treatment decisions for the prevention and management of CVDs.</p></sec><sec id="Sec17"><title>Digoxin</title><p id="Par41">Digoxin, also known as digitalis, is a drug that can enhance the pumping efficiency of damaged or weak hearts, leading to better clinical stability and exercise capacity.<sup><xref ref-type="bibr" rid="CR312">312</xref>,<xref ref-type="bibr" rid="CR313">313</xref></sup> However, in lower-flow congestive heart failure, digoxin may be ineffective in 10% of patients, due to deactivation by specific strains, highlighting the significance of IVDR from humans and microbiota. The deactivation of digoxin is mediated by the transformation of digoxin to an inactivated state, dihydro-digoxin, by <italic toggle="yes">Eggerthella lenta</italic> (<italic toggle="yes">E. lenta</italic>).<sup><xref ref-type="bibr" rid="CR314">314</xref>&#8211;<xref ref-type="bibr" rid="CR317">317</xref></sup> In another groundbreaking research, an operon coding for the <italic toggle="yes">E. lenta</italic> cytochrome, cardiac glycoside reductase (cgr), was identified to be transcriptionally activated by digoxin, suggesting a predictable microbiota biomarker for digoxin deactivation. The researchers also explored the potential that endogenous digoxin-related substances might have been chosen for inactivation and determined if sensible dietary interference could regulate the inactivation of digoxin in vivo. As previously understood, <italic toggle="yes">E. lenta</italic> proliferation relies on arginine, which not only improves proliferation but also prevents digoxin deactivation. Hence, increased arginine concentrations, either dietary or microbiota-derived, may be able to suppress this unwanted microbiota function.<sup><xref ref-type="bibr" rid="CR318">318</xref>,<xref ref-type="bibr" rid="CR319">319</xref></sup> To test this hypothesis, the researchers performed an in vivo experiment using mice given two distinct diets: one devoid of any protein and the other containing 20% of total calorie intake from protein. The results showed that an increase in protein intake notably raised levels of digoxin in the blood and urine, but only in mice colonized with digoxin-reducing strains.<sup><xref ref-type="bibr" rid="CR318">318</xref></sup> Overall, this research offers a new understanding of how <italic toggle="yes">E. lenta</italic> deactivates digoxin and emphasizes the possible utilization of dietary interference to regulate this microbiota process. These findings could have significant clinical applications for individuals with low-flow congestive heart failure who may benefit from digoxin therapy. Furthermore, the identification of predictive microbiota biomarkers for drug inactivation could lead to the identification of personalized treatment guidelines on the basis of individual microbiota.</p></sec><sec id="Sec18"><title>Angiotensin-converting enzyme inhibitors (ACE-Is)</title><p id="Par42">Captopril is a first-generation ACE-Is drug widely used to treat hypertension through the inhibition of the renin-angiotensin system (RAS) in centrally and peripherally sites.<sup><xref ref-type="bibr" rid="CR320">320</xref>,<xref ref-type="bibr" rid="CR321">321</xref></sup> In addition to its anti-hypertensive effects, captopril has also been found to influence the composition of gut microbiota.<sup><xref ref-type="bibr" rid="CR322">322</xref>&#8211;<xref ref-type="bibr" rid="CR325">325</xref></sup> Research has indicated that captopril maintains its anti-hypertensive activity after withdrawal. An animal experiment treating rats with captopril showed an increased abundance of <italic toggle="yes">Parabacteroides, Mucispirillum</italic>, and <italic toggle="yes">Allobaculum</italic>.<sup><xref ref-type="bibr" rid="CR326">326</xref></sup> In addition, captopril reduces neuronal inflammation in the autoregional area and diminishes sympathetic nerve drive, which balances the gut microbiota.<sup><xref ref-type="bibr" rid="CR327">327</xref>,<xref ref-type="bibr" rid="CR328">328</xref></sup> Recent findings also suggest that mothers treated with captopril have a persistent anti-hypertensive response by reconstituting gut microbiota, improving gut pathologies and permeabilities, and restoring the dysregulated gut-brain axis in male offspring.<sup><xref ref-type="bibr" rid="CR329">329</xref></sup> For example, the presence of <italic toggle="yes">Clostridia</italic> and <italic toggle="yes">Clostridiales</italic> were higher in rats of maternal captopril. Pregnant rats treated with captopril exhibited a greater mean abundance of the order <italic toggle="yes">Clostridiales</italic> (e.g., <italic toggle="yes">Dehalobacterium, Oscillospira, Roseburia</italic>, and <italic toggle="yes">Coprococcus</italic>) in gut microbiota, in comparison to pregnant rats. As a result, captopril could affect gut microbiota growth and composition in humans, thereby altering the effectiveness of drugs.<sup><xref ref-type="bibr" rid="CR330">330</xref></sup> The effect of captopril on gut microbiota may be significant in managing hypertension and associated diseases.</p><p id="Par43">Benazepril and Enalapril are second-generation of ACE-Is and are primarily for treating CVDs (e.g., arterial hypertension and congestive heart failure).<sup><xref ref-type="bibr" rid="CR331">331</xref></sup> These drugs work by inhibiting the activity of the angiotensin-converting enzyme (ACE), resulting in a lower generation of angiotensin II, a hormone that narrows the vessels and raises pressure.<sup><xref ref-type="bibr" rid="CR332">332</xref>,<xref ref-type="bibr" rid="CR333">333</xref></sup> Recently, researchers have shown that both benazepril and enalapril have the capacity to positively influence gut microbiota.<sup><xref ref-type="bibr" rid="CR334">334</xref>&#8211;<xref ref-type="bibr" rid="CR337">337</xref></sup> In rats, benazepril treatment was found to promote the restoration of gut microbiota structure by changing the balance of gut microbiota.<sup><xref ref-type="bibr" rid="CR338">338</xref>,<xref ref-type="bibr" rid="CR339">339</xref></sup> Specifically, benazepril is primarily metabolized in the liver and transformed into diacid benazeprilat, which can affect gut microbiota. In contrast, enalapril has been shown to reduce blood levels of trimethylamine N-oxide (TMAO), a compound produced by the gut microbiota metabolizing certain nutrition.<sup><xref ref-type="bibr" rid="CR340">340</xref>,<xref ref-type="bibr" rid="CR341">341</xref></sup> High concentrations of TMAO are linked to a higher incidence of CVDs. Enalapril influences plasma TMAO levels by modifying the composition of gut microbiota and controlling the excretion of methylamines in urine.<sup><xref ref-type="bibr" rid="CR337">337</xref></sup> These findings suggest that ACE-Is might be effective in improving gut microbiota composition and cardiovascular health. Therefore, by promoting the restoration of gut microbiota structure and reducing TMAO levels, benazepril and enalapril may help reduce the risk of CVDs.</p></sec></sec><sec id="Sec19"><title>Pharmacomicrobiomics in endocrine system</title><p id="Par44">The endocrine system is a complicated system of glands that produce hormones, which are responsible for regulating various bodily functions such as metabolism, growth, and development.<sup><xref ref-type="bibr" rid="CR342">342</xref>&#8211;<xref ref-type="bibr" rid="CR344">344</xref></sup> Current evidence suggests that microbiota plays an important role in the regulation of the endocrine system and can influence the IVDR of endocrine disorders.<sup><xref ref-type="bibr" rid="CR345">345</xref></sup> The study of pharmacomicrobiomics in the endocrine system has the potential to enhance our knowledge of the underlying mechanisms of IVDR and to advance precision medicine based on the characteristics of microbiota. Further research in this field is necessary to fully realize the potential benefits of this approach. Below, we will list several cases of interaction between anti-diabetics and gut microbiota (Table <xref rid="Tab3" ref-type="table">3</xref>).</p><sec id="Sec20"><title>Metformin</title><p id="Par45">Metformin (1,1-Metformin Hydrochloride), a widespread anti-diabetic drug, is also known to have other benefits, such as reducing obesity, and reducing the incidence of CVDs and cancers.<sup><xref ref-type="bibr" rid="CR346">346</xref>,<xref ref-type="bibr" rid="CR347">347</xref></sup> However, the precise mechanisms by which metformin works to regulate glucose levels are not yet fully understood.<sup><xref ref-type="bibr" rid="CR347">347</xref>&#8211;<xref ref-type="bibr" rid="CR351">351</xref></sup> While some theories suggest that metformin activates AMP-activated protein kinase (AMPK) and inhibits the mitochondrial respiratory chain, these completely account for all of its positive actions.<sup><xref ref-type="bibr" rid="CR352">352</xref></sup> Thus, researchers have investigated mechanisms underlying gut microbiota regulation of glucose metabolism and energy balance, particularly the potential involvement in IVDR.<sup><xref ref-type="bibr" rid="CR353">353</xref>&#8211;<xref ref-type="bibr" rid="CR355">355</xref></sup> Recently, some work has highlighted how gut microbiota might influence the anti-hyperglycemic effect of metformin. For example, Wu et al. transplanted feces from untreated Type 2 Diabetes Mellitus (T2D) patients to GF mice and observed significant improvement in glucose tolerance compared to control mice. They identified the expression of <italic toggle="yes">A. muciniphila</italic> and its metal-binding proteins as key factors in metformin-microbiota interactions. This contributed to explaining earlier unresolved questions about the relationship between metformin effectiveness and metal balance.<sup><xref ref-type="bibr" rid="CR353">353</xref></sup> Another study by Sun et al. showed that the anti-hyperglycemic effect of metformin involves a new mechanism named the <italic toggle="yes">Bacteroides fragilis</italic>-glycoursodeoxycholic acid (GUDCA)-intestinal farnesoid X receptor (FXR) axis. This pathway relies on gut microbiota and involves the activation of intestinal FXR signaling to ameliorate metabolic dysfunction. Metformin was found to reduce <italic toggle="yes">Bacteroides fragilis</italic>, preventing GUDCA degradation.<sup><xref ref-type="bibr" rid="CR354">354</xref></sup></p><p id="Par46">In addition to its anti-hyperglycemic effect, metformin demonstrated protective efficacy against CVDs through anti-inflammatory mechanisms including activating the AMPK pathway and inhibiting nuclear factor-&#954;B (NF-&#954;B) pathway.<sup><xref ref-type="bibr" rid="CR356">356</xref>&#8211;<xref ref-type="bibr" rid="CR358">358</xref></sup> Growing evidence indicates that microbiota-mediated pathways might be implicated in the therapeutic effects of metformin. For example, changes in gut microbiota structure due to metformin treatment may lead to alterations in glucose, hormones, BAs pool, SCFAs, and immunity.<sup><xref ref-type="bibr" rid="CR351">351</xref>,<xref ref-type="bibr" rid="CR352">352</xref>,<xref ref-type="bibr" rid="CR359">359</xref></sup> Collectively, emerging evidence suggests that the gut plays a vital role in metformin therapy and that microbiota-mediated mechanisms involving changes in gut microbiota structure may be responsible for some of its pleiotropic effects. This has important implications for developing new therapies that target gut microbiota and their interaction with IVDRs.</p></sec><sec id="Sec21"><title>&#945;-Glucosidase inhibitors (AGIs)</title><p id="Par47">AGIs are a class of drugs that alter the absorption and metabolism of carbohydrates in the small intestine.<sup><xref ref-type="bibr" rid="CR360">360</xref>,<xref ref-type="bibr" rid="CR361">361</xref></sup> These drugs have been found to significantly affect the structure and variability of gut microbiota, which may have important implications for managing metabolism diseases (e.g., T2D). Acarbose and miglitol are two commonly prescribed AGIs that have been widely evaluated for their impact on gut microbiota. In vitro, experiments have shown that acarbose selectively inhibits the development of <italic toggle="yes">E. coli</italic> by inhibiting the maltose importer, while clinical trials have indicated that acarbose enhances the abundance of microbiota that produce SCFAs, e.g., <italic toggle="yes">Prevotella, Lactobacillus</italic>, and <italic toggle="yes">Faecalibacterium</italic>.<sup><xref ref-type="bibr" rid="CR362">362</xref>,<xref ref-type="bibr" rid="CR363">363</xref></sup> SCFAs are known to be beneficial for metabolic health, and treatment with <italic toggle="yes">lactobacillus</italic> has been shown to reduce glycemia.<sup><xref ref-type="bibr" rid="CR364">364</xref>&#8211;<xref ref-type="bibr" rid="CR366">366</xref></sup> Furthermore, a study demonstrated that <italic toggle="yes">Dialister</italic>, a taxon found in gut microbiota, was enhanced after acarbose therapy and had a negative correlation with Hemoglobin A1c (HbA1c), suggesting a possible role in controlling glucose metabolism.<sup><xref ref-type="bibr" rid="CR362">362</xref></sup> Acarbose has also been shown to increase <italic toggle="yes">Bifidobacterium</italic> and <italic toggle="yes">Lactobacillus</italic>, and reduce harmful <italic toggle="yes">Bacteroidaceae, Enterobacteriaceae</italic>, and <italic toggle="yes">lecithinase positive Clostridium</italic> in stool collected from people with hyperlipidemia or T2D.<sup><xref ref-type="bibr" rid="CR367">367</xref>,<xref ref-type="bibr" rid="CR368">368</xref></sup></p><p id="Par48">Miglitol, on the other hand, has anti-inflammatory properties in mice, inhibiting histological and molecular indicators of inflammatory reaction and decreasing intestinal transit time generated by high-fat and high-glucose diet (HFHSD).<sup><xref ref-type="bibr" rid="CR369">369</xref></sup> Consuming an energy-dense diet has been shown to increase <italic toggle="yes">Erysipelotrichaceae</italic> and <italic toggle="yes">Coriobacteriaceae</italic>, but miglitol has been found to reverse this effect. It has been hypothesized that the reduction in intestinal inflammation is connected to these alterations in gut microbiota. However, the effect of miglitol on the heterogeneity and structure of gut microbiota remains unknown and requires further study. Overall, the results of these findings indicate that AGIs, particularly acarbose, may be useful in reestablishing gut microbiota balance in individuals with T2D. By increasing SCFAs-producing microbiota and decreasing potentially harmful microbiota, these drugs can potentially impact metabolic health with positive effects. More studies are necessary to fully elucidate the IVDR of AGIs on gut microbiota and their impact on metabolic health.</p></sec><sec id="Sec22"><title>Glucagon-like peptide-1 receptor agonists (GLP1-RAs)</title><p id="Par49">Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by enteroendocrine cells as a result of dietary.<sup><xref ref-type="bibr" rid="CR370">370</xref>&#8211;<xref ref-type="bibr" rid="CR372">372</xref></sup> Its role in enhancing glucose-induced insulin secretion, inhibiting glucagon secretion, and suppressing appetite and gastric emptying makes it a powerful target in treating diabetes and overweight.<sup><xref ref-type="bibr" rid="CR370">370</xref>,<xref ref-type="bibr" rid="CR373">373</xref></sup> Recent studies have emphasized the function of gut microbiota in regulating satiety and glucose homeostasis by inducing GLP-1 secretion.<sup><xref ref-type="bibr" rid="CR374">374</xref>&#8211;<xref ref-type="bibr" rid="CR377">377</xref></sup> Furthermore, GLP1-RAs (e.g., liraglutide), an emerging sub-class of anti-diabetic drugs, have been shown to modulate the intestinal microenvironment and alter gut microbiota composition.<sup><xref ref-type="bibr" rid="CR378">378</xref>&#8211;<xref ref-type="bibr" rid="CR382">382</xref></sup> In general, the <italic toggle="yes">Firmicutes</italic>-to-<italic toggle="yes">Bacteroidetes</italic> ratio is considered an important indicator of gut microbiota structure. Studies have shown that liraglutide can modify gut microbiota to a leaner proportion in normally-weighed diabetes mice, resulting in a higher <italic toggle="yes">Firmicutes</italic>-to-<italic toggle="yes">Bacteroides</italic> ratio.<sup><xref ref-type="bibr" rid="CR378">378</xref></sup> Interestingly, another research demonstrated that liraglutide increased the <italic toggle="yes">Bacteroides</italic>-to-<italic toggle="yes">Firmicutes</italic> ratio to decrease body weight in both simply overweight and diabetes-overweight individuals independent of glycaemic condition.<sup><xref ref-type="bibr" rid="CR380">380</xref></sup> Such differences are probably attributed to varying levels of hyperglycemia and different model systems used. GLP1-RAs have been proven to profoundly change the structure of gut microbiota in diabetic male rats.<sup><xref ref-type="bibr" rid="CR379">379</xref>,<xref ref-type="bibr" rid="CR383">383</xref></sup> These changes include selective enhancement of several SCFAs-producing microbiota, e.g., <italic toggle="yes">Bacteroides</italic>, <italic toggle="yes">Lachnospiraceae</italic>, and <italic toggle="yes">Bifidobacterium</italic>.<sup><xref ref-type="bibr" rid="CR379">379</xref></sup> Furthermore, GLP1-RAs can re-establish, at least in part, the homeostasis of gut microbiota.<sup><xref ref-type="bibr" rid="CR383">383</xref></sup></p></sec><sec id="Sec23"><title>Dipeptidyl peptidase-4 inhibitors (DPP4Is)</title><p id="Par50">DPP4Is (e.g., sitagliptin and vildagliptin) are first-line hypoglycaemic drugs approved by the American Association of Clinical Endocrinologists for T2D.<sup><xref ref-type="bibr" rid="CR370">370</xref>,<xref ref-type="bibr" rid="CR384">384</xref></sup> DPP4Is decrease blood glucose primarily via inhibition of GLP-1 degradation.<sup><xref ref-type="bibr" rid="CR385">385</xref></sup> Previous studies have suggested the DPP-4-related function of gut microbiota may be a goal for DPP4Is, potentially opening up novel therapeutic applications for DPP4Is to modulate gut microbiota discordance. Studies have shown that DPP4Is can improve glycaemic control through increased <italic toggle="yes">Bacteroidetes</italic>, thereby greatly reverting high-fat diet (HFD)-induced alterations in gut microbiota.<sup><xref ref-type="bibr" rid="CR386">386</xref></sup> The study of the effect of sitagliptin on gut microbiota showed decreased <italic toggle="yes">Bacteroidetes</italic>, and increased <italic toggle="yes">Firmicutes</italic> and <italic toggle="yes">Tenericutes</italic>. However, sitagliptin moderately restored microbiota imbalance and modified the abundance of SCFAs-producing microbiota in T2D rats.<sup><xref ref-type="bibr" rid="CR387">387</xref></sup> Similarly, vildagliptin administration was related to increased <italic toggle="yes">Bacteroidetes</italic> and decreased <italic toggle="yes">Firmicutes</italic> coupled with decreased <italic toggle="yes">Firmicutes-to-Bacteroidetes</italic> ratio in diabetic rats.<sup><xref ref-type="bibr" rid="CR388">388</xref></sup> Moreover, vildagliptin has been reported to produce benefits by modulating gut microbiota, leading to increased <italic toggle="yes">Lactobacilli</italic> and decreased <italic toggle="yes">Oscillibacter</italic>.<sup><xref ref-type="bibr" rid="CR385">385</xref></sup> To clarify the mechanisms of variation, researchers experimentally confirmed that vildagliptin inhibited Toll-like receptor (TLR) ligands in caecal content and restoration of antimicrobial peptide levels and ileum crypt depth.<sup><xref ref-type="bibr" rid="CR385">385</xref></sup> Studies have also shown that DPP4Is may indirectly reduce the secretion of pro-inflammatory cytokines in the liver through their effect on gut microbiota. Overall, these studies highlight the importance of DPP4Is on gut microbiota and reveal promising strategies to improve glucose homeostasis and IVDR.</p></sec></sec><sec id="Sec24"><title>Pharmacomicrobiomics in digestive system</title><p id="Par51">The digestive system is one of the most extensive areas of pharmacomicrobiomics because it is home to complicated and varied microbiota that is critical in drug metabolism and efficacy.<sup><xref ref-type="bibr" rid="CR189">189</xref>,<xref ref-type="bibr" rid="CR389">389</xref></sup> Gut microbiota has also been demonstrated to impact outcomes of drugs used to treat a variety of digestive diseases, e.g., inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS).<sup><xref ref-type="bibr" rid="CR390">390</xref></sup> Patients with IBD have been detected to have altered gut microbiota composition and function, which may affect IVDR. This has contributed to the advancement of microbiota-based treatments for IBD, e.g., FMT, which involves transplanting a healthy gut microbiota into a patient to restore microbial balance and improve treatment outcomes. Overall, the field of pharmacomicrobiomics in the digestive system has enormous potential for improving drug efficacy and reducing ADRs. However, deeper studies are necessary to better comprehend the complicated between gut microbiota and drugs, as well as to develop microbiota-based therapies for various digestive and metabolic disorders (Table <xref rid="Tab3" ref-type="table">3</xref>).</p><sec id="Sec25"><title>Sulfasalazine (SAS)</title><p id="Par52">SAS is a medication that was initially developed with the aim of treating inflammatory conditions caused by bacterial infections. However, its effectiveness was later discovered in treating ulcerative colitis (UC).<sup><xref ref-type="bibr" rid="CR391">391</xref></sup> The drug is composed of aminosalicylate and sulfapyridine, which are linked together by an azo bond. One of the unique properties of SAS is that it is not rapidly absorbed in the up-stream gastrointestinal tract. Instead, it is broken down into its components by gut microbiota in the colon. Sulfapyridine is then absorbed into the bloodstream, while mesalazine (5-aminosalicylic acid, 5-ASA) can be inactivated in the colon.<sup><xref ref-type="bibr" rid="CR392">392</xref></sup> A PK study in health subjects revealed that gut microbiota are critical in activating SAS. This discovery might explain why this drug is better at treating UC than Crohn&#8217;s disease (CD).<sup><xref ref-type="bibr" rid="CR393">393</xref></sup> The ability of gut microbiota SAS could be enhanced by administering probiotic strains (e.g., <italic toggle="yes">Lactobacillus acidophilus L10, Bifidobacterium lactis B94</italic>, and <italic toggle="yes">Streptococcus salivarius K12</italic>). In an in vitro trial, researchers incubated the contents of a rat colon with SAS alone or SAS combined with probiotics under anaerobic conditions.<sup><xref ref-type="bibr" rid="CR394">394</xref></sup> They found that the probiotics possessed azoreductase activity, allowing them to metabolize SAS. The samples incubated with SAS plus probiotics had a greater level of 5-ASA and sulfapyridine restored. Despite SAS being an efficient and inexpensive therapy for UC, some patients have reported ADRs when using it, such as nausea, skin rash, and anorexia.<sup><xref ref-type="bibr" rid="CR395">395</xref></sup> This may be caused by the metabolism of SAS through gut microbiota. As a result, SAS is less popular than other treatments for UC.</p></sec><sec id="Sec26"><title>Proton-pump inhibitors (PPIs)</title><p id="Par53">PPIs are widespread drugs for the treatment of acid-induced diseases including peptic ulcers, gastro-oesophageal reflux, dyspepsia, gastro-duodenopathy, and bleeding.<sup><xref ref-type="bibr" rid="CR396">396</xref>&#8211;<xref ref-type="bibr" rid="CR398">398</xref></sup> Due to their effectiveness and safety properties, PPIs therapy has expanded rapidly in the last decades. Controversies have arisen, particularly relating to the safety profile and possible ADRs of chronic therapy with PPIs. Up to 70% of PPIs prescriptions have been estimated to be unneeded.<sup><xref ref-type="bibr" rid="CR399">399</xref></sup> Once started, the original indication for PPIs is rarely re-evaluated, with later withdrawal attempts resulting in needless long-term use.<sup><xref ref-type="bibr" rid="CR400">400</xref>,<xref ref-type="bibr" rid="CR401">401</xref></sup></p><p id="Par54">A large-scale patient-based clinical trial in the Netherlands shown that PPIs are among the drugs in greatest correlation with reduced gut microbiota diversity and taxonomic changes.<sup><xref ref-type="bibr" rid="CR402">402</xref></sup> Studies analyzing <italic toggle="yes">16</italic>&#8201;<italic toggle="yes">S</italic> data from various cohorts found that PPI use led to decreased abundance of gut microbiota and increased oral microbiota.<sup><xref ref-type="bibr" rid="CR403">403</xref>&#8211;<xref ref-type="bibr" rid="CR405">405</xref></sup> For example, <italic toggle="yes">Enterobacteriaceae, Enterococcaceae</italic>, and <italic toggle="yes">Lactobacillaceae</italic> increased, <italic toggle="yes">Ruminococcaceae</italic> and <italic toggle="yes">Bifidobacteriaceae</italic> decreased, while alterations towards typically oral microbiota are represented by <italic toggle="yes">Rothia dentocariosa</italic>, <italic toggle="yes">Rothia mucilaginosa</italic>, <italic toggle="yes">Actinomyces</italic>, and <italic toggle="yes">Micrococcaceae</italic> increased.<sup><xref ref-type="bibr" rid="CR404">404</xref></sup> In addition, the observed changes appear to be a class-efficacy of PPIs, with increased doses linked to greater microbiota changes.<sup><xref ref-type="bibr" rid="CR115">115</xref></sup> Recent research has shown that PPIs use is highly relevant to 24 taxa and 133 pathways, with predictable function alterations including increased biosynthesis of fatty acid, lipid biosynthesis, and L-arginine, and degradation of purine de-oxyribonucleoside.<sup><xref ref-type="bibr" rid="CR115">115</xref></sup> Another in vitro experiment testing direct affected by popular drugs on gut microbiota demonstrated significant alterations in growing speeds, meaning that bonding of PPIs to bacterial H<sup>+</sup>/K<sup>+</sup> ATPases may mediate the directly influence.<sup><xref ref-type="bibr" rid="CR406">406</xref></sup> The reduction in gastric acidity caused by PPIs allows oral microbiota to colonize gut microbiota, resulting in altered taxonomic homeostasis and potentially increased susceptibility to intestinal infections, e.g., <italic toggle="yes">Clostridium difficile</italic> (<italic toggle="yes">C.</italic>
<italic toggle="yes">difficile</italic>), <italic toggle="yes">Campylobacter</italic>, and <italic toggle="yes">Salmonella</italic>.<sup><xref ref-type="bibr" rid="CR407">407</xref>&#8211;<xref ref-type="bibr" rid="CR410">410</xref></sup> Moreover, PPIs initiation and withdrawal may cause alterations in gut microbiota, potentially exacerbating liver cirrhosis.<sup><xref ref-type="bibr" rid="CR411">411</xref></sup> Furthermore, long-term PPIs use, particularly in childhood, can cause permanent alterations in the growing gut microbiota, potentially leading to obesity later in life.<sup><xref ref-type="bibr" rid="CR412">412</xref></sup> Although PPIs are widely recognized as harmless and efficient, medical practitioners should reassess the extensive, long-term impact and OTC accessibility. The rapid and widespread shift to PPIs use has led to variations in changes in gut microbiota, affecting up to one-fifth of the population. Therefore, it is important to meticulously evaluate the long-term impact of PPIs-induced alterations on gut microbiota, especially during early development, and their potential effects on health and disease in later life.</p></sec><sec id="Sec27"><title>Non-steroidal anti-inflammatory drugs (NSAIDs)</title><p id="Par55">NSAIDs are generally used to alleviate pain and inflammation, but their use can cause ADRs, such as stomach ulcers and damage to the mucous membrane of the small intestine.<sup><xref ref-type="bibr" rid="CR413">413</xref>,<xref ref-type="bibr" rid="CR414">414</xref></sup> This is due to the fact that the bacterial glucuronidase metabolizes NSAIDs in the intestine, similar to the case of CPT-11, which converts the drug into toxic metabolites that damage the intestinal mucosa.<sup><xref ref-type="bibr" rid="CR415">415</xref></sup> The glucuronides of NSAIDs produced in the liver reach the intestine via the bile, where bacterial GUSs hydrolyse them into aglycones.<sup><xref ref-type="bibr" rid="CR416">416</xref></sup> These aglycones are then reabsorbed and converted by cytochrome P450 into potentially cytotoxic intermediates that cause intestinal toxicity.<sup><xref ref-type="bibr" rid="CR417">417</xref></sup> Like CPT-11, a recent study demonstrated that Inh1 (Inhibitor 1), a novel microbe-specific GUSs inhibitor, can reduce the intestinal ADRs of diclofenac.<sup><xref ref-type="bibr" rid="CR418">418</xref></sup> This suggests that inhibiting GUSs is a promising approach to reducing the adverse effects of certain drugs. While gut microbiota produces GUSs with beneficial functions to the organism, opportunist or intestine-pathogenic species, e.g., <italic toggle="yes">Clostridium perfrengens</italic> and <italic toggle="yes">E. coli</italic>, are responsible for the de-glucuronidation of drugs producing harmful metabolites. This is due to intracellular variations of GUSs, including variations in conformation, hydrophobicity, and mobility.<sup><xref ref-type="bibr" rid="CR419">419</xref></sup> The enhancing potential of bacterial GUSs-induced ADRs, especially gut injury, is not unique to NSAIDs and CPT-11. Other drugs including Regorafenib, an anti-tumor tyrosine kinase inhibitor, and venotonic flavonoids, have also been shown to be substrates for GUSs.<sup><xref ref-type="bibr" rid="CR420">420</xref>&#8211;<xref ref-type="bibr" rid="CR422">422</xref></sup> Such evidence emphasizes the value of understanding the importance of bacterial enzymes in IVDR to develop strategies to reduce ADRs.</p></sec></sec><sec id="Sec28"><title>Pharmacomicrobiomics in nervous system</title><p id="Par56">Although pharmacomicrobiomics research is still in its infancy, preliminary studies indicate that microbiota may play a key role in regulating IVDR in the nervous system. One example of this is the use of probiotics to enhance the effectiveness of anti-depressant medication.<sup><xref ref-type="bibr" rid="CR423">423</xref></sup> Several researches have indicated that certain strains of gut microbiota can produce neurotransmitters, e.g., serotonin and gamma-aminobutyric acid (GABA), which are known to regulate mood and anxiety. By supplementing these strains with probiotics, the researchers hope to increase the availability of these neurotransmitters and thereby improve the response to treatment with anti-depressants. Another area of interest is the effect of the microbiota on neurodegenerative diseases, e.g., Parkinson&#8217;s disease, for which the commonly used therapeutic drug is levodopa (Table <xref rid="Tab3" ref-type="table">3</xref>).</p><sec id="Sec29"><title>Levodopa, carbidopa, and entacapone</title><p id="Par57">Levodopa is a drug for the treatment of Parkinson&#8217;s disease, a neurological disorder described by tremors, stiffness and difficulty in moving.<sup><xref ref-type="bibr" rid="CR424">424</xref>,<xref ref-type="bibr" rid="CR425">425</xref></sup> Levodopa is taken orally and must be reabsorbed through the small intestine to reach the brain, where it is transformed into dopamine by the tyrosine decarboxylases (tyrDCs). The effectiveness of the drug depends on its bioavailability to the brain, and the drug is usually used alongside inhibitors of catechol metabolic (e.g., carbidopa and entacapone) to inhibit extra-brain metabolism. Emerging evidence suggests that gut microbiota can metabolize levodopa. Certain species, e.g., <italic toggle="yes">Enterococcus faecalis</italic> (<italic toggle="yes">E. faecalis</italic>) and <italic toggle="yes">Lactobacillus</italic>, have been found to contain tyrDCs.<sup><xref ref-type="bibr" rid="CR426">426</xref>,<xref ref-type="bibr" rid="CR427">427</xref></sup> However, this microbiota metabolism reduces the amount of levodopa that is available to the brain, resulting in decreased drug efficacy. Additionally, microbiota metabolism of levodopa can also lead to ADRs, as <italic toggle="yes">E. lenta</italic> and other ten species can further convert dopamine to m-tyramine, which can cause hypertensive crisis.<sup><xref ref-type="bibr" rid="CR427">427</xref></sup></p><p id="Par58">It is interesting to note that gut microbiota can also directly metabolize carbidopa and entacapone. For example, <italic toggle="yes">E. faecalis</italic> has been shown to metabolize both levodopa and entacapone with 98.9% efficiency.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> In turn, entacapone would reduce some species, e.g., <italic toggle="yes">Ruminococcus torques</italic>, which can still metabolize entacapone with 84% efficient.<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR406">406</xref></sup> Such findings illustrate the complex interactions between gut microbiota and IVDR, which can influence drug efficacy and safety. While the field of pharmacomicrobiomics in the nervous system is still in its early stages, it has the opportunity to broaden our insight into drug-microbiota interactions and lead to the emergence of novel therapeutic strategies for neurological and psychiatric disorders.</p></sec></sec><sec id="Sec30"><title>Pharmacomicrobiomics in locomotor system</title><p id="Par59">The locomotor system is an indispensable part of the human body, consisting of bones, muscles, and joints, which work together to allow movement.<sup><xref ref-type="bibr" rid="CR428">428</xref></sup> The health of the locomotor system can be affected by various diseases, e.g., osteoarthritis (OA), rheumatoid arthritis (RA), and osteoporosis, which can result in pain, stiffness, and reduced mobility. In recent years, a growing focus has been placed on the impact of gut microbiota in the pathology and treatment of these diseases.<sup><xref ref-type="bibr" rid="CR429">429</xref></sup> One example of such a drug is methotrexate (MTX), which is commonly used to treat RA (Table <xref rid="Tab3" ref-type="table">3</xref>). Evidence indicates that gut microbiota can influence the effect of MTX, the details of which will be described later.</p><p id="Par60">Another example is NSAIDs, which are frequently applied to treat pain and inflammation related to various locomotor system disorders. However, these drugs can also cause gastrointestinal side effects, such as ulcers and bleeding. Research indicates that gut microbiota plays a crucial role in the metabolism of NSAIDs and can affect their efficacy and safety. Similar to the description of NSAIDs in digestive system diseases above, this will not be repeated.</p><sec id="Sec31"><title>Methotrexate (MTX)</title><p id="Par61">MTX is a potent cytotoxic drug used to treat autoimmune diseases (e.g., RA).<sup><xref ref-type="bibr" rid="CR430">430</xref></sup> Its underlying action is based on inhibiting dihydrofolate reductase and thymidylate synthetase, thereby preventing de novo synthesis of pyrimidines and purines. While MTX is effective, it also has a high incidence of ADRs, including gastrointestinal, hematological, nephrotoxicity, and hepatotoxicity.<sup><xref ref-type="bibr" rid="CR431">431</xref></sup> One potential factor that may impact the response to MTX is gut microbiota. Research has indicated that MTX treatment could modify the composition of gut microbiota, decreasing the abundance of <italic toggle="yes">enterobacterial</italic>, especially <italic toggle="yes">E. faecium</italic>, and increasing the abundance of <italic toggle="yes">Lachnospiraceae</italic>.<sup><xref ref-type="bibr" rid="CR432">432</xref></sup> However, the decrease in beneficial strains (e.g., <italic toggle="yes">Ruminococcaceae, Bacteroidetes</italic>, and <italic toggle="yes">Bacteroides fragilis</italic>) may accentuate the gastrointestinal ADRs, particularly intestinal mucositis.<sup><xref ref-type="bibr" rid="CR433">433</xref>,<xref ref-type="bibr" rid="CR434">434</xref></sup></p><p id="Par62">Interestingly, the association between MTX and gut microbiota is bidirectional.<sup><xref ref-type="bibr" rid="CR435">435</xref>,<xref ref-type="bibr" rid="CR436">436</xref></sup> The variability of gut microbiota may affect MTX therapy responses. The study found that patients with greater gut microbiota diversity, who had statistically abundant <italic toggle="yes">Prevotella maculosa</italic>, responded better to MTX.<sup><xref ref-type="bibr" rid="CR436">436</xref></sup> Despite the promising results, the response rate to MTX has highly IVDR, between 10% and 80%, with just 40% of patients obtaining a therapy blood concentration, and the ADRs are significant.<sup><xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR437">437</xref></sup> Genetic factors have been explored to predict the IVDR to MTX, but they have not achieved clinical relevance.<sup><xref ref-type="bibr" rid="CR438">438</xref>&#8211;<xref ref-type="bibr" rid="CR440">440</xref></sup> More investigations are necessary to assess the feasibility of using gut microbiota as a biomarker for MTX response and to determine its clinical significance. Nevertheless, promising evidence indicates that gut microbiota may play an important role in the PD of MTX, and further exploration may contribute to the emergence of personalized therapy for patients.</p></sec></sec><sec id="Sec32"><title>Pharmacomicrobiomics in genitourinary system</title><p id="Par63">The genitourinary system is an essential system for reproduction and waste excretion.<sup><xref ref-type="bibr" rid="CR441">441</xref></sup> Recently, evidence indicates that microbiota of the genitourinary system affects the efficacy and toxicity of several drugs, leading to the emergence of a field of pharmacomicrobiomics in this system. In particular, genitourinary microbiota has been shown to affect the effectiveness of androgen deprivation therapy (ADT), a frequent therapy for prostate cancer. ADT typically involves the use of androgen synthetic inhibitor (e.g., abiraterone acetate) or androgen receptor antagonist (e.g., enzalutamide, degarelix acetate) (Table <xref rid="Tab3" ref-type="table">3</xref>).</p><sec id="Sec33"><title>Abiraterone acetate (ABI), enzalutamide (ENZ), and degarelix acetate (DEG)</title><p id="Par64">Recently research has revealed the influence of ADT on the immune system and gut microbiota, and how this affects the progression of prostate cancer (PCa).<sup><xref ref-type="bibr" rid="CR442">442</xref></sup> ABI is a widely used drug in ADT, and research by Terrisse et al. underlined the crucial role of thymus-dependent T cells in regulating PCa progression, as CD4<sup>+</sup> and CD8<sup>+</sup> T cells consumption leads to a partial decrease in tumor development controlled by IVDR.<sup><xref ref-type="bibr" rid="CR443">443</xref></sup> Furthermore, the beneficial gut microbiota, e.g., <italic toggle="yes">A. muciniphila</italic> and <italic toggle="yes">Lachnospiraceae</italic>, were depleted in patients treated with ABI. However, this depletion could be reversed by the effects of the drug, which remodels the gut microbiota and promotes the proliferation of anti-inflammatory <italic toggle="yes">A. muciniphila</italic>, thereby elevating microbiota production of vitamin K2.<sup><xref ref-type="bibr" rid="CR444">444</xref></sup> Furthermore, the research suggested that specific gut microbiota, such as those with higher &#945;-diversity and <italic toggle="yes">A. muciniphila</italic>, were related to better efficacy.<sup><xref ref-type="bibr" rid="CR444">444</xref>,<xref ref-type="bibr" rid="CR445">445</xref></sup> Further studies by Sfanos et al. found that the genitourinary microbiota composition of men taking oral androgen-targeted therapy (ATT) differed from those taking Gonadotropin-releasing hormone (GnRH) agonists or antagonists monotherapy or not taking ADT. Species able to synthesize steroids, e.g., <italic toggle="yes">A. muciniphila</italic> and <italic toggle="yes">Ruminoccocaceae</italic>, were enriched in microbiota of men treated with orally ATT, which could affect disease progression and immunotherapies.<sup><xref ref-type="bibr" rid="CR445">445</xref></sup></p><p id="Par65">Another study showed that gut microbiota could regulate the levels of circulated sexual hormones via effects on human cells, but also by direct biotransformation or synthesis, thereby promoting ADT resistances.<sup><xref ref-type="bibr" rid="CR446">446</xref></sup> PCa patients demonstrated higher levels of strains e.g., <italic toggle="yes">A. muciniphila</italic> and <italic toggle="yes">Ruminoccocaceae</italic>, which are capable of synthesizing steroid hormones via CYP17A1-like bacterial enzymes. Treating cultivated bacteria with CYP17A1 inhibitor ABI inhibited androgen biosynthesis. However, the response of the microbiota to reduced androgen levels leading to the expansion of strains capable of synthesizing androgens, has yet to be elucidated. In conclusion, the ability of the microbiota to regulate circulating sex hormones and the expansion of bacteria capable of synthesizing androgens can drive resistance to ADT. Future studies are warranted to clarify the intricate interactions between gut microbiota, PCa, and therapy.</p></sec></sec><sec id="Sec34"><title>Pharmacomicrobiomics in respiratory system</title><p id="Par66">In the respiratory system, microbiota plays an important role in maintaining health by modulating immunity, protecting against pathogens, and maintaining the mucosal barrier.<sup><xref ref-type="bibr" rid="CR447">447</xref>&#8211;<xref ref-type="bibr" rid="CR449">449</xref></sup> Studies have shown that drugs may influence the composition and function of respiratory microbiota, and conversely, microbiota may impact drug metabolism and response. For example, anti-biotics can reduce microbiota diversity and enhance the growth of opportunistic pathogens that can cause chronic respiratory diseases. Inhaled corticosteroids have been shown to increase microbiota diversity and decrease the abundance of pathogenic bacteria, which may contribute to their therapeutic efficacy. Furthermore, the respiratory microbiota can impact drug delivery to the lungs. One of the best-known examples is anti-tuberculosis (anti-TB) therapy with the anti-biotic isoniazid (INH), rifampin, and pyrazinamide (PZA) (Table <xref rid="Tab3" ref-type="table">3</xref>).</p><sec id="Sec35"><title>Isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA)</title><p id="Par67">The impact of anti-TB anti-biotics on the structure of gut microbiota has been studied in mice infected by <italic toggle="yes">Mycobacterium tuberculosis</italic>.<sup><xref ref-type="bibr" rid="CR450">450</xref>,<xref ref-type="bibr" rid="CR451">451</xref></sup> The study found that treatment with INH, RIF, and PZA for three months led to significant and persistent eco-dysbiosis in a mouse model. The composition of gut microbiota was altered, with decreased <italic toggle="yes">Clostridiales</italic> and <italic toggle="yes">Lactobacillus</italic>, while increasing <italic toggle="yes">Porphyromonadaceae, Bacteroidetes</italic>, and <italic toggle="yes">Proteobacteria</italic>.<sup><xref ref-type="bibr" rid="CR452">452</xref></sup> The study further showed that a single dose of RIF decreased microbiota diversity, while either INH or PZA alone resulted in alterations to microbiota composition compared to gut microbiota of mice not treated with anti-biotics. Specifically, INH was found to enrich <italic toggle="yes">Gordonibacter</italic>, while PZA was found to enrich <italic toggle="yes">Marvinbryantia</italic>.<sup><xref ref-type="bibr" rid="CR406">406</xref>,<xref ref-type="bibr" rid="CR452">452</xref>,<xref ref-type="bibr" rid="CR453">453</xref></sup> Although TB infection did not dramatically alter gut microbiota composition, it was found to modulate the mucosal immune response. In humans, first-line anti-TB pharmacotherapy seems to have a minimal impact on gut microbiota.<sup><xref ref-type="bibr" rid="CR454">454</xref></sup> However, some strains have been demonstrated to regulate immunological responses in the host, such as <italic toggle="yes">Bacteroides</italic>, which produce polysaccharides that increase Treg cell responses and mediate mucosal tolerance.<sup><xref ref-type="bibr" rid="CR455">455</xref></sup>
<italic toggle="yes">Prevotella</italic> has been associated with enhanced Th17 cells-mediated inflammation, while <italic toggle="yes">Lactobacillus</italic> promotes innate and adaptive immunological responses.<sup><xref ref-type="bibr" rid="CR456">456</xref>,<xref ref-type="bibr" rid="CR457">457</xref></sup></p><p id="Par68">Studies have also found that anti-TB drugs can reduce the microbiota necessary for intestinal homeostasis, increasing the risk of recurrent TB.<sup><xref ref-type="bibr" rid="CR458">458</xref></sup> T cells in previously treated patients also recognize type-2 epitopes poorly compared to patients without TB. The type 2 epitopes in the human gut are associated with <italic toggle="yes">mycobacteria</italic>. Multi-year trials of anti-TB treatment can contribute to a deeper understanding of the importance of microbiota in the progression of TB. A combination of anti-TB anti-biotics and host modifiers that target the host pathway may reduce treatment time and severity of TB, as well as the risk of reinfection. Emerging studies on host-pathogen correlations, host immunology, and host-targeted therapies indicate that this approach may be beneficial in the treatment of TB.<sup><xref ref-type="bibr" rid="CR459">459</xref></sup></p></sec></sec></sec><sec id="Sec36"><title>Mechanisms of action in pharmacomicrobiomics</title><p id="Par69">Pharmacomicrobiomics is an emerging area that aims to comprehend the intricate relationships among drugs, microbiota, and host physiology.<sup><xref ref-type="bibr" rid="CR460">460</xref></sup> Understanding the multiple mechanisms of action in pharmacomicrobiomics is critical to the advancement of effective and safe treatment strategies that take into account the multiple mechanisms of interaction between IVDR and microbiota.</p><sec id="Sec37"><title>Mechanisms of microbiota influence on IVDR</title><p id="Par70">Gut microbiota is known to affect the effectiveness and acceptability of drugs by enzymatic modification structure and alteration of bioactivity or toxicity. A list of specific families of enzymes encoded by the microbiota and their effects on drugs is presented in Table <xref rid="Tab4" ref-type="table">4</xref>. Conclusively, gut microbiota can impact IVDR in several ways, including (1) Alteration of drug metabolism: Microbiota can influence the activities of enzymes that metabolize drugs within the body, which can influence the efficacy and side effects of drugs.<sup><xref ref-type="bibr" rid="CR461">461</xref>,<xref ref-type="bibr" rid="CR462">462</xref></sup> For instance, the microbiota can produce beta-lactamases that break down beta-lactam anti-biotics, rendering them ineffective.<sup><xref ref-type="bibr" rid="CR463">463</xref>&#8211;<xref ref-type="bibr" rid="CR466">466</xref></sup> (2) Induction of drug resistance: Microbiota can develop resistance to drugs over time, making them less effective in treating infections.<sup><xref ref-type="bibr" rid="CR282">282</xref>,<xref ref-type="bibr" rid="CR467">467</xref></sup> This resistance may be due to mutations in the DNA of microbiota or the acquisition of resistance genes from others. (3) Modification of drug targets: Microbiota can modify the drug targets in the body, making them less susceptible to the drug&#8217;s effects. For example, the microbiota can modify the target site of fluoroquinolone anti-biotics, thereby reducing their ability to bind and inhibit the enzyme.<sup><xref ref-type="bibr" rid="CR468">468</xref>,<xref ref-type="bibr" rid="CR469">469</xref></sup> (4) Interaction with PK: Microbiota can also impact PK, which can affect drug efficacy and safety. For example, gut microbiota can modify the ADME of drugs, altering their therapeutic effects and toxicity.<sup><xref ref-type="bibr" rid="CR470">470</xref></sup> (5) Destruction of the host microbiota: The use of anti-biotics can interfere with the natural ecosystem of the host&#8217;s microbiota, leading to the overgrowth of pathogenic species (e.g., <italic toggle="yes">C. difficile</italic>).<sup><xref ref-type="bibr" rid="CR471">471</xref>&#8211;<xref ref-type="bibr" rid="CR473">473</xref></sup> This can cause infections and other ADRs, which can impact drug safety. (6) Modulation of host immune response: Gut microbiota can modulate immune function in the host, which may influence the activity and toxicity of drugs that target the immune system.<sup><xref ref-type="bibr" rid="CR474">474</xref></sup> For example, gut microbiota can modulate the effectiveness of ICIs in tumor treatment by modulating the host immune response.<sup><xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR475">475</xref>&#8211;<xref ref-type="bibr" rid="CR478">478</xref></sup> (7) Regulation of gut barrier function: Gut microbiota may influence the integrity of the gut barrier, thereby affecting drug absorption and gut-host interactions.<sup><xref ref-type="bibr" rid="CR479">479</xref>,<xref ref-type="bibr" rid="CR480">480</xref></sup> For example, gut microbiota can regulate the level of tight junction protein expression in the intestine, thereby affecting drug absorption.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Some enzyme families encoded in gut microbiota and their impact on drugs</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Microbiota enzyme</th><th colspan="1" rowspan="1">Effects on drugs</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Beta-glucosidases</td><td colspan="1" rowspan="1">These enzymes hydrolyze sugar moiety that are often present in plant glucosides.</td></tr><tr><td colspan="1" rowspan="1">Beta-glucuronidases</td><td colspan="1" rowspan="1">These enzymes hydrolyze glucuronic acid, which are often formed during drug metabolism in the liver. Cleavage by beta-glucuronidases can increase drug reabsorption in the gut, leading to higher systemic exposure and potentially increasing the risk of toxicity.</td></tr><tr><td colspan="1" rowspan="1">Beta-lactamases</td><td colspan="1" rowspan="1">These enzymes break down beta-lactam anti-biotics, rendering them ineffective.</td></tr><tr><td colspan="1" rowspan="1">Sulfatases</td><td colspan="1" rowspan="1">These enzymes cleave sulfate groups of phase II host metabolism.</td></tr><tr><td colspan="1" rowspan="1">Azoreductases</td><td colspan="1" rowspan="1">These enzymes can reduce azo bonds that are present in some drugs.</td></tr><tr><td colspan="1" rowspan="1">Nitroreductases</td><td colspan="1" rowspan="1">These enzymes can reduce nitro groups that are present in some drugs, resulting in more toxic or inactive metabolites.</td></tr><tr><td colspan="1" rowspan="1">Proteases</td><td colspan="1" rowspan="1">These enzymes can cleave proteins and hydrolyze polypeptide chains.</td></tr><tr><td colspan="1" rowspan="1">Glycosidases</td><td colspan="1" rowspan="1">These enzymes can reduce the polarity of molecules.</td></tr><tr><td colspan="1" rowspan="1">C&#8211;S beta-lyases</td><td colspan="1" rowspan="1">These enzymes can cleave C-S bonds in drugs, generating ammonia for bacterial growth.</td></tr><tr><td colspan="1" rowspan="1">Cytidine deaminase</td><td colspan="1" rowspan="1">These enzymes catalyze conversion of cytidine to uridine by the of an amino group (-NH2) from the tidine molecule.</td></tr><tr><td colspan="1" rowspan="1">Tyrosine decarboxylases</td><td colspan="1" rowspan="1">These enzymes catalyze the conversion of the amino acid tyrosine to the biogenic amine tyramine by removing a carboxyl group (-COOH) from tyrosine.</td></tr><tr><td colspan="1" rowspan="1">Transferases</td><td colspan="1" rowspan="1">These enzymes can transfer functional groups, such as methyl or acetyl groups, to drugs, impacting their activity and toxicity.</td></tr></tbody></table></table-wrap></p><p id="Par71">In summary, microbiota can impact IVDR through a variety of complex and multifaceted mechanisms. A deeper insight into such relationships may help in the discovery of more beneficial and safer drugs, as well as in the management of IVDR.</p></sec><sec id="Sec38"><title>Mechanisms for drug-altered gut microbiota</title><p id="Par72">There has been an increasing emphasis on the influence of drugs on gut microbiota and its influence on human healthcare. In a significant and comprehensive study, the authors evaluated the anti-microbial properties of more than 1000 drugs, among them 835 targeted agents that affect human cells.<sup><xref ref-type="bibr" rid="CR406">406</xref></sup> Of these, 24% showed anti-bacterial effects, influencing the proliferation of a minimum of 50% of bacterial strains tested. To sum up, several mechanisms are involved by which drugs affect gut microbiota, (1) Direct anti-biotic effects: Anti-biotics can selectively kill off certain microbiota, including both harmful and beneficial species.<sup><xref ref-type="bibr" rid="CR392">392</xref>,<xref ref-type="bibr" rid="CR481">481</xref>,<xref ref-type="bibr" rid="CR482">482</xref></sup> This can lead to imbalances in gut microbiota, which can have negative effects on human health. (2) Altered gut motility: The speed at which food passes through the intestine affects the proliferation and function of gut microbiota. Certain drugs, such as opioid painkillers, can slow down gut motility, which can lead to overgrowth of harmful bacteria.<sup><xref ref-type="bibr" rid="CR483">483</xref>,<xref ref-type="bibr" rid="CR484">484</xref></sup> This may result in gastrointestinal symptoms like constipation and bloating, and in some cases can cause infections (e.g., <italic toggle="yes">C. difficile</italic>).<sup><xref ref-type="bibr" rid="CR485">485</xref></sup> (3) Modulation of immune function: Gut microbiota has a key function in modulating gut immunity. Several drugs, such as ICIs, can affect gut immunity which in turn can affect gut microbiota.<sup><xref ref-type="bibr" rid="CR486">486</xref></sup> For example, ICIs can decrease gut inflammation, which can lead to alterations in gut microbiota.<sup><xref ref-type="bibr" rid="CR487">487</xref></sup> (4) Changes in pH: The pH value in the intestine affects the growth and survival of different types of bacteria. Some drugs, such as PPIs used to treat acid reflux, can change the pH value of the gut, which affects the proliferation of different microbiota, thereby affecting the overall composition of gut microbiota.<sup><xref ref-type="bibr" rid="CR404">404</xref></sup> (5) Interference with microbial metabolism: Gut microbiota has a vital function in metabolizing compounds in the gut. Several drugs, such as NSAIDs, can interfere with microbial metabolism, which may have an effect on gut microbiota. In particular, NSAIDs can interfere with gut microbiota metabolism of BAs, leading to changes in gut microbial community.<sup><xref ref-type="bibr" rid="CR488">488</xref></sup> (6) Dietary changes: Certain drugs, such as laxatives or anti-diarrheal agents, can change the dietary environment in the gut.<sup><xref ref-type="bibr" rid="CR489">489</xref>,<xref ref-type="bibr" rid="CR490">490</xref></sup> This may influence gut microbiota by changing the availability of nutrients and other compounds that gut microbiota use to grow and survive.</p><p id="Par73">It&#8217;s important to note that a drug&#8217;s impact on gut microbiota can be either positive or negative. For example, certain probiotics or prebiotics are able to actively regulate gut microbiota, which may have a positive effect on the individual&#8217;s well-being.<sup><xref ref-type="bibr" rid="CR491">491</xref></sup> However, taking anti-biotics or other drugs that negatively affect gut microbiota can result in dysbiosis, which negatively affects human health. Therefore, it is essential to carefully evaluate the potential impact of drugs on gut microbiota and to develop personalized drug treatments that take into account an individual&#8217;s gut microbiota composition and function.</p></sec></sec><sec id="Sec39"><title>Challenges and strategies</title><p id="Par74">This review section identifies challenges and offers strategies for professionals, clinicians, and scientists involved in microbiota research and its influence on human well-being.</p><sec id="Sec40"><title>Challenges</title><p id="Par75">Pharmacomicrobiomics is a fast-developing discipline that aims to comprehend the intricate interaction between gut microbiota and drug response. While there have been significant advancements in this area, several challenges remain: (1) Lack of standardized methodologies: Currently, there is a lack of standardization in sample collection, sequencing, and data analysis in pharmacomicrobiomics studies. This creates a challenge in comparing findings among different studies and hinders the development of guidelines for clinical practice. (2) Complexity of gut microbiota: Gut microbiota is an intricate and ever-changing ecosystem that is impacted by various elements, including diet, lifestyle, and host genetics. It is difficult to disentangle the effects of these factors from drug-induced changes in the microbiota. (3) IVDR: There is significant inter-individual variability in gut microbiota, which can impact drug-microbiota interactions. (4) Limited understanding of mechanisms: Despite increasing evidence of drug-microbiota interactions, there is still a lack of comprehensive understanding regarding the mechanisms behind these interactions. It is also unclear how these interactions vary across different drugs and different patients. (5) Clinical translation: Although the potential clinical applications of pharmacomicrobiomics are promising, there are still many obstacles to be overcome before these findings can be translated into clinical practice. For example, the development of microbiota-based biomarkers for drug response will require large-scale validation studies and regulatory approval. (6) Ethical considerations: As with any field of personalized medicine, there are ethical considerations when using microbiota data to make clinical decisions. These include issues around privacy, data sharing, and potential discrimination based on microbiota characteristics. (7) Sample size: Numerous pharmacomicrobiomics studies often have limited sample sizes, potentially restricting their statistical power and the ability to generalize findings. Additional research of greater scale is required to confirm and expand upon preliminary results. (8) Diversity of populations: Most studies in pharmacomicrobiomics have been conducted on Western populations, and there is a lack of diversity in terms of ethnicity, geography, and lifestyle factors. This limits our understanding of how drug-microbiota interactions may vary across different populations. (9) Confounding factors: Various elements, such as diet, age, sex, and environmental exposures, can have an impact on gut microbiota and confuse the interpretation of the results, making it challenging to distinguish the effects of the drug from other factors.</p><p id="Par76">Overall, addressing these challenges will require collaboration between researchers, clinicians, and industry partners to develop standardized methodologies, improve our understanding of the mechanisms underlying drug-microbiota interactions, and ensure that findings are translated into safe and effective clinical practice.</p></sec><sec id="Sec41"><title>Strategies</title><p id="Par77">In light of these facts, to overcome these challenges, several strategies have been proposed.</p><sec id="Sec42"><title>Open-access curated database</title><p id="Par78">To advance research in the field, it is important to provide practitioners and researchers with a ready-made database of selected knowledge. Current web resources are highlighted in Table <xref rid="Tab5" ref-type="table">5</xref>. However, such databases are scarce, which can lead to valuable time being wasted and hinder research efforts. Therefore, it is necessary to establish new databases or contribute to existing ones as a member of a volunteer team, a crowdsourcing participant, or a crowdfunding supporter. In particular, it is important to link the microbiota reference genome databases, the microbiota-diseases relationships databases, and the microbiota-drug association prediction databases to the pharmacomicrobiomic data resource.<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Database for pharmacomicrobiomics studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Category</th><th colspan="1" rowspan="1">Abbreviations</th><th colspan="1" rowspan="1">PMID</th></tr></thead><tbody><tr><td rowspan="7" colspan="1">Microbiota reference genome</td><td colspan="1" rowspan="1">SILVA</td><td colspan="1" rowspan="1">17947321</td></tr><tr><td colspan="1" rowspan="1">RDP</td><td colspan="1" rowspan="1">24288368</td></tr><tr><td colspan="1" rowspan="1">NCBI-RefSeq</td><td colspan="1" rowspan="1">24316578</td></tr><tr><td colspan="1" rowspan="1">MG-RAST</td><td colspan="1" rowspan="1">26656948</td></tr><tr><td colspan="1" rowspan="1">MGnify</td><td colspan="1" rowspan="1">31696235</td></tr><tr><td colspan="1" rowspan="1">IGC</td><td colspan="1" rowspan="1">24997786</td></tr><tr><td colspan="1" rowspan="1">UHGG</td><td colspan="1" rowspan="1">32690973</td></tr><tr><td rowspan="6" colspan="1">Microbiota and disease relationships</td><td colspan="1" rowspan="1">HMDAD</td><td colspan="1" rowspan="1">26883326</td></tr><tr><td colspan="1" rowspan="1">Disbiome</td><td colspan="1" rowspan="1">29866037</td></tr><tr><td colspan="1" rowspan="1">gutMDisorder</td><td colspan="1" rowspan="1">31584099</td></tr><tr><td colspan="1" rowspan="1">KATZHMDA</td><td colspan="1" rowspan="1">28025197</td></tr><tr><td colspan="1" rowspan="1">BMCMDA</td><td colspan="1" rowspan="1">30367598</td></tr><tr><td colspan="1" rowspan="1">LGRSH</td><td colspan="1" rowspan="1">32351464</td></tr><tr><td rowspan="4" colspan="1">Microbiota-drugs associations prediction</td><td colspan="1" rowspan="1">PharmacoMicrobiomics database</td><td colspan="1" rowspan="1">29652572</td></tr><tr><td colspan="1" rowspan="1">MDAD</td><td colspan="1" rowspan="1">30581775</td></tr><tr><td colspan="1" rowspan="1">RapidAIM</td><td colspan="1" rowspan="1">32160905</td></tr><tr><td colspan="1" rowspan="1">GCNMDA</td><td colspan="1" rowspan="1">32597948</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec43"><title>Techniques and approaches</title><p id="Par79">The methods for investigating pharmacomicrobiomics are identical to the overall techniques employed to decipher the microbiota at various levels, including its taxonomic and genomic makeup, gene inventory, functional capacity, the tangible manifestation of its genes (at the RNA or protein level), and ultimately, its true functionality is indicated by the amalgamation of metabolites derived from the microbiota. Therefore, the analysis of drug-microbiota interactions can be effectively conducted using various techniques including amplicon sequencing (<italic toggle="yes">16</italic>&#8201;<italic toggle="yes">S</italic> or <italic toggle="yes">18</italic>&#8201;<italic toggle="yes">S</italic> rRNA subunit), shotgun microbiota sequencing or metagenomics, metatranscriptomics, metaproteomics, as well as metabolomics and metabonomics, as listed in Fig. <xref rid="Fig5" ref-type="fig">5</xref>.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Multi-omics strategies facilitating pharmacomicrobiomics towards human precision medicine</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e3765" position="float" orientation="portrait" xlink:href="41392_2023_1619_Fig5_HTML.jpg"/></fig></p><p id="Par80">These high-throughput data need to be modeled by artificial intelligence (AI) algorithms using advanced computational techniques.<sup><xref ref-type="bibr" rid="CR492">492</xref></sup> Machine learning is a sub-field of AI in which machines can acquire knowledge from data without the need for explicit programming.<sup><xref ref-type="bibr" rid="CR199">199</xref></sup> Machine learning includes both supervised and unsupervised algorithms. Classification or prediction tasks often use supervised algorithms, while clustering tasks often use unsupervised algorithms to group data based on similarity. The application of these methods could effectively address the needs of clustering and predicting patients, as well as discovering new biomarkers.<sup><xref ref-type="bibr" rid="CR493">493</xref></sup> The integrated analysis of multi-omics data has been enhanced by advances in machine learning. These approaches consist mainly of concatenation, modeling, and transformation-based techniques.</p></sec><sec id="Sec44"><title>Predictive model and software engineering</title><p id="Par81">It is essential to develop predictive models and software that simulate drug-microbiota interactions to reduce research time and costs. A major limitation in developing such models is the need for aggregated evidence to drive reliable assumptions that can be applied for testing and validation. By combining chemoinformatics with genomic and proteomic similarities, new interactions between drugs and various microbial enzymes can be predicted. This would significantly facilitate the establishment of predictive models for drug-microbiota interactions.</p></sec><sec id="Sec45"><title>Prebiotics and probiotics</title><p id="Par82">Prebiotics, which are indigestible components of food, stimulate the development of beneficial microbiota in the gut, while probiotics are live microorganisms that can be beneficial to health when ingested in moderation.<sup><xref ref-type="bibr" rid="CR494">494</xref></sup> Both prebiotics and probiotics have the potential to modify the composition and activity of gut microbiota and potentially enhance drug efficacy and reduce ADRs.<sup><xref ref-type="bibr" rid="CR495">495</xref></sup> Several recognized effects include: anti-bacterial effects by modulating pathogens&#8217; genetic code composition, inhibiting competition for pathogens&#8217; binding domains, inhibiting pathogens&#8217; virus code or proteome composition, and stimulating the immune response by increasing anti-inflammatory cytokines and rescuing and modulating pro-inflammatory compounds.<sup><xref ref-type="bibr" rid="CR495">495</xref></sup></p></sec><sec id="Sec46"><title>Fecal microbiota transplantation</title><p id="Par83">FMT involves the transfer of fecal material from healthy donors to patients to restore gut microbiota.<sup><xref ref-type="bibr" rid="CR496">496</xref></sup> Initially, FMT was developed to treat <italic toggle="yes">C. difficile</italic> infection, more recently it has been highlighted as a promising approach to treating some complex digestive diseases.<sup><xref ref-type="bibr" rid="CR497">497</xref>,<xref ref-type="bibr" rid="CR498">498</xref></sup> In addition to providing a diverse, stable gut microbiota, FMT also provides AAs, SCFAs, and BAs that assist in restoring normal gut physiological activity.<sup><xref ref-type="bibr" rid="CR499">499</xref></sup> Furthermore, the donor microbiota and their related anti-bacterial products, like adhesins, may be able to competitively match the site, inhibiting pathogenic microbiota colonization of the gut and preventing damage, which is a key action of FMT treatment.<sup><xref ref-type="bibr" rid="CR500">500</xref></sup></p></sec><sec id="Sec47"><title>Bacteriophage therapy</title><p id="Par84">Bacteriophage therapy, a practice dating back to the 1940s, utilizes naturally-occurring viruses to combat bacterial infections but has recently been enhanced with bio-engineered phages and associated lysing proteins to fight multi-drug resistant microbiota.<sup><xref ref-type="bibr" rid="CR501">501</xref></sup> Phages infect and lyse bacteria, and have several advantages, such as minimal harm to humans, breakdown of biofilms, specificity to certain hosts, and self-replication.<sup><xref ref-type="bibr" rid="CR502">502</xref>&#8211;<xref ref-type="bibr" rid="CR504">504</xref></sup> Additionally, phages play a crucial role in ecosystem regulation by controlling microbiota.<sup><xref ref-type="bibr" rid="CR505">505</xref>&#8211;<xref ref-type="bibr" rid="CR507">507</xref></sup> Phage therapy involves the use of &#8216;phage cocktail&#8217;, a mixture of lytic phages proven effective against the targeted pathogen.<sup><xref ref-type="bibr" rid="CR502">502</xref></sup> However, there are challenges associated with the therapy, including the need to selectively induce lysogenic phages, persistence in the gut, and immune responses.<sup><xref ref-type="bibr" rid="CR508">508</xref>,<xref ref-type="bibr" rid="CR509">509</xref></sup> Phage therapy must also avoid interfering with standard microbiota function and creating selective pressure on non-target microbiota, which can lead to resistant offspring and disrupt beneficial bacteria and host adaptation mechanisms.<sup><xref ref-type="bibr" rid="CR510">510</xref></sup> The field is still expanding and requires further exploration.</p></sec></sec></sec><sec id="Sec48"><title>Conclusions and perspectives</title><sec id="Sec49"><title>Microbiota biomarkers as promising targets in precision medicine</title><p id="Par85">Human microbiota are valuable resources for identifying targets associated with various illnesses and IVDR. These biomarkers could potentially be used as effective replacements for procedures such as biomicroscopy and endoscopy, making them a promising tool for diagnosis and prediction.<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR511">511</xref></sup> The microbiota releases substances and metabolites that can influence the occurrence, development, and outcome of disease, which highlights the value of microbiota biomarkers for individualized treatment.<sup><xref ref-type="bibr" rid="CR512">512</xref>,<xref ref-type="bibr" rid="CR513">513</xref></sup> However, the inter-individual variability of the human microbiota, the emergence of new multi-drug resistance microbiota strains, and different microbiota drugs modify mechanisms hamper precision medicine. Nevertheless, precision medicine still holds the ideal opportunity for future theranostics, with a full understanding of the impact of the microbiota on IVDR allowing stratifying patients on the basis of identified biomarkers, microbiota types, and metabotypes.<sup><xref ref-type="bibr" rid="CR514">514</xref>,<xref ref-type="bibr" rid="CR515">515</xref></sup></p></sec><sec id="Sec50"><title>Multi-omics enabling pharmacomicrobiomics</title><p id="Par86">The integration of multiple high-throughput multi-omics datasets can provide a comprehensive profile of IVDR, both at a populational and single-cell level. The database includes five modules: amplicon sequencing (<italic toggle="yes">16</italic>&#8201;<italic toggle="yes">S</italic> or <italic toggle="yes">18</italic>&#8201;<italic toggle="yes">S</italic> rRNA subunit), metagenomics, metatranscriptomics, metaproteomics, and Metabolomics/Metabonomics (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). This approach allows the investigation into the genetic variation and the regulation of molecular pathways in diseases and facilitates novel therapeutic strategies. To support extensive IVDR research, an open and integrated database, called the IVDR Atlas, has been established. These modules provide researchers with the opportunity to explore extensive gene variation and modulation datasets generated by multi-omics sequencing.</p></sec><sec id="Sec51"><title>From the lab to the clinical practice</title><p id="Par87">Hopefully, the nascent discipline of pharmacomicrobiomics, which involves the study of drug-microbiota and drug-microenzyme interactions, is gaining traction due to the accessibility of on-line information, biomarker identification, and advances in methods, models, and software. The continuation of this pattern is anticipated through increased systematic screening, which will aid in the creation of new clinical practice recommendations and the implementation of existing guidelines. These developments, which are encouraged by the current advancements in technology, contribute to a growing tendency towards &#8216;precision medicine&#8217; and the &#8216;One Health approach&#8217;. It is anticipated that the inclusion of microbiota typing and pharmacomicrobiomic testing in treatment protocols and drug labels will become customary, although the timing of this paradigm change is difficult to forecast. However, it is clear that the field is moving towards precision medicine, which is increasingly favored from an experimental, ethical, and economic point of view.</p><p id="Par88">If you have reached this point, we cordially invite you to participate in these endeavors. To achieve the dream of developing precision medicine based on a thorough understanding of the human microbiota and a diverse set of tools for manipulating it, a collaborative effort across multiple traditional disciplines is essential. However, the challenges in this field are enormous, and our current knowledge is limited. Therefore, without a significant increase in research efforts, we will not be able to realize the whole value of pharmacomicrobiomic.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>We thank the other members of the Department of Clinical Pharmacology (Xiangya Hospital, Central South University) for pivotal discussions and critical feedback on the manuscript.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>H.Z. and W.Z.: conceptualization and supervision. Q.Z.: writing the original draft and drawing the diagrams. Y.C.: review and revision. W.H.: modification. All authors have read and approved the article.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the National Key Research and Development Program (No. 2021YFA1301200), the National Scientific Foundation of China (No. 82373961, 82073945, 82373960, and 81974513), the Natural Science Foundation of Hunan Province (grant 2022JJ80113, 2022JJ80097).</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par89">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spear</surname><given-names>BB</given-names></name><name name-style="western"><surname>Heath-Chiozzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Huff</surname><given-names>J</given-names></name></person-group><article-title>Clinical application of pharmacogenetics</article-title><source>Trends Mol. Med.</source><year>2001</year><volume>7</volume><fpage>201</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/S1471-4914(01)01986-4</pub-id><pub-id pub-id-type="pmid">11325631</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazarou</surname><given-names>J</given-names></name><name name-style="western"><surname>Pomeranz</surname><given-names>BH</given-names></name><name name-style="western"><surname>Corey</surname><given-names>PN</given-names></name></person-group><article-title>Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies</article-title><source>JAMA</source><year>1998</year><volume>279</volume><fpage>1200</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1001/jama.279.15.1200</pub-id><pub-id pub-id-type="pmid">9555760</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pirmohamed</surname><given-names>M</given-names></name><etal/></person-group><article-title>Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients</article-title><source>BMJ</source><year>2004</year><volume>329</volume><fpage>15</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1136/bmj.329.7456.15</pub-id><pub-id pub-id-type="pmid">15231615</pub-id><pub-id pub-id-type="pmcid">PMC443443</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feitosa Ramos</surname><given-names>S</given-names></name><etal/></person-group><article-title>Adverse drug reactions to anti-infectives in hospitalized children: a multicenter study in Brazil</article-title><source>J. Pediatr. Infect. Dis. Soc.</source><year>2023</year><volume>12</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1093/jpids/piac121</pub-id><pub-id pub-id-type="pmid">36461778</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Adverse drug reactions and correlations with drug-drug interactions: a retrospective study of reports from 2011 to 2020</article-title><source>Front. Pharm.</source><year>2022</year><volume>13</volume><fpage>923939</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.923939</pub-id><pub-id pub-id-type="pmcid">PMC9483724</pub-id><pub-id pub-id-type="pmid">36133826</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Emergency hospitalizations for adverse drug events in China: clinical pharmacists&#8217; approach to assessment and categorization</article-title><source>Pharmacoepidemiol. Drug Saf.</source><year>2021</year><volume>30</volume><fpage>636</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1002/pds.5215</pub-id><pub-id pub-id-type="pmid">33630347</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konig</surname><given-names>IR</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>O</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>G</given-names></name><name name-style="western"><surname>von Mutius</surname><given-names>E</given-names></name><name name-style="western"><surname>Kopp</surname><given-names>MV</given-names></name></person-group><article-title>What is precision medicine?</article-title><source>Eur. Respir. J.</source><year>2017</year><volume>50</volume><fpage>1700391</fpage><pub-id pub-id-type="doi">10.1183/13993003.00391-2017</pub-id><pub-id pub-id-type="pmid">29051268</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramaswami</surname><given-names>R</given-names></name><name name-style="western"><surname>Bayer</surname><given-names>R</given-names></name><name name-style="western"><surname>Galea</surname><given-names>S</given-names></name></person-group><article-title>Precision medicine from a public health perspective</article-title><source>Annu. Rev. Public Health</source><year>2018</year><volume>39</volume><fpage>153</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1146/annurev-publhealth-040617-014158</pub-id><pub-id pub-id-type="pmid">29166244</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>RB</given-names></name><name name-style="western"><surname>Groop</surname><given-names>L</given-names></name></person-group><article-title>Precision medicine in type 2 diabetes</article-title><source>J. Intern. Med.</source><year>2019</year><volume>285</volume><fpage>40</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1111/joim.12859</pub-id><pub-id pub-id-type="pmid">30403316</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buitelaar</surname><given-names>J</given-names></name><etal/></person-group><article-title>Toward precision medicine in ADHD</article-title><source>Front. Behav. Neurosci.</source><year>2022</year><volume>16</volume><fpage>900981</fpage><pub-id pub-id-type="doi">10.3389/fnbeh.2022.900981</pub-id><pub-id pub-id-type="pmid">35874653</pub-id><pub-id pub-id-type="pmcid">PMC9299434</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>SQ</given-names></name></person-group><article-title>Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine</article-title><source>Genom. Proteom. Bioinforma.</source><year>2016</year><volume>14</volume><fpage>298</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.gpb.2016.03.008</pub-id><pub-id pub-id-type="pmcid">PMC5093856</pub-id><pub-id pub-id-type="pmid">27729266</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clarke</surname><given-names>JD</given-names></name><name name-style="western"><surname>Cherrington</surname><given-names>NJ</given-names></name></person-group><article-title>Nonalcoholic steatohepatitis in precision medicine: unraveling the factors that contribute to individual variability</article-title><source>Pharm. Ther.</source><year>2015</year><volume>151</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2015.03.005</pub-id><pub-id pub-id-type="pmcid">PMC4457694</pub-id><pub-id pub-id-type="pmid">25805597</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tremmel</surname><given-names>R</given-names></name><name name-style="western"><surname>Schaeffeler</surname><given-names>E</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>M</given-names></name><name name-style="western"><surname>Lauschke</surname><given-names>VM</given-names></name></person-group><article-title>Challenges and opportunities associated with rare-variant pharmacogenomics</article-title><source>Trends Pharm. Sci.</source><year>2022</year><volume>43</volume><fpage>852</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2022.07.002</pub-id><pub-id pub-id-type="pmid">36008164</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>WC</given-names></name><name name-style="western"><surname>Tanoshima</surname><given-names>R</given-names></name><name name-style="western"><surname>Ross</surname><given-names>CJD</given-names></name><name name-style="western"><surname>Carleton</surname><given-names>BC</given-names></name></person-group><article-title>Challenges and opportunities in implementing pharmacogenetic testing in clinical settings</article-title><source>Annu. Rev. Pharm. Toxicol.</source><year>2021</year><volume>61</volume><fpage>65</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-030920-025745</pub-id><pub-id pub-id-type="pmid">33006916</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Cavallari</surname><given-names>LH</given-names></name></person-group><article-title>Pharmacogenetics and cardiovascular disease-implications for personalized medicine</article-title><source>Pharm. Rev.</source><year>2013</year><volume>65</volume><fpage>987</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1124/pr.112.007252</pub-id><pub-id pub-id-type="pmid">23686351</pub-id><pub-id pub-id-type="pmcid">PMC3698938</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Limdi</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>3827</fpage><lpage>3834</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-12-255992</pub-id><pub-id pub-id-type="pmid">20203262</pub-id><pub-id pub-id-type="pmcid">PMC2865873</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children&#8217;s Oncology Group</article-title><source>Blood</source><year>2008</year><volume>111</volume><fpage>2984</fpage><lpage>2990</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-09-114082</pub-id><pub-id pub-id-type="pmid">18182569</pub-id><pub-id pub-id-type="pmcid">PMC2265447</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roses</surname><given-names>AD</given-names></name></person-group><article-title>Pharmacogenetics in drug discovery and development: a translational perspective</article-title><source>Nat. Rev. Drug Discov.</source><year>2008</year><volume>7</volume><fpage>807</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1038/nrd2593</pub-id><pub-id pub-id-type="pmid">18806753</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swen</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study</article-title><source>Lancet</source><year>2023</year><volume>401</volume><fpage>347</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)01841-4</pub-id><pub-id pub-id-type="pmid">36739136</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haidar</surname><given-names>CE</given-names></name><name name-style="western"><surname>Crews</surname><given-names>KR</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Relling</surname><given-names>MV</given-names></name><name name-style="western"><surname>Caudle</surname><given-names>KE</given-names></name></person-group><article-title>Advancing pharmacogenomics from single-gene to preemptive testing</article-title><source>Annu Rev. Genom. Hum. Genet</source><year>2022</year><volume>23</volume><fpage>449</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1146/annurev-genom-111621-102737</pub-id><pub-id pub-id-type="pmcid">PMC9483991</pub-id><pub-id pub-id-type="pmid">35537468</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavertu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pharmacogenomics and big genomic data: from lab to clinic and back again</article-title><source>Hum. Mol. Genet</source><year>2018</year><volume>27</volume><fpage>R72</fpage><lpage>R78</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy116</pub-id><pub-id pub-id-type="pmid">29635477</pub-id><pub-id pub-id-type="pmcid">PMC5946941</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinshilboum</surname><given-names>RM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Pharmacogenomics: precision medicine and drug response</article-title><source>Mayo Clin. Proc.</source><year>2017</year><volume>92</volume><fpage>1711</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2017.09.001</pub-id><pub-id pub-id-type="pmid">29101939</pub-id><pub-id pub-id-type="pmcid">PMC5682947</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roden</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Pharmacogenomics: challenges and opportunities</article-title><source>Ann. Intern. Med.</source><year>2006</year><volume>145</volume><fpage>749</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-145-10-200611210-00007</pub-id><pub-id pub-id-type="pmid">17116919</pub-id><pub-id pub-id-type="pmcid">PMC5006954</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eichelbaum</surname><given-names>M</given-names></name><name name-style="western"><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Evans</surname><given-names>WE</given-names></name></person-group><article-title>Pharmacogenomics and individualized drug therapy</article-title><source>Annu. Rev. Med.</source><year>2006</year><volume>57</volume><fpage>119</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1146/annurev.med.56.082103.104724</pub-id><pub-id pub-id-type="pmid">16409140</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>WE</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JA</given-names></name></person-group><article-title>Pharmacogenomics: the inherited basis for interindividual differences in drug response</article-title><source>Annu Rev. Genom. Hum. Genet</source><year>2001</year><volume>2</volume><fpage>9</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1146/annurev.genom.2.1.9</pub-id><pub-id pub-id-type="pmid">11701642</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pirmohamed</surname><given-names>M</given-names></name></person-group><article-title>Pharmacogenomics: current status and future perspectives</article-title><source>Nat. Rev. Genet</source><year>2023</year><volume>24</volume><fpage>350</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1038/s41576-022-00572-8</pub-id><pub-id pub-id-type="pmid">36707729</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalow</surname><given-names>W</given-names></name><name name-style="western"><surname>Tang</surname><given-names>BK</given-names></name><name name-style="western"><surname>Endrenyi</surname><given-names>L</given-names></name></person-group><article-title>Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research</article-title><source>Pharmacogenetics</source><year>1998</year><volume>8</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1097/00008571-199808000-00001</pub-id><pub-id pub-id-type="pmid">9731714</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindell</surname><given-names>AE</given-names></name><name name-style="western"><surname>Zimmermann-Kogadeeva</surname><given-names>M</given-names></name><name name-style="western"><surname>Patil</surname><given-names>KR</given-names></name></person-group><article-title>Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota</article-title><source>Nat. Rev. Microbiol.</source><year>2022</year><volume>20</volume><fpage>431</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00681-5</pub-id><pub-id pub-id-type="pmid">35102308</pub-id><pub-id pub-id-type="pmcid">PMC7615390</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>P</given-names></name><etal/></person-group><article-title>Gut microbiome interventions in human health and diseases</article-title><source>Med. Res. Rev.</source><year>2019</year><volume>39</volume><fpage>2286</fpage><lpage>2313</lpage><pub-id pub-id-type="doi">10.1002/med.21584</pub-id><pub-id pub-id-type="pmid">30994937</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>K</given-names></name><etal/></person-group><article-title>Microbiota in health and diseases</article-title><source>Signal Transduct. Target Ther.</source><year>2022</year><volume>7</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-00974-4</pub-id><pub-id pub-id-type="pmid">35461318</pub-id><pub-id pub-id-type="pmcid">PMC9034083</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steiner</surname><given-names>HE</given-names></name><etal/></person-group><article-title>Role of the gut microbiome in cardiovascular drug response: the potential for clinical application</article-title><source>Pharmacotherapy</source><year>2022</year><volume>42</volume><fpage>165</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1002/phar.2650</pub-id><pub-id pub-id-type="pmid">34820870</pub-id><pub-id pub-id-type="pmcid">PMC10321137</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>CB</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>YL</given-names></name><name name-style="western"><surname>Fang</surname><given-names>JY</given-names></name></person-group><article-title>Gut microbiota in cancer immune response and immunotherapy</article-title><source>Trends Cancer</source><year>2021</year><volume>7</volume><fpage>647</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2021.01.010</pub-id><pub-id pub-id-type="pmid">33674230</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roviello</surname><given-names>G</given-names></name><name name-style="western"><surname>Iannone</surname><given-names>LF</given-names></name><name name-style="western"><surname>Bersanelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Mini</surname><given-names>E</given-names></name><name name-style="western"><surname>Catalano</surname><given-names>M</given-names></name></person-group><article-title>The gut microbiome and efficacy of cancer immunotherapy</article-title><source>Pharm. Ther.</source><year>2022</year><volume>231</volume><fpage>107973</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107973</pub-id><pub-id pub-id-type="pmid">34453999</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>535</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01695-5</pub-id><pub-id pub-id-type="pmid">35228751</pub-id><pub-id pub-id-type="pmcid">PMC8938272</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scepanovic</surname><given-names>P</given-names></name><etal/></person-group><article-title>A comprehensive assessment of demographic, environmental, and host genetic associations with gut microbiome diversity in healthy individuals</article-title><source>Microbiome</source><year>2019</year><volume>7</volume><fpage>130</fpage><pub-id pub-id-type="doi">10.1186/s40168-019-0747-x</pub-id><pub-id pub-id-type="pmid">31519223</pub-id><pub-id pub-id-type="pmcid">PMC6744716</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>P</given-names></name><etal/></person-group><article-title>Gut microbial signatures can discriminate unipolar from bipolar depression</article-title><source>Adv. Sci. (Weinh.)</source><year>2020</year><volume>7</volume><fpage>1902862</fpage><pub-id pub-id-type="pmid">32274300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.201902862</pub-id><pub-id pub-id-type="pmcid">PMC7140990</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinje</surname><given-names>S</given-names></name><name name-style="western"><surname>Stroes</surname><given-names>E</given-names></name><name name-style="western"><surname>Nieuwdorp</surname><given-names>M</given-names></name><name name-style="western"><surname>Hazen</surname><given-names>SL</given-names></name></person-group><article-title>The gut microbiome as novel cardio-metabolic target: the time has come!</article-title><source>Eur. Heart J.</source><year>2014</year><volume>35</volume><fpage>883</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/eht467</pub-id><pub-id pub-id-type="pmid">24216389</pub-id><pub-id pub-id-type="pmcid">PMC3977135</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>MY</given-names></name><etal/></person-group><article-title>The microbiota and microbiome in pancreatic cancer: more influential than expected</article-title><source>Mol. Cancer</source><year>2019</year><volume>18</volume><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/s12943-019-1008-0</pub-id><pub-id pub-id-type="pmid">31109338</pub-id><pub-id pub-id-type="pmcid">PMC6526613</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robertson</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota</article-title><source>Microbiome</source><year>2018</year><volume>6</volume><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/s40168-018-0476-6</pub-id><pub-id pub-id-type="pmid">29793531</pub-id><pub-id pub-id-type="pmcid">PMC5968592</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gill</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Metagenomic analysis of the human distal gut microbiome</article-title><source>Science</source><year>2006</year><volume>312</volume><fpage>1355</fpage><lpage>1359</lpage><pub-id pub-id-type="doi">10.1126/science.1124234</pub-id><pub-id pub-id-type="pmid">16741115</pub-id><pub-id pub-id-type="pmcid">PMC3027896</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>J</given-names></name><etal/></person-group><article-title>A human gut microbial gene catalogue established by metagenomic sequencing</article-title><source>Nature</source><year>2010</year><volume>464</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/nature08821</pub-id><pub-id pub-id-type="pmid">20203603</pub-id><pub-id pub-id-type="pmcid">PMC3779803</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>M</given-names></name><name name-style="western"><surname>Zimmermann-Kogadeeva</surname><given-names>M</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>R</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>AL</given-names></name></person-group><article-title>Mapping human microbiome drug metabolism by gut bacteria and their genes</article-title><source>Nature</source><year>2019</year><volume>570</volume><fpage>462</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1291-3</pub-id><pub-id pub-id-type="pmid">31158845</pub-id><pub-id pub-id-type="pmcid">PMC6597290</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penalver Bernabe</surname><given-names>B</given-names></name><name name-style="western"><surname>Cralle</surname><given-names>L</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>JA</given-names></name></person-group><article-title>Systems biology of the human microbiome</article-title><source>Curr. Opin. Biotechnol.</source><year>2018</year><volume>51</volume><fpage>146</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2018.01.018</pub-id><pub-id pub-id-type="pmid">29453029</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enright</surname><given-names>EF</given-names></name><name name-style="western"><surname>Gahan</surname><given-names>CG</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>SA</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>BT</given-names></name></person-group><article-title>The impact of the gut microbiota on drug metabolism and clinical outcome</article-title><source>Yale J. Biol. Med.</source><year>2016</year><volume>89</volume><fpage>375</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">27698621</pub-id><pub-id pub-id-type="pmcid">PMC5045146</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinross</surname><given-names>JM</given-names></name><name name-style="western"><surname>Darzi</surname><given-names>AW</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>JK</given-names></name></person-group><article-title>Gut microbiome-host interactions in health and disease</article-title><source>Genome Med.</source><year>2011</year><volume>3</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/gm228</pub-id><pub-id pub-id-type="pmid">21392406</pub-id><pub-id pub-id-type="pmcid">PMC3092099</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>JM</given-names></name><etal/></person-group><article-title>The composition of the gut microbiota throughout life, with an emphasis on early life</article-title><source>Micro. Ecol. Health Dis.</source><year>2015</year><volume>26</volume><fpage>26050</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3402/mehd.v26.26050</pub-id><pub-id pub-id-type="pmcid">PMC4315782</pub-id><pub-id pub-id-type="pmid">25651996</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piazzon</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Under control: how a dietary additive can restore the gut microbiome and proteomic profile, and improve disease resilience in a marine teleostean fish fed vegetable diets</article-title><source>Microbiome</source><year>2017</year><volume>5</volume><fpage>164</fpage><pub-id pub-id-type="doi">10.1186/s40168-017-0390-3</pub-id><pub-id pub-id-type="pmid">29282153</pub-id><pub-id pub-id-type="pmcid">PMC5745981</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shkoporov</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Reproducible protocols for metagenomic analysis of human faecal phageomes</article-title><source>Microbiome</source><year>2018</year><volume>6</volume><fpage>68</fpage><pub-id pub-id-type="doi">10.1186/s40168-018-0446-z</pub-id><pub-id pub-id-type="pmid">29631623</pub-id><pub-id pub-id-type="pmcid">PMC5892011</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montassier</surname><given-names>E</given-names></name><etal/></person-group><article-title>CLOUD: a non-parametric detection test for microbiome outliers</article-title><source>Microbiome</source><year>2018</year><volume>6</volume><fpage>137</fpage><pub-id pub-id-type="doi">10.1186/s40168-018-0514-4</pub-id><pub-id pub-id-type="pmid">30081949</pub-id><pub-id pub-id-type="pmcid">PMC6080375</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Analysis of microbiota in elderly patients with Acute Cerebral Infarction</article-title><source>PeerJ</source><year>2019</year><volume>7</volume><fpage>e6928</fpage><pub-id pub-id-type="doi">10.7717/peerj.6928</pub-id><pub-id pub-id-type="pmid">31223522</pub-id><pub-id pub-id-type="pmcid">PMC6571007</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Impact of host intraspecies genetic variation, diet, and age on bacterial and fungal intestinal microbiota in tigers</article-title><source>Microbiologyopen</source><year>2020</year><volume>9</volume><fpage>e1050</fpage><pub-id pub-id-type="doi">10.1002/mbo3.1050</pub-id><pub-id pub-id-type="pmid">32395912</pub-id><pub-id pub-id-type="pmcid">PMC7349146</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visconti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Interplay between the human gut microbiome and host metabolism</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>4505</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-12476-z</pub-id><pub-id pub-id-type="pmid">31582752</pub-id><pub-id pub-id-type="pmcid">PMC6776654</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation</article-title><source>Microbiome</source><year>2017</year><volume>5</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/s40168-017-0250-1</pub-id><pub-id pub-id-type="pmid">28320465</pub-id><pub-id pub-id-type="pmcid">PMC5359958</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Gut microbiota associations with common diseases and prescription medications in a population-based cohort</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>2655</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-05184-7</pub-id><pub-id pub-id-type="pmid">29985401</pub-id><pub-id pub-id-type="pmcid">PMC6037668</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heirali</surname><given-names>AA</given-names></name><etal/></person-group><article-title>The effects of inhaled aztreonam on the cystic fibrosis lung microbiome</article-title><source>Microbiome</source><year>2017</year><volume>5</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.1186/s40168-017-0265-7</pub-id><pub-id pub-id-type="pmid">28476135</pub-id><pub-id pub-id-type="pmcid">PMC5420135</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Javdan</surname><given-names>B</given-names></name><etal/></person-group><article-title>Personalized mapping of drug metabolism by the human gut microbiome</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>1661</fpage><lpage>1679.e22</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.001</pub-id><pub-id pub-id-type="pmid">32526207</pub-id><pub-id pub-id-type="pmcid">PMC8591631</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weersma</surname><given-names>RK</given-names></name><name name-style="western"><surname>Zhernakova</surname><given-names>A</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name></person-group><article-title>Interaction between drugs and the gut microbiome</article-title><source>Gut</source><year>2020</year><volume>69</volume><fpage>1510</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2019-320204</pub-id><pub-id pub-id-type="pmid">32409589</pub-id><pub-id pub-id-type="pmcid">PMC7398478</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Gut microbiota modulation of chemotherapy efficacy and toxicity</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2017</year><volume>14</volume><fpage>356</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2017.20</pub-id><pub-id pub-id-type="pmid">28270698</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saad</surname><given-names>R</given-names></name><name name-style="western"><surname>Rizkallah</surname><given-names>MR</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>RK</given-names></name></person-group><article-title>Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes</article-title><source>Gut Pathog.</source><year>2012</year><volume>4</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1186/1757-4749-4-16</pub-id><pub-id pub-id-type="pmid">23194438</pub-id><pub-id pub-id-type="pmcid">PMC3529681</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scher</surname><given-names>JU</given-names></name><name name-style="western"><surname>Nayak</surname><given-names>RR</given-names></name><name name-style="western"><surname>Ubeda</surname><given-names>C</given-names></name><name name-style="western"><surname>Turnbaugh</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Abramson</surname><given-names>SB</given-names></name></person-group><article-title>Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response</article-title><source>Nat. Rev. Rheumatol.</source><year>2020</year><volume>16</volume><fpage>282</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1038/s41584-020-0395-3</pub-id><pub-id pub-id-type="pmid">32157196</pub-id><pub-id pub-id-type="pmcid">PMC11221369</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ting</surname><given-names>NL</given-names></name><name name-style="western"><surname>Lau</surname><given-names>HC</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes</article-title><source>Gut</source><year>2022</year><volume>71</volume><fpage>1412</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2021-326264</pub-id><pub-id pub-id-type="pmid">35277453</pub-id><pub-id pub-id-type="pmcid">PMC9185832</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panebianco</surname><given-names>C</given-names></name><name name-style="western"><surname>Andriulli</surname><given-names>A</given-names></name><name name-style="western"><surname>Pazienza</surname><given-names>V</given-names></name></person-group><article-title>Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies</article-title><source>Microbiome</source><year>2018</year><volume>6</volume><fpage>92</fpage><pub-id pub-id-type="doi">10.1186/s40168-018-0483-7</pub-id><pub-id pub-id-type="pmid">29789015</pub-id><pub-id pub-id-type="pmcid">PMC5964925</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doestzada</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pharmacomicrobiomics: a novel route towards personalized medicine?</article-title><source>Protein Cell</source><year>2018</year><volume>9</volume><fpage>432</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1007/s13238-018-0547-2</pub-id><pub-id pub-id-type="pmid">29705929</pub-id><pub-id pub-id-type="pmcid">PMC5960471</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>R</given-names></name><etal/></person-group><article-title>Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine</article-title><source>Brief. Bioinform</source><year>2021</year><volume>22</volume><fpage>bbaa292</fpage><pub-id pub-id-type="doi">10.1093/bib/bbaa292</pub-id><pub-id pub-id-type="pmid">33253350</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Buschmann</surname><given-names>MM</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>JA</given-names></name></person-group><article-title>Pharmacomicrobiomics: the holy grail to variability in drug response?</article-title><source>Clin. Pharm. Ther.</source><year>2019</year><volume>106</volume><fpage>317</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1002/cpt.1437</pub-id><pub-id pub-id-type="pmid">30937887</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsunoda</surname><given-names>SM</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>C</given-names></name><name name-style="western"><surname>Jarmusch</surname><given-names>AK</given-names></name><name name-style="western"><surname>Momper</surname><given-names>JD</given-names></name><name name-style="western"><surname>Ma</surname><given-names>JD</given-names></name></person-group><article-title>Contribution of the gut microbiome to drug disposition, pharmacokinetic and pharmacodynamic variability</article-title><source>Clin. Pharmacokinet.</source><year>2021</year><volume>60</volume><fpage>971</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1007/s40262-021-01032-y</pub-id><pub-id pub-id-type="pmid">33959897</pub-id><pub-id pub-id-type="pmcid">PMC8332605</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Targeted approaches for in situ gut microbiome manipulation</article-title><source>Genes (Basel)</source><year>2018</year><volume>9</volume><fpage>351</fpage><pub-id pub-id-type="doi">10.3390/genes9070351</pub-id><pub-id pub-id-type="pmid">30002345</pub-id><pub-id pub-id-type="pmcid">PMC6071227</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>WF</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>M</given-names></name></person-group><article-title>Microbial approaches for targeting antibiotic-resistant bacteria</article-title><source>Micro. Biotechnol.</source><year>2017</year><volume>10</volume><fpage>1047</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1111/1751-7915.12783</pub-id><pub-id pub-id-type="pmcid">PMC5609231</pub-id><pub-id pub-id-type="pmid">28771951</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Rouby</surname><given-names>N</given-names></name><name name-style="western"><surname>Lima</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>JA</given-names></name></person-group><article-title>Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><year>2018</year><volume>14</volume><fpage>447</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1080/17425255.2018.1461835</pub-id><pub-id pub-id-type="pmid">29620484</pub-id><pub-id pub-id-type="pmcid">PMC5942154</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauser</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Pharmacogenomics of GPCR drug targets</article-title><source>Cell</source><year>2018</year><volume>172</volume><fpage>41</fpage><lpage>54 e19</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.11.033</pub-id><pub-id pub-id-type="pmid">29249361</pub-id><pub-id pub-id-type="pmcid">PMC5766829</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhry</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms</article-title><source>Curr. Drug Metab.</source><year>2014</year><volume>15</volume><fpage>711</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.2174/1389200215666141125121952</pub-id><pub-id pub-id-type="pmid">25429673</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muszkat</surname><given-names>M</given-names></name></person-group><article-title>Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9</article-title><source>Clin. Pharm. Ther.</source><year>2007</year><volume>82</volume><fpage>215</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/sj.clpt.6100142</pub-id><pub-id pub-id-type="pmid">17329986</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamath</surname><given-names>A</given-names></name><etal/></person-group><article-title>Role of drug transporters in elucidating inter-individual variability in pediatric chemotherapy-related toxicities and response</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><fpage>990</fpage><pub-id pub-id-type="doi">10.3390/ph15080990</pub-id><pub-id pub-id-type="pmid">36015138</pub-id><pub-id pub-id-type="pmcid">PMC9415926</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joharatnam-Hogan</surname><given-names>N</given-names></name><name name-style="western"><surname>Shiu</surname><given-names>KK</given-names></name><name name-style="western"><surname>Khan</surname><given-names>K</given-names></name></person-group><article-title>Challenges in the treatment of gastric cancer in the older patient</article-title><source>Cancer Treat. Rev.</source><year>2020</year><volume>85</volume><fpage>101980</fpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2020.101980</pub-id><pub-id pub-id-type="pmid">32065879</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murgo</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Espinoza-Delgado</surname><given-names>I</given-names></name></person-group><article-title>Development of novel anticancer agents in older patients: pharmacokinetic, pharmacodynamic, and other considerations</article-title><source>Cancer J.</source><year>2005</year><volume>11</volume><fpage>481</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1097/00130404-200511000-00007</pub-id><pub-id pub-id-type="pmid">16393482</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>JB</given-names></name></person-group><article-title>The current state of knowledge on age, sex, and their interactions on clinical pharmacology</article-title><source>Clin. Pharm. Ther.</source><year>2007</year><volume>82</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1038/sj.clpt.6100226</pub-id><pub-id pub-id-type="pmid">17495875</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deneer</surname><given-names>VH</given-names></name><name name-style="western"><surname>van Hemel</surname><given-names>NM</given-names></name></person-group><article-title>Is antiarrhythmic treatment in the elderly different? a review of the specific changes</article-title><source>Drugs Aging</source><year>2011</year><volume>28</volume><fpage>617</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.2165/11591680-000000000-00000</pub-id><pub-id pub-id-type="pmid">21812498</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Besir</surname><given-names>FH</given-names></name><etal/></person-group><article-title>Enoxaparin-associated giant retroperitoneal hematoma in pulmonary embolism treatment</article-title><source>N. Am. J. Med. Sci.</source><year>2011</year><volume>3</volume><fpage>524</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.4297/najms.2011.3524</pub-id><pub-id pub-id-type="pmid">22361501</pub-id><pub-id pub-id-type="pmcid">PMC3271411</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spirk</surname><given-names>D</given-names></name><etal/></person-group><article-title>Predictors of in-hospital mortality in elderly patients with acute venous thrombo-embolism: the SWIss Venous ThromboEmbolism Registry (SWIVTER)</article-title><source>Eur. Heart J.</source><year>2012</year><volume>33</volume><fpage>921</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehr392</pub-id><pub-id pub-id-type="pmid">22036872</pub-id><pub-id pub-id-type="pmcid">PMC3345553</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saltalamacchia</surname><given-names>G</given-names></name><name name-style="western"><surname>Frascaroli</surname><given-names>M</given-names></name><name name-style="western"><surname>Bernardo</surname><given-names>A</given-names></name><name name-style="western"><surname>Quaquarini</surname><given-names>E</given-names></name></person-group><article-title>Renal and cardiovascular toxicities by new systemic treatments for prostate cancer</article-title><source>Cancers (Basel)</source><year>2020</year><volume>12</volume><fpage>1750</fpage><pub-id pub-id-type="doi">10.3390/cancers12071750</pub-id><pub-id pub-id-type="pmid">32630204</pub-id><pub-id pub-id-type="pmcid">PMC7407336</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masnoon</surname><given-names>N</given-names></name><name name-style="western"><surname>Shakib</surname><given-names>S</given-names></name><name name-style="western"><surname>Kalisch-Ellett</surname><given-names>L</given-names></name><name name-style="western"><surname>Caughey</surname><given-names>GE</given-names></name></person-group><article-title>What is polypharmacy? A systematic review of definitions</article-title><source>BMC Geriatr.</source><year>2017</year><volume>17</volume><fpage>230</fpage><pub-id pub-id-type="doi">10.1186/s12877-017-0621-2</pub-id><pub-id pub-id-type="pmid">29017448</pub-id><pub-id pub-id-type="pmcid">PMC5635569</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scherholz</surname><given-names>ML</given-names></name><name name-style="western"><surname>Rao</surname><given-names>RT</given-names></name><name name-style="western"><surname>Androulakis</surname><given-names>IP</given-names></name></person-group><article-title>Modeling inter-sex and inter-individual variability in response to chronopharmacological administration of synthetic glucocorticoids</article-title><source>Chronobiol. Int.</source><year>2020</year><volume>37</volume><fpage>281</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1080/07420528.2019.1660357</pub-id><pub-id pub-id-type="pmid">31797700</pub-id><pub-id pub-id-type="pmcid">PMC7054177</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conforti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials</article-title><source>ESMO Open</source><year>2021</year><volume>6</volume><fpage>100251</fpage><pub-id pub-id-type="doi">10.1016/j.esmoop.2021.100251</pub-id><pub-id pub-id-type="pmid">34455288</pub-id><pub-id pub-id-type="pmcid">PMC8403740</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Federman</surname><given-names>DD</given-names></name></person-group><article-title>The biology of human sex differences</article-title><source>N. Engl. J. Med.</source><year>2006</year><volume>354</volume><fpage>1507</fpage><lpage>1514</lpage><pub-id pub-id-type="doi">10.1056/NEJMra052529</pub-id><pub-id pub-id-type="pmid">16598047</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soldin</surname><given-names>OP</given-names></name><name name-style="western"><surname>Mattison</surname><given-names>DR</given-names></name></person-group><article-title>Sex differences in pharmacokinetics and pharmacodynamics</article-title><source>Clin. Pharmacokinet.</source><year>2009</year><volume>48</volume><fpage>143</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.2165/00003088-200948030-00001</pub-id><pub-id pub-id-type="pmid">19385708</pub-id><pub-id pub-id-type="pmcid">PMC3644551</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scandlyn</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>EC</given-names></name><name name-style="western"><surname>Rosengren</surname><given-names>RJ</given-names></name></person-group><article-title>Sex-specific differences in CYP450 isoforms in humans</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><year>2008</year><volume>4</volume><fpage>413</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1517/17425255.4.4.413</pub-id><pub-id pub-id-type="pmid">18524030</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodenburg</surname><given-names>EM</given-names></name><name name-style="western"><surname>Stricker</surname><given-names>BH</given-names></name><name name-style="western"><surname>Visser</surname><given-names>LE</given-names></name></person-group><article-title>Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands</article-title><source>Br. J. Clin. Pharm.</source><year>2011</year><volume>71</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2010.03811.x</pub-id><pub-id pub-id-type="pmcid">PMC3018030</pub-id><pub-id pub-id-type="pmid">21143505</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calcagno</surname><given-names>A</given-names></name><etal/></person-group><article-title>Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function</article-title><source>Antimicrob. Agents Chemother.</source><year>2013</year><volume>57</volume><fpage>1840</fpage><lpage>1843</lpage><pub-id pub-id-type="doi">10.1128/AAC.02434-12</pub-id><pub-id pub-id-type="pmid">23380733</pub-id><pub-id pub-id-type="pmcid">PMC3623307</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerrato</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cardiovascular disease in HIV patients: from bench to bedside and backwards</article-title><source>Open Heart</source><year>2015</year><volume>2</volume><fpage>e000174</fpage><pub-id pub-id-type="doi">10.1136/openhrt-2014-000174</pub-id><pub-id pub-id-type="pmid">25815207</pub-id><pub-id pub-id-type="pmcid">PMC4368980</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>GD</given-names></name></person-group><article-title>Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics</article-title><source>J. Women&#8217;s Health (Larchmt.)</source><year>2005</year><volume>14</volume><fpage>19</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1089/jwh.2005.14.19</pub-id><pub-id pub-id-type="pmid">15692274</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>GD</given-names></name></person-group><article-title>Gender differences in pharmacological response</article-title><source>Int. Rev. Neurobiol.</source><year>2008</year><volume>83</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/S0074-7742(08)00001-9</pub-id><pub-id pub-id-type="pmid">18929073</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siguret</surname><given-names>V</given-names></name><name name-style="western"><surname>Pautas</surname><given-names>E</given-names></name><name name-style="western"><surname>Gouin-Thibault</surname><given-names>I</given-names></name></person-group><article-title>Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin</article-title><source>Vitam. Horm.</source><year>2008</year><volume>78</volume><fpage>247</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/S0083-6729(07)00012-X</pub-id><pub-id pub-id-type="pmid">18374198</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirsh</surname><given-names>J</given-names></name><etal/></person-group><article-title>Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range</article-title><source>Chest</source><year>2001</year><volume>119</volume><fpage>8S</fpage><lpage>21S</lpage><pub-id pub-id-type="doi">10.1378/chest.119.1_suppl.8S</pub-id><pub-id pub-id-type="pmid">11157640</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavallari</surname><given-names>LH</given-names></name><name name-style="western"><surname>Limdi</surname><given-names>NA</given-names></name></person-group><article-title>Warfarin pharmacogenomics</article-title><source>Curr. Opin. Mol. Ther.</source><year>2009</year><volume>11</volume><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">19479657</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JN</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name><name name-style="western"><surname>Noh</surname><given-names>MY</given-names></name><name name-style="western"><surname>Sung</surname><given-names>MK</given-names></name></person-group><article-title>Association between usual vitamin K intake and anticoagulation in patients under warfarin therapy</article-title><source>Clin. Nutr. Res.</source><year>2015</year><volume>4</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.7762/cnr.2015.4.4.235</pub-id><pub-id pub-id-type="pmid">26566518</pub-id><pub-id pub-id-type="pmcid">PMC4641985</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guaraldi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Efficacy and safety of atazanavir in patients with end-stage liver disease</article-title><source>Infection</source><year>2009</year><volume>37</volume><fpage>250</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1007/s15010-008-8025-z</pub-id><pub-id pub-id-type="pmid">19471855</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenblatt</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Shader</surname><given-names>RI</given-names></name><name name-style="western"><surname>Lofgren</surname><given-names>S</given-names></name></person-group><article-title>Rational psycho-pharmacology for patients with medical diseases</article-title><source>Annu Rev. Med.</source><year>1976</year><volume>27</volume><fpage>407</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1146/annurev.me.27.020176.002203</pub-id><pub-id pub-id-type="pmid">7180</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>C</given-names></name><name name-style="western"><surname>Lv</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zou</surname><given-names>D</given-names></name></person-group><article-title>Pediatric pharmaceutical care with anti-infective medication in a patient with acute hematogenous osteomyelitis caused by methicillin-resistant Staphylococcus aureus</article-title><source>Int J. Immunopathol. Pharm.</source><year>2020</year><volume>34</volume><fpage>2058738420925713</fpage><pub-id pub-id-type="doi">10.1177/2058738420925713</pub-id><pub-id pub-id-type="pmcid">PMC7307395</pub-id><pub-id pub-id-type="pmid">32567423</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldinger</surname><given-names>R</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>G</given-names></name><name name-style="western"><surname>Gitman</surname><given-names>M</given-names></name></person-group><article-title>Local anesthetic toxicity in the geriatric population</article-title><source>Drugs Aging</source><year>2020</year><volume>37</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s40266-019-00718-0</pub-id><pub-id pub-id-type="pmid">31598909</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosmarin</surname><given-names>DM</given-names></name><name name-style="western"><surname>Lebwohl</surname><given-names>M</given-names></name><name name-style="western"><surname>Elewski</surname><given-names>BE</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><collab>National Psoriasis, F.</collab></person-group><article-title>Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference</article-title><source>J. Am. Acad. Dermatol.</source><year>2010</year><volume>62</volume><fpage>838</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2009.05.017</pub-id><pub-id pub-id-type="pmid">19932926</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>JH</given-names></name><name name-style="western"><surname>Stine</surname><given-names>JG</given-names></name></person-group><article-title>Review article: prescribing medications in patients with cirrhosis - a practical guide</article-title><source>Aliment Pharm. Ther.</source><year>2013</year><volume>37</volume><fpage>1132</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1111/apt.12324</pub-id><pub-id pub-id-type="pmid">23638982</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verbeeck</surname><given-names>RK</given-names></name></person-group><article-title>Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction</article-title><source>Eur. J. Clin. Pharm.</source><year>2008</year><volume>64</volume><fpage>1147</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1007/s00228-008-0553-z</pub-id><pub-id pub-id-type="pmid">18762933</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macpherson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Heikenwalder</surname><given-names>M</given-names></name><name name-style="western"><surname>Ganal-Vonarburg</surname><given-names>SC</given-names></name></person-group><article-title>The liver at the nexus of host-microbial interactions</article-title><source>Cell Host Microbe</source><year>2016</year><volume>20</volume><fpage>561</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.10.016</pub-id><pub-id pub-id-type="pmid">27832587</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mani</surname><given-names>R</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>JR</given-names></name></person-group><article-title>Antiepileptic drugs and other medications: what interactions may arise?</article-title><source>Curr. Treat. Options Neurol.</source><year>2009</year><volume>11</volume><fpage>253</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1007/s11940-009-0029-1</pub-id><pub-id pub-id-type="pmid">19523351</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lizak</surname><given-names>P</given-names></name><name name-style="western"><surname>Dvorak</surname><given-names>CC</given-names></name><name name-style="western"><surname>Aweeka</surname><given-names>F</given-names></name><name name-style="western"><surname>Long-Boyle</surname><given-names>J</given-names></name></person-group><article-title>Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS</article-title><source>J. Chromatogr. B Anal. Technol. Biomed. Life Sci.</source><year>2014</year><volume>960</volume><fpage>194</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2014.04.045</pub-id><pub-id pub-id-type="pmcid">PMC4110960</pub-id><pub-id pub-id-type="pmid">24820973</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Relling</surname><given-names>MV</given-names></name><etal/></person-group><article-title>Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia</article-title><source>Lancet</source><year>2000</year><volume>356</volume><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02503-4</pub-id><pub-id pub-id-type="pmid">11071183</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rendic</surname><given-names>S</given-names></name></person-group><article-title>Summary of information on human CYP enzymes: human P450 metabolism data</article-title><source>Drug Metab. Rev.</source><year>2002</year><volume>34</volume><fpage>83</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1081/DMR-120001392</pub-id><pub-id pub-id-type="pmid">11996015</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Malley</surname><given-names>M</given-names></name><name name-style="western"><surname>Healy</surname><given-names>P</given-names></name><name name-style="western"><surname>Daignault</surname><given-names>S</given-names></name><name name-style="western"><surname>Ramnath</surname><given-names>N</given-names></name></person-group><article-title>Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors</article-title><source>Oncology</source><year>2013</year><volume>85</volume><fpage>216</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1159/000355107</pub-id><pub-id pub-id-type="pmid">24080957</pub-id><pub-id pub-id-type="pmcid">PMC4768297</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of smoking on the pharmacokinetics of erlotinib</article-title><source>Clin. Cancer Res.</source><year>2006</year><volume>12</volume><fpage>2166</fpage><lpage>2171</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2235</pub-id><pub-id pub-id-type="pmid">16609030</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers</article-title><source>J. Clin. Oncol.</source><year>2009</year><volume>27</volume><fpage>1220</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.19.3995</pub-id><pub-id pub-id-type="pmid">19164205</pub-id><pub-id pub-id-type="pmcid">PMC2667823</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Bol</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia</article-title><source>J. Clin. Oncol.</source><year>2007</year><volume>25</volume><fpage>2719</fpage><lpage>2726</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.09.6115</pub-id><pub-id pub-id-type="pmid">17563393</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanai</surname><given-names>M</given-names></name><etal/></person-group><article-title>A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia</article-title><source>Ann. Oncol.</source><year>2009</year><volume>20</volume><fpage>1397</fpage><lpage>1401</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdp008</pub-id><pub-id pub-id-type="pmid">19457938</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dikeocha</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Al-Kabsi</surname><given-names>AM</given-names></name><name name-style="western"><surname>Miftahussurur</surname><given-names>M</given-names></name><name name-style="western"><surname>Alshawsh</surname><given-names>MA</given-names></name></person-group><article-title>Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism</article-title><source>FASEB J.</source><year>2022</year><volume>36</volume><fpage>e22350</fpage><pub-id pub-id-type="doi">10.1096/fj.202101986R</pub-id><pub-id pub-id-type="pmid">35579628</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enright</surname><given-names>EF</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>BT</given-names></name><name name-style="western"><surname>Gahan</surname><given-names>CGM</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>SA</given-names></name></person-group><article-title>Microbiome-mediated bile acid modification: Role in intestinal drug absorption and metabolism</article-title><source>Pharm. Res.</source><year>2018</year><volume>133</volume><fpage>170</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.04.009</pub-id><pub-id pub-id-type="pmid">29660405</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vich Vila</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impact of commonly used drugs on the composition and metabolic function of the gut microbiota</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>362</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-14177-z</pub-id><pub-id pub-id-type="pmid">31953381</pub-id><pub-id pub-id-type="pmcid">PMC6969170</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garrod</surname><given-names>AE</given-names></name></person-group><article-title>The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article]</article-title><source>Yale J. Biol. Med.</source><year>2002</year><volume>75</volume><fpage>221</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">12784973</pub-id><pub-id pub-id-type="pmcid">PMC2588790</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perlman</surname><given-names>RL</given-names></name><name name-style="western"><surname>Govindaraju</surname><given-names>DR</given-names></name></person-group><article-title>Archibald E. Garrod: the father of precision medicine</article-title><source>Genet Med.</source><year>2016</year><volume>18</volume><fpage>1088</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1038/gim.2016.5</pub-id><pub-id pub-id-type="pmid">26963281</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>WE</given-names></name><name name-style="western"><surname>Relling</surname><given-names>MV</given-names></name></person-group><article-title>Moving towards individualized medicine with pharmacogenomics</article-title><source>Nature</source><year>2004</year><volume>429</volume><fpage>464</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1038/nature02626</pub-id><pub-id pub-id-type="pmid">15164072</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>WE</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>HL</given-names></name></person-group><article-title>Pharmacogenomics-drug disposition, drug targets, and side effects</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>538</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1056/NEJMra020526</pub-id><pub-id pub-id-type="pmid">12571262</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinshilboum</surname><given-names>R</given-names></name></person-group><article-title>Inheritance and drug response</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>529</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1056/NEJMra020021</pub-id><pub-id pub-id-type="pmid">12571261</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dawed</surname><given-names>AY</given-names></name><etal/></person-group><article-title>Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials</article-title><source>Lancet Diabetes Endocrinol.</source><year>2023</year><volume>11</volume><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(22)00340-0</pub-id><pub-id pub-id-type="pmid">36528349</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beutler</surname><given-names>E</given-names></name></person-group><article-title>Drug-induced hemolytic anemia</article-title><source>Pharm. Rev.</source><year>1969</year><volume>21</volume><fpage>73</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">4887725</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beutler</surname><given-names>E</given-names></name></person-group><article-title>The hemolytic effect of primaquine and related compounds: a review</article-title><source>Blood</source><year>1959</year><volume>14</volume><fpage>103</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1182/blood.V14.2.103.103</pub-id><pub-id pub-id-type="pmid">13618370</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beutler</surname><given-names>E</given-names></name><name name-style="western"><surname>Dern</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Alving</surname><given-names>AS</given-names></name></person-group><article-title>The hemolytic effect of primaquine. III. A study of primaquine-sensitive erythrocytes</article-title><source>J. Lab Clin. Med.</source><year>1954</year><volume>44</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">13184225</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogel</surname><given-names>F</given-names></name></person-group><article-title>Moderne probleme der humangenetik</article-title><source>Ergebn. Inn. Med. Kinderheilk</source><year>1959</year><volume>12</volume><fpage>52</fpage><lpage>125</lpage></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Multiplexed SNP genotyping using the Qbead system: a quantum dot-encoded microsphere-based assay</article-title><source>Nucleic Acids Res.</source><year>2003</year><volume>31</volume><fpage>e43</fpage><pub-id pub-id-type="doi">10.1093/nar/gng043</pub-id><pub-id pub-id-type="pmid">12682378</pub-id><pub-id pub-id-type="pmcid">PMC153755</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibbs</surname><given-names>RA</given-names></name></person-group><article-title>The Human Genome Project changed everything</article-title><source>Nat. Rev. Genet</source><year>2020</year><volume>21</volume><fpage>575</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1038/s41576-020-0275-3</pub-id><pub-id pub-id-type="pmid">32770171</pub-id><pub-id pub-id-type="pmcid">PMC7413016</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nebert</surname><given-names>DW</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Vesell</surname><given-names>ES</given-names></name></person-group><article-title>From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions</article-title><source>Drug Metab. Rev.</source><year>2008</year><volume>40</volume><fpage>187</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1080/03602530801952864</pub-id><pub-id pub-id-type="pmid">18464043</pub-id><pub-id pub-id-type="pmcid">PMC2752627</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz</surname><given-names>C</given-names></name><name name-style="western"><surname>Zitnik</surname><given-names>M</given-names></name><name name-style="western"><surname>Leskovec</surname><given-names>J</given-names></name></person-group><article-title>Identification of disease treatment mechanisms through the multiscale interactome</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>1796</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-21770-8</pub-id><pub-id pub-id-type="pmid">33741907</pub-id><pub-id pub-id-type="pmcid">PMC7979814</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ming</surname><given-names>X</given-names></name><name name-style="western"><surname>Laing</surname><given-names>B</given-names></name></person-group><article-title>Bioconjugates for targeted delivery of therapeutic oligonucleotides</article-title><source>Adv. Drug Deliv. Rev.</source><year>2015</year><volume>87</volume><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.02.002</pub-id><pub-id pub-id-type="pmid">25689735</pub-id><pub-id pub-id-type="pmcid">PMC4504788</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>GA</given-names></name><name name-style="western"><surname>Williams</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ade</surname><given-names>AS</given-names></name><name name-style="western"><surname>Alam</surname><given-names>HB</given-names></name><name name-style="western"><surname>Athey</surname><given-names>BD</given-names></name></person-group><article-title>Druggable transcriptional networks in the human neurogenic epigenome</article-title><source>Pharm. Rev.</source><year>2019</year><volume>71</volume><fpage>520</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1124/pr.119.017681</pub-id><pub-id pub-id-type="pmid">31530573</pub-id><pub-id pub-id-type="pmcid">PMC6750186</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varga</surname><given-names>J</given-names></name><name name-style="western"><surname>Dobson</surname><given-names>L</given-names></name><name name-style="western"><surname>Remenyi</surname><given-names>I</given-names></name><name name-style="western"><surname>Tusnady</surname><given-names>GE</given-names></name></person-group><article-title>TSTMP: target selection for structural genomics of human transmembrane proteins</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>D325</fpage><lpage>D330</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw939</pub-id><pub-id pub-id-type="pmid">27924015</pub-id><pub-id pub-id-type="pmcid">PMC5210638</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Somogyi</surname><given-names>AA</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>E</given-names></name></person-group><article-title>Genomic testing as a tool to optimise drug therapy</article-title><source>Aust. Prescr.</source><year>2017</year><volume>40</volume><fpage>101</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.18773/austprescr.2017.027</pub-id><pub-id pub-id-type="pmid">28798515</pub-id><pub-id pub-id-type="pmcid">PMC5478394</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tam</surname><given-names>HK</given-names></name><etal/></person-group><article-title>Allosteric drug transport mechanism of multidrug transporter AcrB</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>3889</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-24151-3</pub-id><pub-id pub-id-type="pmid">34188038</pub-id><pub-id pub-id-type="pmcid">PMC8242077</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van de Ven</surname><given-names>R</given-names></name><etal/></person-group><article-title>A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>2353</fpage><lpage>2359</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-03-147850</pub-id><pub-id pub-id-type="pmid">18625884</pub-id><pub-id pub-id-type="pmcid">PMC2532808</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oslin</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial</article-title><source>JAMA</source><year>2022</year><volume>328</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.9805</pub-id><pub-id pub-id-type="pmid">35819423</pub-id><pub-id pub-id-type="pmcid">PMC9277497</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tardif</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial</article-title><source>Eur. Heart J.</source><year>2022</year><volume>43</volume><fpage>3947</fpage><lpage>3956</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehac374</pub-id><pub-id pub-id-type="pmid">35856777</pub-id><pub-id pub-id-type="pmcid">PMC9565632</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsutsumi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Structures of the wild-type MexAB-OprM tripartite pump reveal its complex formation and drug efflux mechanism</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>1520</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-09463-9</pub-id><pub-id pub-id-type="pmid">30944318</pub-id><pub-id pub-id-type="pmcid">PMC6447562</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nigam</surname><given-names>SK</given-names></name></person-group><article-title>What do drug transporters really do?</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>29</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/nrd4461</pub-id><pub-id pub-id-type="pmid">25475361</pub-id><pub-id pub-id-type="pmcid">PMC4750486</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Surendiran</surname><given-names>A</given-names></name><name name-style="western"><surname>Pradhan</surname><given-names>SC</given-names></name><name name-style="western"><surname>Adithan</surname><given-names>C</given-names></name></person-group><article-title>Role of pharmacogenomics in drug discovery and development</article-title><source>Indian J. Pharm.</source><year>2008</year><volume>40</volume><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.4103/0253-7613.43158</pub-id><pub-id pub-id-type="pmcid">PMC2792612</pub-id><pub-id pub-id-type="pmid">20040945</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clayton</surname><given-names>TA</given-names></name><name name-style="western"><surname>Baker</surname><given-names>D</given-names></name><name name-style="western"><surname>Lindon</surname><given-names>JC</given-names></name><name name-style="western"><surname>Everett</surname><given-names>JR</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>JK</given-names></name></person-group><article-title>Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>14728</fpage><lpage>14733</lpage><pub-id pub-id-type="doi">10.1073/pnas.0904489106</pub-id><pub-id pub-id-type="pmid">19667173</pub-id><pub-id pub-id-type="pmcid">PMC2731842</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>HH</given-names></name><name name-style="western"><surname>Koshakji</surname><given-names>RP</given-names></name><name name-style="western"><surname>Silberstein</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>GR</given-names></name><name name-style="western"><surname>Wood</surname><given-names>AJ</given-names></name></person-group><article-title>Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites</article-title><source>N. Engl. J. Med.</source><year>1989</year><volume>320</volume><fpage>565</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1056/NEJM198903023200905</pub-id><pub-id pub-id-type="pmid">2536896</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasuda</surname><given-names>SU</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SM</given-names></name></person-group><article-title>The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies</article-title><source>Clin. Pharm. Ther.</source><year>2008</year><volume>84</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1038/clpt.2008.141</pub-id><pub-id pub-id-type="pmid">18615002</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Man</surname><given-names>M</given-names></name><etal/></person-group><article-title>Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans</article-title><source>J. Clin. Pharm.</source><year>2010</year><volume>50</volume><fpage>929</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1177/0091270009355161</pub-id><pub-id pub-id-type="pmid">20173083</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scharfe</surname><given-names>CPI</given-names></name><name name-style="western"><surname>Tremmel</surname><given-names>R</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>M</given-names></name><name name-style="western"><surname>Kohlbacher</surname><given-names>O</given-names></name><name name-style="western"><surname>Marks</surname><given-names>DS</given-names></name></person-group><article-title>Genetic variation in human drug-related genes</article-title><source>Genome Med.</source><year>2017</year><volume>9</volume><fpage>117</fpage><pub-id pub-id-type="doi">10.1186/s13073-017-0502-5</pub-id><pub-id pub-id-type="pmid">29273096</pub-id><pub-id pub-id-type="pmcid">PMC5740940</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernard</surname><given-names>E</given-names></name><etal/></person-group><article-title>Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>1549</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-1008-z</pub-id><pub-id pub-id-type="pmid">32747829</pub-id><pub-id pub-id-type="pmcid">PMC8381722</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>CA</given-names></name><etal/></person-group><article-title>IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>2592</fpage><lpage>2600</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-02095-5</pub-id><pub-id pub-id-type="pmid">36526722</pub-id><pub-id pub-id-type="pmcid">PMC9800275</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funnell</surname><given-names>T</given-names></name><etal/></person-group><article-title>Single-cell genomic variation induced by mutational processes in cancer</article-title><source>Nature</source><year>2022</year><volume>612</volume><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05249-0</pub-id><pub-id pub-id-type="pmid">36289342</pub-id><pub-id pub-id-type="pmcid">PMC9712114</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Ruiz</surname><given-names>C</given-names></name><etal/></person-group><article-title>Genomic-transcriptomic evolution in lung cancer and metastasis</article-title><source>Nature</source><year>2023</year><volume>616</volume><fpage>543</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05706-4</pub-id><pub-id pub-id-type="pmid">37046093</pub-id><pub-id pub-id-type="pmcid">PMC10115639</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naranbhai</surname><given-names>V</given-names></name><etal/></person-group><article-title>HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study</article-title><source>Lancet Oncol.</source><year>2022</year><volume>23</volume><fpage>172</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00582-9</pub-id><pub-id pub-id-type="pmid">34895481</pub-id><pub-id pub-id-type="pmcid">PMC8742225</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>CW</given-names></name><name name-style="western"><surname>Preclaro</surname><given-names>IAC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>WH</given-names></name><name name-style="western"><surname>Chung</surname><given-names>WH</given-names></name></person-group><article-title>An updated review of genetic associations with severe adverse drug reactions: translation and implementation of pharmacogenomic testing in clinical practice</article-title><source>Front. Pharm.</source><year>2022</year><volume>13</volume><fpage>886377</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.886377</pub-id><pub-id pub-id-type="pmcid">PMC9081981</pub-id><pub-id pub-id-type="pmid">35548363</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>DA</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>SR</given-names></name><name name-style="western"><surname>Shear</surname><given-names>NH</given-names></name></person-group><article-title>Sulfonamide hypersensitivity: fact and fiction</article-title><source>J. Allergy Clin. Immunol. Pract.</source><year>2019</year><volume>7</volume><fpage>2116</fpage><lpage>2123</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2019.05.034</pub-id><pub-id pub-id-type="pmid">31495421</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>TG</given-names></name><name name-style="western"><surname>Khan</surname><given-names>DA</given-names></name></person-group><article-title>Sulfonamide hypersensitivity</article-title><source>Clin. Rev. Allergy Immunol.</source><year>2022</year><volume>62</volume><fpage>400</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1007/s12016-021-08872-3</pub-id><pub-id pub-id-type="pmid">34212341</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuman</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides</article-title><source>Transl. Res.</source><year>2007</year><volume>149</volume><fpage>243</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2006.12.001</pub-id><pub-id pub-id-type="pmid">17466923</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Relman</surname><given-names>DA</given-names></name><name name-style="western"><surname>Falkow</surname><given-names>S</given-names></name></person-group><article-title>The meaning and impact of the human genome sequence for microbiology</article-title><source>Trends Microbiol.</source><year>2001</year><volume>9</volume><fpage>206</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/S0966-842X(01)02041-8</pub-id><pub-id pub-id-type="pmid">11336835</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maringanti</surname><given-names>VS</given-names></name><name name-style="western"><surname>Bucci</surname><given-names>V</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>GK</given-names></name></person-group><article-title>MDITRE: scalable and interpretable machine learning for predicting host status from temporal microbiome dynamics</article-title><source>mSystems</source><year>2022</year><volume>7</volume><fpage>e0013222</fpage><pub-id pub-id-type="doi">10.1128/msystems.00132-22</pub-id><pub-id pub-id-type="pmid">36069455</pub-id><pub-id pub-id-type="pmcid">PMC9600536</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pflughoeft</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Versalovic</surname><given-names>J</given-names></name></person-group><article-title>Human microbiome in health and disease</article-title><source>Annu. Rev. Pathol.</source><year>2012</year><volume>7</volume><fpage>99</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-011811-132421</pub-id><pub-id pub-id-type="pmid">21910623</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geurtsen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis</article-title><source>Infect. Immun.</source><year>2006</year><volume>74</volume><fpage>5574</fpage><lpage>5585</lpage><pub-id pub-id-type="doi">10.1128/IAI.00834-06</pub-id><pub-id pub-id-type="pmid">16988232</pub-id><pub-id pub-id-type="pmcid">PMC1594925</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>ElRakaiby</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics</article-title><source>OMICS</source><year>2014</year><volume>18</volume><fpage>402</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1089/omi.2014.0018</pub-id><pub-id pub-id-type="pmid">24785449</pub-id><pub-id pub-id-type="pmcid">PMC4086029</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gutierrez Lopez</surname><given-names>DE</given-names></name><name name-style="western"><surname>Lashinger</surname><given-names>LM</given-names></name><name name-style="western"><surname>Weinstock</surname><given-names>GM</given-names></name><name name-style="western"><surname>Bray</surname><given-names>MS</given-names></name></person-group><article-title>Circadian rhythms and the gut microbiome synchronize the host&#8217;s metabolic response to diet</article-title><source>Cell Metab.</source><year>2021</year><volume>33</volume><fpage>873</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.03.015</pub-id><pub-id pub-id-type="pmid">33789092</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>P</given-names></name><etal/></person-group><article-title>Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host&#8217;s metabolism</article-title><source>Mol. Psychiatry</source><year>2016</year><volume>21</volume><fpage>786</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1038/mp.2016.44</pub-id><pub-id pub-id-type="pmid">27067014</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>MY</given-names></name><name name-style="western"><surname>Sun</surname><given-names>HZ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>XH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>JX</given-names></name><name name-style="western"><surname>Guan</surname><given-names>LL</given-names></name></person-group><article-title>Multi-omics reveals that the rumen microbiome and its metabolome together with the host metabolome contribute to individualized dairy cow performance</article-title><source>Microbiome</source><year>2020</year><volume>8</volume><fpage>64</fpage><pub-id pub-id-type="doi">10.1186/s40168-020-00819-8</pub-id><pub-id pub-id-type="pmid">32398126</pub-id><pub-id pub-id-type="pmcid">PMC7218573</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>ID</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>JK</given-names></name></person-group><article-title>Gut microbiome interactions with drug metabolism, efficacy, and toxicity</article-title><source>Transl. Res.</source><year>2017</year><volume>179</volume><fpage>204</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2016.08.002</pub-id><pub-id pub-id-type="pmid">27591027</pub-id><pub-id pub-id-type="pmcid">PMC5718288</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koppel</surname><given-names>N</given-names></name><name name-style="western"><surname>Maini Rekdal</surname><given-names>V</given-names></name><name name-style="western"><surname>Balskus</surname><given-names>EP</given-names></name></person-group><article-title>Chemical transformation of xenobiotics by the human gut microbiota</article-title><source>Science</source><year>2017</year><volume>356</volume><fpage>eaag2770</fpage><pub-id pub-id-type="doi">10.1126/science.aag2770</pub-id><pub-id pub-id-type="pmid">28642381</pub-id><pub-id pub-id-type="pmcid">PMC5534341</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalsa</surname><given-names>J</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>LC</given-names></name><name name-style="western"><surname>Riscuta</surname><given-names>G</given-names></name><name name-style="western"><surname>Starke-Reed</surname><given-names>P</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>VS</given-names></name></person-group><article-title>Omics for understanding the gut-liver-microbiome axis and precision medicine</article-title><source>Clin. Pharm. Drug Dev.</source><year>2017</year><volume>6</volume><fpage>176</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1002/cpdd.310</pub-id><pub-id pub-id-type="pmid">28263462</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><etal/></person-group><article-title>Targeting the human genome-microbiome axis for drug discovery: inspirations from global systems biology and traditional Chinese medicine</article-title><source>J. Proteome Res.</source><year>2012</year><volume>11</volume><fpage>3509</fpage><lpage>3519</lpage><pub-id pub-id-type="doi">10.1021/pr3001628</pub-id><pub-id pub-id-type="pmid">22624854</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yachida</surname><given-names>S</given-names></name><etal/></person-group><article-title>Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer</article-title><source>Nat. Med.</source><year>2019</year><volume>25</volume><fpage>968</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0458-7</pub-id><pub-id pub-id-type="pmid">31171880</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>A</given-names></name><etal/></person-group><article-title>A new genomic blueprint of the human gut microbiota</article-title><source>Nature</source><year>2019</year><volume>568</volume><fpage>499</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0965-1</pub-id><pub-id pub-id-type="pmid">30745586</pub-id><pub-id pub-id-type="pmcid">PMC6784870</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort</article-title><source>Nat. Genet</source><year>2022</year><volume>54</volume><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00991-z</pub-id><pub-id pub-id-type="pmid">35115689</pub-id><pub-id pub-id-type="pmcid">PMC9883041</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Main active components of Jiawei Gegen Qinlian decoction protects against ulcerative colitis under different dietary environments in a gut microbiota-dependent manner</article-title><source>Pharm. Res.</source><year>2021</year><volume>170</volume><fpage>105694</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2021.105694</pub-id><pub-id pub-id-type="pmid">34087350</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaddurah-Daouk</surname><given-names>R</given-names></name><name name-style="western"><surname>Weinshilboum</surname><given-names>R</given-names></name><collab>Pharmacometabolomics Research Network</collab></person-group><article-title>Metabolomic signatures for drug response phenotypes: pharmacometabolomics enables precision medicine</article-title><source>Clin. Pharm. Ther.</source><year>2015</year><volume>98</volume><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1002/cpt.134</pub-id><pub-id pub-id-type="pmcid">PMC4938244</pub-id><pub-id pub-id-type="pmid">25871646</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakladar</surname><given-names>J</given-names></name><etal/></person-group><article-title>The liver microbiome is implicated in cancer prognosis and modulated by alcohol and hepatitis B</article-title><source>Cancers (Basel)</source><year>2020</year><volume>12</volume><fpage>1642</fpage><pub-id pub-id-type="doi">10.3390/cancers12061642</pub-id><pub-id pub-id-type="pmid">32575865</pub-id><pub-id pub-id-type="pmcid">PMC7353057</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grierson</surname><given-names>J</given-names></name><name name-style="western"><surname>Flies</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Bissett</surname><given-names>A</given-names></name><name name-style="western"><surname>Ammitzboll</surname><given-names>H</given-names></name><name name-style="western"><surname>Jones</surname><given-names>P</given-names></name></person-group><article-title>Which soil microbiome? Bacteria, fungi, and protozoa communities show different relationships with urban green space type and use-intensity</article-title><source>Sci. Total Environ.</source><year>2023</year><volume>863</volume><fpage>160468</fpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2022.160468</pub-id><pub-id pub-id-type="pmid">36464041</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Ren</surname><given-names>W</given-names></name></person-group><article-title>Intestinal mycobiota in health and diseases: from a disrupted equilibrium to clinical opportunities</article-title><source>Microbiome</source><year>2021</year><volume>9</volume><fpage>60</fpage><pub-id pub-id-type="doi">10.1186/s40168-021-01024-x</pub-id><pub-id pub-id-type="pmid">33715629</pub-id><pub-id pub-id-type="pmcid">PMC7958491</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berg</surname><given-names>G</given-names></name><etal/></person-group><article-title>Microbiome definition re-visited: old concepts and new challenges</article-title><source>Microbiome</source><year>2020</year><volume>8</volume><fpage>103</fpage><pub-id pub-id-type="doi">10.1186/s40168-020-00875-0</pub-id><pub-id pub-id-type="pmid">32605663</pub-id><pub-id pub-id-type="pmcid">PMC7329523</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Sayed</surname><given-names>A</given-names></name><name name-style="western"><surname>Aleya</surname><given-names>L</given-names></name><name name-style="western"><surname>Kamel</surname><given-names>M</given-names></name></person-group><article-title>Microbiota&#8217;s role in health and diseases</article-title><source>Environ. Sci. Pollut. Res. Int.</source><year>2021</year><volume>28</volume><fpage>36967</fpage><lpage>36983</lpage><pub-id pub-id-type="doi">10.1007/s11356-021-14593-z</pub-id><pub-id pub-id-type="pmid">34043164</pub-id><pub-id pub-id-type="pmcid">PMC8155182</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchesi</surname><given-names>JR</given-names></name><name name-style="western"><surname>Ravel</surname><given-names>J</given-names></name></person-group><article-title>The vocabulary of microbiome research: a proposal</article-title><source>Microbiome</source><year>2015</year><volume>3</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.1186/s40168-015-0094-5</pub-id><pub-id pub-id-type="pmid">26229597</pub-id><pub-id pub-id-type="pmcid">PMC4520061</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajendhran</surname><given-names>J</given-names></name><name name-style="western"><surname>Gunasekaran</surname><given-names>P</given-names></name></person-group><article-title>Microbial phylogeny and diversity: small subunit ribosomal RNA sequence analysis and beyond</article-title><source>Microbiol. Res.</source><year>2011</year><volume>166</volume><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2010.02.003</pub-id><pub-id pub-id-type="pmid">20223646</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>PS</given-names></name></person-group><article-title>Microbiomics: were we all wrong before?</article-title><source>Periodontol 2000</source><year>2021</year><volume>85</volume><fpage>8</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1111/prd.12373</pub-id><pub-id pub-id-type="pmid">33226670</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez-Bello</surname><given-names>MG</given-names></name><name name-style="western"><surname>Godoy-Vitorino</surname><given-names>F</given-names></name><name name-style="western"><surname>Knight</surname><given-names>R</given-names></name><name name-style="western"><surname>Blaser</surname><given-names>MJ</given-names></name></person-group><article-title>Role of the microbiome in human development</article-title><source>Gut</source><year>2019</year><volume>68</volume><fpage>1108</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-317503</pub-id><pub-id pub-id-type="pmid">30670574</pub-id><pub-id pub-id-type="pmcid">PMC6580755</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turnbaugh</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>The human microbiome project</article-title><source>Nature</source><year>2007</year><volume>449</volume><fpage>804</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1038/nature06244</pub-id><pub-id pub-id-type="pmid">17943116</pub-id><pub-id pub-id-type="pmcid">PMC3709439</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proctor</surname><given-names>LM</given-names></name></person-group><article-title>The National Institutes of Health Human Microbiome Project</article-title><source>Semin. Fetal Neonatal Med.</source><year>2016</year><volume>21</volume><fpage>368</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/j.siny.2016.05.002</pub-id><pub-id pub-id-type="pmid">27350143</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Integrative, H.M.P.R.N.C.</collab></person-group><article-title>The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease</article-title><source>Cell Host Microbe</source><year>2014</year><volume>16</volume><fpage>276</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2014.08.014</pub-id><pub-id pub-id-type="pmid">25211071</pub-id><pub-id pub-id-type="pmcid">PMC5109542</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilbert</surname><given-names>JA</given-names></name><etal/></person-group><article-title>The Earth Microbiome Project: Meeting report of the &#8220;1 EMP meeting on sample selection and acquisition&#8221; at Argonne National Laboratory October 6 2010</article-title><source>Stand Genom. Sci.</source><year>2010</year><volume>3</volume><fpage>249</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.4056/aigs.1443528</pub-id><pub-id pub-id-type="pmcid">PMC3035312</pub-id><pub-id pub-id-type="pmid">21304728</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilbert</surname><given-names>JA</given-names></name><name name-style="western"><surname>Jansson</surname><given-names>JK</given-names></name><name name-style="western"><surname>Knight</surname><given-names>R</given-names></name></person-group><article-title>The Earth Microbiome project: successes and aspirations</article-title><source>BMC Biol.</source><year>2014</year><volume>12</volume><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s12915-014-0069-1</pub-id><pub-id pub-id-type="pmid">25184604</pub-id><pub-id pub-id-type="pmcid">PMC4141107</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCoubrey</surname><given-names>LE</given-names></name><name name-style="western"><surname>Gaisford</surname><given-names>S</given-names></name><name name-style="western"><surname>Orlu</surname><given-names>M</given-names></name><name name-style="western"><surname>Basit</surname><given-names>AW</given-names></name></person-group><article-title>Predicting drug-microbiome interactions with machine learning</article-title><source>Biotechnol. Adv.</source><year>2022</year><volume>54</volume><fpage>107797</fpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2021.107797</pub-id><pub-id pub-id-type="pmid">34260950</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pryor</surname><given-names>R</given-names></name><name name-style="western"><surname>Martinez-Martinez</surname><given-names>D</given-names></name><name name-style="western"><surname>Quintaneiro</surname><given-names>L</given-names></name><name name-style="western"><surname>Cabreiro</surname><given-names>F</given-names></name></person-group><article-title>The role of the microbiome in drug response</article-title><source>Annu. Rev. Pharm. Toxicol.</source><year>2020</year><volume>60</volume><fpage>417</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010919-023612</pub-id><pub-id pub-id-type="pmid">31386593</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamath</surname><given-names>S</given-names></name><name name-style="western"><surname>Stringer</surname><given-names>AM</given-names></name><name name-style="western"><surname>Prestidge</surname><given-names>CA</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>P</given-names></name></person-group><article-title>Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery</article-title><source>Expert Opin. Drug Deliv</source><year>2023</year><volume>7</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425247.2023.2233900</pub-id><pub-id pub-id-type="pmid">37405390</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>HEF</given-names></name><name name-style="western"><surname>Demers</surname><given-names>K</given-names></name><name name-style="western"><surname>Derijks</surname><given-names>LJJ</given-names></name><name name-style="western"><surname>Jonkers</surname><given-names>D</given-names></name><name name-style="western"><surname>Penders</surname><given-names>J</given-names></name></person-group><article-title>Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease</article-title><source>Front. Microbiol.</source><year>2023</year><volume>14</volume><fpage>1107976</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2023.1107976</pub-id><pub-id pub-id-type="pmid">36910207</pub-id><pub-id pub-id-type="pmcid">PMC9996055</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizkallah</surname><given-names>MR</given-names></name><name name-style="western"><surname>Saad</surname><given-names>R</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>RK</given-names></name></person-group><article-title>The Human Microbiome Project, personalized medicine and the birth of pharmacomicrobiomics</article-title><source>Curr. Pharm. Pers. Med.</source><year>2010</year><volume>8</volume><fpage>182</fpage><lpage>193</lpage></element-citation></ref><ref id="CR191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clayton</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Pharmaco-metabonomic phenotyping and personalized drug treatment</article-title><source>Nature</source><year>2006</year><volume>440</volume><fpage>1073</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1038/nature04648</pub-id><pub-id pub-id-type="pmid">16625200</pub-id></element-citation></ref><ref id="CR192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicholson</surname><given-names>JK</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>ID</given-names></name><name name-style="western"><surname>Lindon</surname><given-names>JC</given-names></name></person-group><article-title>Pharmacometabonomics as an effector for personalized medicine</article-title><source>Pharmacogenomics</source><year>2011</year><volume>12</volume><fpage>103</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.2217/pgs.10.157</pub-id><pub-id pub-id-type="pmid">21174625</pub-id></element-citation></ref><ref id="CR193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nayak</surname><given-names>RR</given-names></name><name name-style="western"><surname>Turnbaugh</surname><given-names>PJ</given-names></name></person-group><article-title>Mirror, mirror on the wall: which microbiomes will help heal them all?</article-title><source>BMC Med.</source><year>2016</year><volume>14</volume><fpage>72</fpage><pub-id pub-id-type="doi">10.1186/s12916-016-0622-6</pub-id><pub-id pub-id-type="pmid">27146150</pub-id><pub-id pub-id-type="pmcid">PMC4857263</pub-id></element-citation></ref><ref id="CR194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balasopoulou</surname><given-names>A</given-names></name><name name-style="western"><surname>Patrinos</surname><given-names>GP</given-names></name><name name-style="western"><surname>Katsila</surname><given-names>T</given-names></name></person-group><article-title>Pharmacometabolomics informs viromics toward precision medicine</article-title><source>Front. Pharm.</source><year>2016</year><volume>7</volume><fpage>411</fpage><pub-id pub-id-type="doi">10.3389/fphar.2016.00411</pub-id><pub-id pub-id-type="pmcid">PMC5081366</pub-id><pub-id pub-id-type="pmid">27833560</pub-id></element-citation></ref><ref id="CR195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katsila</surname><given-names>T</given-names></name><name name-style="western"><surname>Balasopoulou</surname><given-names>A</given-names></name><name name-style="western"><surname>Tsagaraki</surname><given-names>I</given-names></name><name name-style="western"><surname>Patrinos</surname><given-names>GP</given-names></name></person-group><article-title>Pharmacomicrobiomics informs clinical pharmacogenomics</article-title><source>Pharmacogenomics</source><year>2019</year><volume>20</volume><fpage>731</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.2217/pgs-2019-0027</pub-id><pub-id pub-id-type="pmid">31368841</pub-id></element-citation></ref><ref id="CR196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>ID</given-names></name></person-group><article-title>Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>14187</fpage><lpage>14188</lpage><pub-id pub-id-type="doi">10.1073/pnas.0907721106</pub-id><pub-id pub-id-type="pmid">19706501</pub-id><pub-id pub-id-type="pmcid">PMC2732874</pub-id></element-citation></ref><ref id="CR197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pharmacometabonomics: data processing and statistical analysis</article-title><source>Brief. Bioinform.</source><year>2021</year><volume>22</volume><fpage>bbab138</fpage><pub-id pub-id-type="doi">10.1093/bib/bbab138</pub-id><pub-id pub-id-type="pmid">33866355</pub-id></element-citation></ref><ref id="CR198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Everett</surname><given-names>JR</given-names></name></person-group><article-title>From metabonomics to pharmacometabonomics: the role of metabolic profiling in personalized medicine</article-title><source>Front. Pharm.</source><year>2016</year><volume>7</volume><fpage>297</fpage><pub-id pub-id-type="doi">10.3389/fphar.2016.00297</pub-id><pub-id pub-id-type="pmcid">PMC5014868</pub-id><pub-id pub-id-type="pmid">27660611</pub-id></element-citation></ref><ref id="CR199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorbara</surname><given-names>MT</given-names></name><name name-style="western"><surname>Pamer</surname><given-names>EG</given-names></name></person-group><article-title>Microbiome-based therapeutics</article-title><source>Nat. Rev. Microbiol.</source><year>2022</year><volume>20</volume><fpage>365</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00667-9</pub-id><pub-id pub-id-type="pmid">34992261</pub-id></element-citation></ref><ref id="CR200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wainwright</surname><given-names>M</given-names></name><name name-style="western"><surname>Kristiansen</surname><given-names>JE</given-names></name></person-group><article-title>On the 75th anniversary of Prontosil</article-title><source>Dyes Pigments</source><year>2010</year><volume>88</volume><fpage>231</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.dyepig.2010.08.012</pub-id></element-citation></ref><ref id="CR201"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bentley</surname><given-names>R</given-names></name></person-group><article-title>Different roads to discovery; Prontosil (hence sulfa drugs) and penicillin (hence beta-lactams)</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2009</year><volume>36</volume><fpage>775</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1007/s10295-009-0553-8</pub-id><pub-id pub-id-type="pmid">19283418</pub-id></element-citation></ref><ref id="CR202"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paranjape</surname><given-names>K</given-names></name><etal/></person-group><article-title>Unravelling the importance of the eukaryotic and bacterial communities and their relationship with Legionella spp. ecology in cooling towers: a complex network</article-title><source>Microbiome</source><year>2020</year><volume>8</volume><fpage>157</fpage><pub-id pub-id-type="doi">10.1186/s40168-020-00926-6</pub-id><pub-id pub-id-type="pmid">33183356</pub-id><pub-id pub-id-type="pmcid">PMC7664032</pub-id></element-citation></ref><ref id="CR203"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lepage</surname><given-names>P</given-names></name><etal/></person-group><article-title>A metagenomic insight into our gut&#8217;s microbiome</article-title><source>Gut</source><year>2013</year><volume>62</volume><fpage>146</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2011-301805</pub-id><pub-id pub-id-type="pmid">22525886</pub-id></element-citation></ref><ref id="CR204"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valles-Colomer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Meta-omics in inflammatory bowel disease research: applications, challenges, and guidelines</article-title><source>J. Crohns Colitis</source><year>2016</year><volume>10</volume><fpage>735</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjw024</pub-id><pub-id pub-id-type="pmid">26802086</pub-id></element-citation></ref><ref id="CR205"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sha</surname><given-names>G</given-names></name><etal/></person-group><article-title>Integrated meta-omics study on rapid tylosin removal mechanism and dynamics of antibiotic resistance genes during aerobic thermophilic fermentation of tylosin mycelial dregs</article-title><source>Bioresour. Technol.</source><year>2022</year><volume>351</volume><fpage>127010</fpage><pub-id pub-id-type="doi">10.1016/j.biortech.2022.127010</pub-id><pub-id pub-id-type="pmid">35307520</pub-id></element-citation></ref><ref id="CR206"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDaniel</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Prospects for multi-omics in the microbial ecology of water engineering</article-title><source>Water Res.</source><year>2021</year><volume>205</volume><fpage>117608</fpage><pub-id pub-id-type="doi">10.1016/j.watres.2021.117608</pub-id><pub-id pub-id-type="pmid">34555741</pub-id></element-citation></ref><ref id="CR207"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaddurah-Daouk</surname><given-names>R</given-names></name><name name-style="western"><surname>Weinshilboum</surname><given-names>RM</given-names></name><collab>Pharmacometabolomics Research Network</collab></person-group><article-title>Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology</article-title><source>Clin. Pharm. Ther.</source><year>2014</year><volume>95</volume><fpage>154</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1038/clpt.2013.217</pub-id><pub-id pub-id-type="pmid">24193171</pub-id></element-citation></ref><ref id="CR208"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaddurah-Daouk</surname><given-names>R</given-names></name><name name-style="western"><surname>Kristal</surname><given-names>BS</given-names></name><name name-style="western"><surname>Weinshilboum</surname><given-names>RM</given-names></name></person-group><article-title>Metabolomics: a global biochemical approach to drug response and disease</article-title><source>Annu. Rev. Pharm. Toxicol.</source><year>2008</year><volume>48</volume><fpage>653</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.48.113006.094715</pub-id><pub-id pub-id-type="pmid">18184107</pub-id></element-citation></ref><ref id="CR209"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicholson</surname><given-names>JK</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>ID</given-names></name></person-group><article-title>Opinion: understanding &#8216;global&#8217; systems biology: metabonomics and the continuum of metabolism</article-title><source>Nat. Rev. Drug Discov.</source><year>2003</year><volume>2</volume><fpage>668</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1038/nrd1157</pub-id><pub-id pub-id-type="pmid">12904817</pub-id></element-citation></ref><ref id="CR210"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beger</surname><given-names>RD</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kaddurah-Daouk</surname><given-names>R</given-names></name></person-group><article-title>Current concepts in pharmacometabolomics, biomarker discovery, and precision medicine</article-title><source>Metabolites</source><year>2020</year><volume>10</volume><fpage>129</fpage><pub-id pub-id-type="doi">10.3390/metabo10040129</pub-id><pub-id pub-id-type="pmid">32230776</pub-id><pub-id pub-id-type="pmcid">PMC7241083</pub-id></element-citation></ref><ref id="CR211"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Everett</surname><given-names>JR</given-names></name><name name-style="western"><surname>Loo</surname><given-names>RL</given-names></name><name name-style="western"><surname>Pullen</surname><given-names>FS</given-names></name></person-group><article-title>Pharmacometabonomics and personalized medicine</article-title><source>Ann. Clin. Biochem.</source><year>2013</year><volume>50</volume><fpage>523</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1177/0004563213497929</pub-id><pub-id pub-id-type="pmid">23888060</pub-id></element-citation></ref><ref id="CR212"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Everett</surname><given-names>JR</given-names></name></person-group><article-title>Pharmacometabonomics in humans: a new tool for personalized medicine</article-title><source>Pharmacogenomics</source><year>2015</year><volume>16</volume><fpage>737</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.2217/pgs.15.20</pub-id><pub-id pub-id-type="pmid">25929853</pub-id></element-citation></ref><ref id="CR213"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosato</surname><given-names>A</given-names></name><etal/></person-group><article-title>From correlation to causation: analysis of metabolomics data using systems biology approaches</article-title><source>Metabolomics</source><year>2018</year><volume>14</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.1007/s11306-018-1335-y</pub-id><pub-id pub-id-type="pmid">29503602</pub-id><pub-id pub-id-type="pmcid">PMC5829120</pub-id></element-citation></ref><ref id="CR214"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McWhinney</surname><given-names>SR</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>HL</given-names></name></person-group><article-title>Using germline genotype in cancer pharmacogenetic studies</article-title><source>Pharmacogenomics</source><year>2009</year><volume>10</volume><fpage>489</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.2217/14622416.10.3.489</pub-id><pub-id pub-id-type="pmid">19650256</pub-id><pub-id pub-id-type="pmcid">PMC2722037</pub-id></element-citation></ref><ref id="CR215"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derosa</surname><given-names>L</given-names></name><etal/></person-group><article-title>Microbiota-centered interventions: the next breakthrough in immuno-oncology?</article-title><source>Cancer Discov.</source><year>2021</year><volume>11</volume><fpage>2396</fpage><lpage>2412</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-0236</pub-id><pub-id pub-id-type="pmid">34400407</pub-id></element-citation></ref><ref id="CR216"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>QW</given-names></name><name name-style="western"><surname>Liao</surname><given-names>HX</given-names></name><name name-style="western"><surname>Xu</surname><given-names>WW</given-names></name></person-group><article-title>Microbiota in cancer chemoradiotherapy resistance</article-title><source>Clin. Transl. Med.</source><year>2021</year><volume>11</volume><fpage>e250</fpage><pub-id pub-id-type="doi">10.1002/ctm2.250</pub-id><pub-id pub-id-type="pmid">33463064</pub-id><pub-id pub-id-type="pmcid">PMC7774460</pub-id></element-citation></ref><ref id="CR217"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emadi</surname><given-names>A</given-names></name><name name-style="western"><surname>Jones</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Brodsky</surname><given-names>RA</given-names></name></person-group><article-title>Cyclophosphamide and cancer: golden anniversary</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2009</year><volume>6</volume><fpage>638</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2009.146</pub-id><pub-id pub-id-type="pmid">19786984</pub-id></element-citation></ref><ref id="CR218"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gershwin</surname><given-names>ME</given-names></name><name name-style="western"><surname>Goetzl</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>AD</given-names></name></person-group><article-title>Cyclophosphamide: use in practice</article-title><source>Ann. Intern. Med.</source><year>1974</year><volume>80</volume><fpage>531</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-80-4-531</pub-id><pub-id pub-id-type="pmid">4621265</pub-id></element-citation></ref><ref id="CR219"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>JM</given-names></name></person-group><article-title>Metabolism and pulmonary toxicity of cyclophosphamide</article-title><source>Pharm. Ther.</source><year>1990</year><volume>47</volume><fpage>137</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/0163-7258(90)90049-8</pub-id><pub-id pub-id-type="pmid">2195554</pub-id></element-citation></ref><ref id="CR220"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>H</given-names></name><name name-style="western"><surname>Holland</surname><given-names>AE</given-names></name><name name-style="western"><surname>Westall</surname><given-names>GP</given-names></name><name name-style="western"><surname>Goh</surname><given-names>NS</given-names></name><name name-style="western"><surname>Glaspole</surname><given-names>IN</given-names></name></person-group><article-title>Cyclophosphamide for connective tissue disease-associated interstitial lung disease</article-title><source>Cochrane Database Syst. Rev.</source><year>2018</year><volume>1</volume><fpage>CD010908</fpage><pub-id pub-id-type="pmid">29297205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD010908.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6491200</pub-id></element-citation></ref><ref id="CR221"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemente</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma</article-title><source>Cancer</source><year>1996</year><volume>77</volume><fpage>1303</fpage><lpage>1310</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0142(19960401)77:7&amp;#x0003c;1303::AID-CNCR12&amp;#x0003e;3.0.CO;2-5</pub-id><pub-id pub-id-type="pmid">8608507</pub-id></element-citation></ref><ref id="CR222"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa020177</pub-id><pub-id pub-id-type="pmid">12529460</pub-id></element-citation></ref><ref id="CR223"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katz</surname><given-names>SC</given-names></name><etal/></person-group><article-title>T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases</article-title><source>Ann. Surg. Oncol.</source><year>2009</year><volume>16</volume><fpage>2524</fpage><lpage>2530</lpage><pub-id pub-id-type="doi">10.1245/s10434-009-0585-3</pub-id><pub-id pub-id-type="pmid">19568816</pub-id></element-citation></ref><ref id="CR224"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jamiyan</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast</article-title><source>Breast Cancer</source><year>2020</year><volume>27</volume><fpage>880</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1007/s12282-020-01084-1</pub-id><pub-id pub-id-type="pmid">32222891</pub-id><pub-id pub-id-type="pmcid">PMC7438376</pub-id></element-citation></ref><ref id="CR225"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>S</given-names></name><name name-style="western"><surname>Trinchieri</surname><given-names>G</given-names></name></person-group><article-title>Microbiota: a key orchestrator of cancer therapy</article-title><source>Nat. Rev. Cancer</source><year>2017</year><volume>17</volume><fpage>271</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.13</pub-id><pub-id pub-id-type="pmid">28303904</pub-id></element-citation></ref><ref id="CR226"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viaud</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cyclophosphamide induces differentiation of Th17 cells in cancer patients</article-title><source>Cancer Res.</source><year>2011</year><volume>71</volume><fpage>661</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1259</pub-id><pub-id pub-id-type="pmid">21148486</pub-id></element-citation></ref><ref id="CR227"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakahara</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>4384</fpage><lpage>4392</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-11-251231</pub-id><pub-id pub-id-type="pmid">20154220</pub-id><pub-id pub-id-type="pmcid">PMC2881499</pub-id></element-citation></ref><ref id="CR228"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghiringhelli</surname><given-names>F</given-names></name><etal/></person-group><article-title>CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative</article-title><source>Eur. J. Immunol.</source><year>2004</year><volume>34</volume><fpage>336</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1002/eji.200324181</pub-id><pub-id pub-id-type="pmid">14768038</pub-id></element-citation></ref><ref id="CR229"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bracci</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration</article-title><source>Clin. Cancer Res.</source><year>2007</year><volume>13</volume><fpage>644</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1209</pub-id><pub-id pub-id-type="pmid">17255288</pub-id></element-citation></ref><ref id="CR230"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sistigu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immunomodulatory effects of cyclophosphamide and implementations for vaccine design</article-title><source>Semin. Immunopathol.</source><year>2011</year><volume>33</volume><fpage>369</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1007/s00281-011-0245-0</pub-id><pub-id pub-id-type="pmid">21611872</pub-id></element-citation></ref><ref id="CR231"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>E</given-names></name><etal/></person-group><article-title>T-cell modulation by cyclophosphamide for tumour therapy</article-title><source>Immunology</source><year>2018</year><volume>154</volume><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1111/imm.12913</pub-id><pub-id pub-id-type="pmid">29460448</pub-id><pub-id pub-id-type="pmcid">PMC5904691</pub-id></element-citation></ref><ref id="CR232"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madondo</surname><given-names>MT</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>M</given-names></name><name name-style="western"><surname>Plebanski</surname><given-names>M</given-names></name></person-group><article-title>Low dose cyclophosphamide: mechanisms of T cell modulation</article-title><source>Cancer Treat. Rev.</source><year>2016</year><volume>42</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2015.11.005</pub-id><pub-id pub-id-type="pmid">26620820</pub-id></element-citation></ref><ref id="CR233"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name><etal/></person-group><article-title>Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant</article-title><source>J. Hematol. Oncol.</source><year>2022</year><volume>15</volume><fpage>64</fpage><pub-id pub-id-type="doi">10.1186/s13045-022-01287-3</pub-id><pub-id pub-id-type="pmid">35590334</pub-id><pub-id pub-id-type="pmcid">PMC9118756</pub-id></element-citation></ref><ref id="CR234"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toulmonde</surname><given-names>M</given-names></name><name name-style="western"><surname>Demolis</surname><given-names>P</given-names></name><name name-style="western"><surname>Houede</surname><given-names>N</given-names></name></person-group><article-title>Salvage chemotherapy for hormone-refractory prostate cancer: association of Adriamycin and ifosfamide</article-title><source>Exp. Ther. Med.</source><year>2010</year><volume>1</volume><fpage>1005</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.3892/etm.2010.138</pub-id><pub-id pub-id-type="pmid">22993633</pub-id><pub-id pub-id-type="pmcid">PMC3445988</pub-id></element-citation></ref><ref id="CR235"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viaud</surname><given-names>S</given-names></name><etal/></person-group><article-title>The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>971</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1126/science.1240537</pub-id><pub-id pub-id-type="pmid">24264990</pub-id><pub-id pub-id-type="pmcid">PMC4048947</pub-id></element-citation></ref><ref id="CR236"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>KX</given-names></name><name name-style="western"><surname>Qu</surname><given-names>JM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XD</given-names></name></person-group><article-title>The changes induced by cyclophosphamide in intestinal barrier and microflora in mice</article-title><source>Eur. J. Pharm.</source><year>2013</year><volume>714</volume><fpage>120</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2013.06.006</pub-id><pub-id pub-id-type="pmid">23791611</pub-id></element-citation></ref><ref id="CR237"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>Effects of cyclophosphamide on immune system and gut microbiota in mice</article-title><source>Microbiol. Res.</source><year>2015</year><volume>171</volume><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2014.11.002</pub-id><pub-id pub-id-type="pmid">25553830</pub-id></element-citation></ref><ref id="CR238"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daillere</surname><given-names>R</given-names></name><etal/></person-group><article-title>Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects</article-title><source>Immunity</source><year>2016</year><volume>45</volume><fpage>931</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.09.009</pub-id><pub-id pub-id-type="pmid">27717798</pub-id></element-citation></ref><ref id="CR239"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mego</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study</article-title><source>Complement Ther. Med.</source><year>2015</year><volume>23</volume><fpage>356</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.ctim.2015.03.008</pub-id><pub-id pub-id-type="pmid">26051570</pub-id></element-citation></ref><ref id="CR240"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bleiberg</surname><given-names>H</given-names></name></person-group><article-title>CPT-11 in gastrointestinal cancer</article-title><source>Eur. J. Cancer</source><year>1999</year><volume>35</volume><fpage>371</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(98)00423-7</pub-id><pub-id pub-id-type="pmid">10448285</pub-id></element-citation></ref><ref id="CR241"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobi</surname><given-names>A</given-names></name><name name-style="western"><surname>Gasque</surname><given-names>P</given-names></name><name name-style="western"><surname>Guiraud</surname><given-names>P</given-names></name><name name-style="western"><surname>Selambarom</surname><given-names>J</given-names></name></person-group><article-title>Irinotecan (CPT-11) canonical anti-cancer drug can also modulate antiviral and pro-inflammatory responses of primary human synovial fibroblasts</article-title><source>Cells</source><year>2021</year><volume>10</volume><fpage>1431</fpage><pub-id pub-id-type="doi">10.3390/cells10061431</pub-id><pub-id pub-id-type="pmid">34201243</pub-id><pub-id pub-id-type="pmcid">PMC8230279</pub-id></element-citation></ref><ref id="CR242"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bailly</surname><given-names>C</given-names></name></person-group><article-title>Irinotecan: 25 years of cancer treatment</article-title><source>Pharm. Res.</source><year>2019</year><volume>148</volume><fpage>104398</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.104398</pub-id><pub-id pub-id-type="pmid">31415916</pub-id></element-citation></ref><ref id="CR243"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group><article-title>In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy</article-title><source>Biomaterials</source><year>2021</year><volume>268</volume><fpage>120542</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120542</pub-id><pub-id pub-id-type="pmid">33249316</pub-id></element-citation></ref><ref id="CR244"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karas</surname><given-names>S</given-names></name><etal/></person-group><article-title>Optimal sampling strategies for irinotecan (CPT-11) and its active metabolite (SN-38) in cancer patients</article-title><source>AAPS J.</source><year>2020</year><volume>22</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.1208/s12248-020-0429-4</pub-id><pub-id pub-id-type="pmid">32185579</pub-id></element-citation></ref><ref id="CR245"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stringer</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats</article-title><source>Cancer Biol. Ther.</source><year>2008</year><volume>7</volume><fpage>1919</fpage><lpage>1925</lpage><pub-id pub-id-type="doi">10.4161/cbt.7.12.6940</pub-id><pub-id pub-id-type="pmid">18927500</pub-id></element-citation></ref><ref id="CR246"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flieger</surname><given-names>D</given-names></name><etal/></person-group><article-title>Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma</article-title><source>Oncology</source><year>2007</year><volume>72</volume><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1159/000111083</pub-id><pub-id pub-id-type="pmid">17998785</pub-id></element-citation></ref><ref id="CR247"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kehrer</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients</article-title><source>Clin. Cancer Res.</source><year>2001</year><volume>7</volume><fpage>1136</fpage><lpage>1141</lpage><pub-id pub-id-type="pmid">11350876</pub-id></element-citation></ref><ref id="CR248"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leibovici</surname><given-names>L</given-names></name><etal/></person-group><article-title>Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions</article-title><source>Cancer</source><year>2006</year><volume>107</volume><fpage>1743</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1002/cncr.22205</pub-id><pub-id pub-id-type="pmid">16977651</pub-id></element-citation></ref><ref id="CR249"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>BD</given-names></name><etal/></person-group><article-title>Alleviating cancer drug toxicity by inhibiting a bacterial enzyme</article-title><source>Science</source><year>2010</year><volume>330</volume><fpage>831</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1126/science.1191175</pub-id><pub-id pub-id-type="pmid">21051639</pub-id><pub-id pub-id-type="pmcid">PMC3110694</pub-id></element-citation></ref><ref id="CR250"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>R</given-names></name><etal/></person-group><article-title>Old drug new use-amoxapine and its metabolites as potent bacterial beta-glucuronidase inhibitors for alleviating cancer drug toxicity</article-title><source>Clin. Cancer Res.</source><year>2014</year><volume>20</volume><fpage>3521</fpage><lpage>3530</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0395</pub-id><pub-id pub-id-type="pmid">24780296</pub-id><pub-id pub-id-type="pmcid">PMC4079752</pub-id></element-citation></ref><ref id="CR251"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>PT</given-names></name><etal/></person-group><article-title>Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of beta-glucuronidase in tumors</article-title><source>Cancer Gene Ther.</source><year>2011</year><volume>18</volume><fpage>381</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1038/cgt.2011.3</pub-id><pub-id pub-id-type="pmid">21350582</pub-id></element-citation></ref><ref id="CR252"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Pharmacological inhibition of bacterial beta-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo</article-title><source>Pharm. Res.</source><year>2019</year><volume>139</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.10.029</pub-id><pub-id pub-id-type="pmid">30391354</pub-id></element-citation></ref><ref id="CR253"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chamseddine</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Intestinal bacterial beta-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity</article-title><source>Pharm. Ther.</source><year>2019</year><volume>199</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2019.03.002</pub-id><pub-id pub-id-type="pmid">30831128</pub-id></element-citation></ref><ref id="CR254"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallotti</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effects of dietary fibre intake in chemotherapy-induced mucositis in murine model</article-title><source>Br. J. Nutr.</source><year>2021</year><volume>126</volume><fpage>853</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1017/S0007114520004924</pub-id><pub-id pub-id-type="pmid">33298215</pub-id></element-citation></ref><ref id="CR255"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takasuna</surname><given-names>K</given-names></name><etal/></person-group><article-title>Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats</article-title><source>Cancer Res.</source><year>1996</year><volume>56</volume><fpage>3752</fpage><lpage>3757</lpage><pub-id pub-id-type="pmid">8706020</pub-id></element-citation></ref><ref id="CR256"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Songjang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Tumor-promoting activity and proteomic profiling of cisplatin/oxaliplatin-derived DAMPs in cholangiocarcinoma cells</article-title><source>Int J. Mol. Sci.</source><year>2022</year><volume>23</volume><fpage>10540</fpage><pub-id pub-id-type="doi">10.3390/ijms231810540</pub-id><pub-id pub-id-type="pmid">36142453</pub-id><pub-id pub-id-type="pmcid">PMC9502173</pub-id></element-citation></ref><ref id="CR257"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skripova</surname><given-names>V</given-names></name><name name-style="western"><surname>Vlasenkova</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Astsaturov</surname><given-names>I</given-names></name><name name-style="western"><surname>Kiyamova</surname><given-names>R</given-names></name></person-group><article-title>Identification of new regulators of pancreatic cancer cell sensitivity to oxaliplatin and cisplatin</article-title><source>Molecules</source><year>2022</year><volume>27</volume><fpage>1289</fpage><pub-id pub-id-type="doi">10.3390/molecules27041289</pub-id><pub-id pub-id-type="pmid">35209078</pub-id><pub-id pub-id-type="pmcid">PMC8875979</pub-id></element-citation></ref><ref id="CR258"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Q</given-names></name></person-group><article-title>Platinum-based drugs for cancer therapy and anti-tumor strategies</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><fpage>2115</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.7150/thno.69424</pub-id><pub-id pub-id-type="pmid">35265202</pub-id><pub-id pub-id-type="pmcid">PMC8899578</pub-id></element-citation></ref><ref id="CR259"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer</article-title><source>Ann. Oncol.</source><year>2015</year><volume>26</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu472</pub-id><pub-id pub-id-type="pmid">25316259</pub-id></element-citation></ref><ref id="CR260"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaisman</surname><given-names>A</given-names></name><name name-style="western"><surname>Masutani</surname><given-names>C</given-names></name><name name-style="western"><surname>Hanaoka</surname><given-names>F</given-names></name><name name-style="western"><surname>Chaney</surname><given-names>SG</given-names></name></person-group><article-title>Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta</article-title><source>Biochemistry</source><year>2000</year><volume>39</volume><fpage>4575</fpage><lpage>4580</lpage><pub-id pub-id-type="doi">10.1021/bi000130k</pub-id><pub-id pub-id-type="pmid">10769112</pub-id></element-citation></ref><ref id="CR261"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruet-Hennequart</surname><given-names>S</given-names></name><name name-style="western"><surname>Glynn</surname><given-names>MT</given-names></name><name name-style="western"><surname>Murillo</surname><given-names>LS</given-names></name><name name-style="western"><surname>Coyne</surname><given-names>S</given-names></name><name name-style="western"><surname>Carty</surname><given-names>MP</given-names></name></person-group><article-title>Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin</article-title><source>DNA Repair (Amst.)</source><year>2008</year><volume>7</volume><fpage>582</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2007.12.012</pub-id><pub-id pub-id-type="pmid">18289945</pub-id></element-citation></ref><ref id="CR262"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lokody</surname><given-names>I</given-names></name></person-group><article-title>Tumour microenvironment: bacterial balance affects cancer treatment</article-title><source>Nat. Rev. Cancer</source><year>2014</year><volume>14</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1038/nrc3827</pub-id><pub-id pub-id-type="pmid">24505616</pub-id></element-citation></ref><ref id="CR263"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iida</surname><given-names>N</given-names></name><etal/></person-group><article-title>Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>967</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1126/science.1240527</pub-id><pub-id pub-id-type="pmid">24264989</pub-id><pub-id pub-id-type="pmcid">PMC6709532</pub-id></element-citation></ref><ref id="CR264"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberti</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>919</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0882-8</pub-id><pub-id pub-id-type="pmid">32451498</pub-id></element-citation></ref><ref id="CR265"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachem</surname><given-names>A</given-names></name><etal/></person-group><article-title>Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8(+) T cells</article-title><source>Immunity</source><year>2019</year><volume>51</volume><fpage>285</fpage><lpage>297 e5</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.06.002</pub-id><pub-id pub-id-type="pmid">31272808</pub-id></element-citation></ref><ref id="CR266"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity</article-title><source>Cell Metab.</source><year>2021</year><volume>33</volume><fpage>988</fpage><lpage>1000 e7</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.03.002</pub-id><pub-id pub-id-type="pmid">33761313</pub-id></element-citation></ref><ref id="CR267"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4</article-title><source>Mol. Cancer</source><year>2019</year><volume>18</volume><fpage>155</fpage><pub-id pub-id-type="doi">10.1186/s12943-019-1091-2</pub-id><pub-id pub-id-type="pmid">31690319</pub-id><pub-id pub-id-type="pmcid">PMC6833286</pub-id></element-citation></ref><ref id="CR268"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>LP</given-names></name><name name-style="western"><surname>Yano</surname><given-names>H</given-names></name><name name-style="western"><surname>Vignali</surname><given-names>DAA</given-names></name></person-group><article-title>Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups</article-title><source>Nat. Immunol.</source><year>2019</year><volume>20</volume><fpage>1425</fpage><lpage>1434</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0512-0</pub-id><pub-id pub-id-type="pmid">31611702</pub-id></element-citation></ref><ref id="CR269"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burugu</surname><given-names>S</given-names></name><name name-style="western"><surname>Dancsok</surname><given-names>AR</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>TO</given-names></name></person-group><article-title>Emerging targets in cancer immunotherapy</article-title><source>Semin Cancer Biol.</source><year>2018</year><volume>52</volume><fpage>39</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2017.10.001</pub-id><pub-id pub-id-type="pmid">28987965</pub-id></element-citation></ref><ref id="CR270"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vetizou</surname><given-names>M</given-names></name><etal/></person-group><article-title>Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota</article-title><source>Science</source><year>2015</year><volume>350</volume><fpage>1079</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1126/science.aad1329</pub-id><pub-id pub-id-type="pmid">26541610</pub-id><pub-id pub-id-type="pmcid">PMC4721659</pub-id></element-citation></ref><ref id="CR271"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy</article-title><source>Science</source><year>2015</year><volume>350</volume><fpage>1084</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1126/science.aac4255</pub-id><pub-id pub-id-type="pmid">26541606</pub-id><pub-id pub-id-type="pmcid">PMC4873287</pub-id></element-citation></ref><ref id="CR272"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaput</surname><given-names>N</given-names></name><etal/></person-group><article-title>Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab</article-title><source>Ann. Oncol.</source><year>2017</year><volume>28</volume><fpage>1368</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdx108</pub-id><pub-id pub-id-type="pmid">28368458</pub-id></element-citation></ref><ref id="CR273"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gopalakrishnan</surname><given-names>V</given-names></name><etal/></person-group><article-title>Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1126/science.aan4236</pub-id><pub-id pub-id-type="pmid">29097493</pub-id><pub-id pub-id-type="pmcid">PMC5827966</pub-id></element-citation></ref><ref id="CR274"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Routy</surname><given-names>B</given-names></name><etal/></person-group><article-title>Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1126/science.aan3706</pub-id><pub-id pub-id-type="pmid">29097494</pub-id></element-citation></ref><ref id="CR275"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matson</surname><given-names>V</given-names></name><etal/></person-group><article-title>The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>104</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1126/science.aao3290</pub-id><pub-id pub-id-type="pmid">29302014</pub-id><pub-id pub-id-type="pmcid">PMC6707353</pub-id></element-citation></ref><ref id="CR276"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanoue</surname><given-names>T</given-names></name><etal/></person-group><article-title>A defined commensal consortium elicits CD8 T cells and anti-cancer immunity</article-title><source>Nature</source><year>2019</year><volume>565</volume><fpage>600</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-0878-z</pub-id><pub-id pub-id-type="pmid">30675064</pub-id></element-citation></ref><ref id="CR277"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helmink</surname><given-names>BA</given-names></name><etal/></person-group><article-title>B cells and tertiary lymphoid structures promote immunotherapy response</article-title><source>Nature</source><year>2020</year><volume>577</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1922-8</pub-id><pub-id pub-id-type="pmid">31942075</pub-id><pub-id pub-id-type="pmcid">PMC8762581</pub-id></element-citation></ref><ref id="CR278"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poore</surname><given-names>GD</given-names></name><etal/></person-group><article-title>Microbiome analyses of blood and tissues suggest cancer diagnostic approach</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>567</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2095-1</pub-id><pub-id pub-id-type="pmid">32214244</pub-id><pub-id pub-id-type="pmcid">PMC7500457</pub-id></element-citation></ref><ref id="CR279"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costea</surname><given-names>PI</given-names></name><etal/></person-group><article-title>Towards standards for human fecal sample processing in metagenomic studies</article-title><source>Nat. Biotechnol.</source><year>2017</year><volume>35</volume><fpage>1069</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1038/nbt.3960</pub-id><pub-id pub-id-type="pmid">28967887</pub-id></element-citation></ref><ref id="CR280"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tam</surname><given-names>V</given-names></name><etal/></person-group><article-title>Benefits and limitations of genome-wide association studies</article-title><source>Nat. Rev. Genet</source><year>2019</year><volume>20</volume><fpage>467</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1038/s41576-019-0127-1</pub-id><pub-id pub-id-type="pmid">31068683</pub-id></element-citation></ref><ref id="CR281"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baruch</surname><given-names>EN</given-names></name><etal/></person-group><article-title>Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>602</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1126/science.abb5920</pub-id><pub-id pub-id-type="pmid">33303685</pub-id></element-citation></ref><ref id="CR282"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davar</surname><given-names>D</given-names></name><etal/></person-group><article-title>Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1126/science.abf3363</pub-id><pub-id pub-id-type="pmid">33542131</pub-id><pub-id pub-id-type="pmcid">PMC8097968</pub-id></element-citation></ref><ref id="CR283"><label>283.</label><mixed-citation publication-type="other">Jamison, D. T. et al. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): The International Bank for Reconstruction and Development/ The World Bank (2006).<pub-id pub-id-type="pmid">21250309</pub-id></mixed-citation></ref><ref id="CR284"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cardiovascular disease (CVD) and associated risk factors among older adults in six low-and middle-income countries: results from SAGE Wave 1</article-title><source>BMC Public Health</source><year>2018</year><volume>18</volume><fpage>778</fpage><pub-id pub-id-type="doi">10.1186/s12889-018-5653-9</pub-id><pub-id pub-id-type="pmid">29925336</pub-id><pub-id pub-id-type="pmcid">PMC6011508</pub-id></element-citation></ref><ref id="CR285"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nitsa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vitamin D in cardiovascular disease</article-title><source>Vivo</source><year>2018</year><volume>32</volume><fpage>977</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.21873/invivo.11338</pub-id><pub-id pub-id-type="pmcid">PMC6199603</pub-id><pub-id pub-id-type="pmid">30150419</pub-id></element-citation></ref><ref id="CR286"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015</article-title><source>J. Am. Coll. Cardiol.</source><year>2017</year><volume>70</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2017.04.052</pub-id><pub-id pub-id-type="pmid">28527533</pub-id><pub-id pub-id-type="pmcid">PMC5491406</pub-id></element-citation></ref><ref id="CR287"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuo</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Interactions of antithrombotic herbal medicines with Western cardiovascular drugs</article-title><source>Pharm. Res.</source><year>2020</year><volume>159</volume><fpage>104963</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104963</pub-id><pub-id pub-id-type="pmid">32497719</pub-id></element-citation></ref><ref id="CR288"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curini</surname><given-names>L</given-names></name><name name-style="western"><surname>Amedei</surname><given-names>A</given-names></name></person-group><article-title>Cardiovascular diseases and pharmacomicrobiomics: a perspective on possible treatment relevance</article-title><source>Biomedicines</source><year>2021</year><volume>9</volume><fpage>1338</fpage><pub-id pub-id-type="doi">10.3390/biomedicines9101338</pub-id><pub-id pub-id-type="pmid">34680455</pub-id><pub-id pub-id-type="pmcid">PMC8533057</pub-id></element-citation></ref><ref id="CR289"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyoung</surname><given-names>J</given-names></name><name name-style="western"><surname>Atluri</surname><given-names>RR</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name></person-group><article-title>Resistance to antihypertensive drugs: is gut microbiota the missing link?</article-title><source>Hypertension</source><year>2022</year><volume>79</volume><fpage>2138</fpage><lpage>2147</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.122.19826</pub-id><pub-id pub-id-type="pmid">35862173</pub-id></element-citation></ref><ref id="CR290"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakaroun</surname><given-names>RM</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>LM</given-names></name><name name-style="western"><surname>Backhed</surname><given-names>F</given-names></name></person-group><article-title>The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease</article-title><source>Nat. Rev. Cardiol.</source><year>2023</year><volume>20</volume><fpage>217</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1038/s41569-022-00771-0</pub-id><pub-id pub-id-type="pmid">36241728</pub-id></element-citation></ref><ref id="CR291"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Gut microbiota and hypertension: association, mechanisms and treatment</article-title><source>Clin. Exp. Hypertens.</source><year>2023</year><volume>45</volume><fpage>2195135</fpage><pub-id pub-id-type="doi">10.1080/10641963.2023.2195135</pub-id><pub-id pub-id-type="pmid">36994745</pub-id></element-citation></ref><ref id="CR292"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>HQ</given-names></name><etal/></person-group><article-title>Pharmacomicrobiomics: exploiting the drug-microbiota interactions in antihypertensive treatment</article-title><source>Front. Med. (Lausanne)</source><year>2021</year><volume>8</volume><fpage>742394</fpage><pub-id pub-id-type="doi">10.3389/fmed.2021.742394</pub-id><pub-id pub-id-type="pmid">35127738</pub-id><pub-id pub-id-type="pmcid">PMC8808336</pub-id></element-citation></ref><ref id="CR293"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pirmohamed</surname><given-names>M</given-names></name></person-group><article-title>Warfarin: almost 60 years old and still causing problems</article-title><source>Br. J. Clin. Pharm.</source><year>2006</year><volume>62</volume><fpage>509</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2006.02806.x</pub-id><pub-id pub-id-type="pmcid">PMC1885167</pub-id><pub-id pub-id-type="pmid">17061959</pub-id></element-citation></ref><ref id="CR294"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimmel</surname><given-names>SE</given-names></name></person-group><article-title>Warfarin pharmacogenomics: current best evidence</article-title><source>J. Thromb. Haemost.</source><year>2015</year><volume>13</volume><fpage>S266</fpage><lpage>S271</lpage><pub-id pub-id-type="doi">10.1111/jth.12978</pub-id><pub-id pub-id-type="pmid">26149035</pub-id></element-citation></ref><ref id="CR295"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition</article-title><source>Blood</source><year>2018</year><volume>132</volume><fpage>647</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-01-830901</pub-id><pub-id pub-id-type="pmid">29743176</pub-id><pub-id pub-id-type="pmcid">PMC6085993</pub-id></element-citation></ref><ref id="CR296"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czogalla</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Warfarin and vitamin K compete for binding to Phe55 in human VKOR</article-title><source>Nat. Struct. Mol. Biol.</source><year>2017</year><volume>24</volume><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3338</pub-id><pub-id pub-id-type="pmid">27941861</pub-id></element-citation></ref><ref id="CR297"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>A novel vitamin K derived anticoagulant tolerant to genetic variations of vitamin K epoxide reductase</article-title><source>J. Thromb. Haemost.</source><year>2021</year><volume>19</volume><fpage>689</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1111/jth.15209</pub-id><pub-id pub-id-type="pmid">33314621</pub-id><pub-id pub-id-type="pmcid">PMC7925372</pub-id></element-citation></ref><ref id="CR298"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rishavy</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase</article-title><source>Blood</source><year>2018</year><volume>131</volume><fpage>2826</fpage><lpage>2835</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-09-804666</pub-id><pub-id pub-id-type="pmid">29592891</pub-id><pub-id pub-id-type="pmcid">PMC6014353</pub-id></element-citation></ref><ref id="CR299"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wise</surname><given-names>ES</given-names></name><etal/></person-group><article-title>The influence of VKORC1 and CYP2C9 mutations on warfarin response after total hip and knee arthroplasty</article-title><source>J. Orthop.</source><year>2015</year><volume>12</volume><fpage>S145</fpage><lpage>S151</lpage><pub-id pub-id-type="doi">10.1016/j.jor.2015.10.023</pub-id><pub-id pub-id-type="pmid">27047214</pub-id><pub-id pub-id-type="pmcid">PMC4796661</pub-id></element-citation></ref><ref id="CR300"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jorgensen</surname><given-names>AL</given-names></name><name name-style="western"><surname>FitzGerald</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Oyee</surname><given-names>J</given-names></name><name name-style="western"><surname>Pirmohamed</surname><given-names>M</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>PR</given-names></name></person-group><article-title>Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e44064</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0044064</pub-id><pub-id pub-id-type="pmid">22952875</pub-id><pub-id pub-id-type="pmcid">PMC3430615</pub-id></element-citation></ref><ref id="CR301"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>L</given-names></name><etal/></person-group><article-title>Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients</article-title><source>Br. J. Clin. Pharm.</source><year>2017</year><volume>83</volume><fpage>823</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1111/bcp.13157</pub-id><pub-id pub-id-type="pmcid">PMC5346875</pub-id><pub-id pub-id-type="pmid">27763679</pub-id></element-citation></ref><ref id="CR302"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>The gut microbes, Enterococcus and Escherichia-Shigella, affect the responses of heart valve replacement patients to the anticoagulant warfarin</article-title><source>Pharm. Res.</source><year>2020</year><volume>159</volume><fpage>104979</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104979</pub-id><pub-id pub-id-type="pmid">32505835</pub-id></element-citation></ref><ref id="CR303"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>NC</given-names></name><name name-style="western"><surname>Watts</surname><given-names>GF</given-names></name><name name-style="western"><surname>Eckel</surname><given-names>RH</given-names></name></person-group><article-title>Statin toxicity</article-title><source>Circ. Res.</source><year>2019</year><volume>124</volume><fpage>328</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.312782</pub-id><pub-id pub-id-type="pmid">30653440</pub-id></element-citation></ref><ref id="CR304"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>GB</given-names></name></person-group><article-title>Statins outperform dietary supplements for LDL-C lowering</article-title><source>Nat. Rev. Cardiol.</source><year>2023</year><volume>20</volume><fpage>6</fpage><pub-id pub-id-type="pmid">36376434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-022-00809-3</pub-id></element-citation></ref><ref id="CR305"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dehnavi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Statins and autoimmunity: state-of-the-art</article-title><source>Pharm. Ther.</source><year>2020</year><volume>214</volume><fpage>107614</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107614</pub-id><pub-id pub-id-type="pmid">32592715</pub-id></element-citation></ref><ref id="CR306"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnett</surname><given-names>DK</given-names></name><etal/></person-group><article-title>ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title><source>Circulation</source><year>2019</year><volume>140</volume><fpage>e596</fpage><lpage>e646</lpage><pub-id pub-id-type="pmid">30879355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000000678</pub-id><pub-id pub-id-type="pmcid">PMC7734661</pub-id></element-citation></ref><ref id="CR307"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liao</surname><given-names>JK</given-names></name></person-group><article-title>Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy</article-title><source>Curr. Pharm. Des.</source><year>2009</year><volume>15</volume><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.2174/138161209787315684</pub-id><pub-id pub-id-type="pmid">19199975</pub-id><pub-id pub-id-type="pmcid">PMC2896785</pub-id></element-citation></ref><ref id="CR308"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oesterle</surname><given-names>A</given-names></name><name name-style="western"><surname>Laufs</surname><given-names>U</given-names></name><name name-style="western"><surname>Liao</surname><given-names>JK</given-names></name></person-group><article-title>Pleiotropic effects of statins on the cardiovascular system</article-title><source>Circ. Res.</source><year>2017</year><volume>120</volume><fpage>229</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.308537</pub-id><pub-id pub-id-type="pmid">28057795</pub-id><pub-id pub-id-type="pmcid">PMC5467317</pub-id></element-citation></ref><ref id="CR309"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group><article-title>Alterations in gut microbiota by statin therapy and possible intermediate effects on hyperglycemia and hyperlipidemia</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><fpage>1947</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.01947</pub-id><pub-id pub-id-type="pmid">31551944</pub-id><pub-id pub-id-type="pmcid">PMC6736992</pub-id></element-citation></ref><ref id="CR310"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caparros-Martin</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism</article-title><source>Microbiome</source><year>2017</year><volume>5</volume><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/s40168-017-0312-4</pub-id><pub-id pub-id-type="pmid">28793934</pub-id><pub-id pub-id-type="pmcid">PMC5550934</pub-id></element-citation></ref><ref id="CR311"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuteja</surname><given-names>S</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>JF</given-names></name></person-group><article-title>Gut microbiome and response to cardiovascular drugs</article-title><source>Circ. Genom. Precis Med.</source><year>2019</year><volume>12</volume><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1161/CIRCGEN.119.002314</pub-id><pub-id pub-id-type="pmid">31462078</pub-id><pub-id pub-id-type="pmcid">PMC6751004</pub-id></element-citation></ref><ref id="CR312"><label>312.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>TJ</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>PS</given-names></name></person-group><article-title>Digoxin in heart failure and cardiac arrhythmias</article-title><source>Med. J. Aust.</source><year>2003</year><volume>179</volume><fpage>98</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.5694/j.1326-5377.2003.tb05445.x</pub-id><pub-id pub-id-type="pmid">12864722</pub-id></element-citation></ref><ref id="CR313"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patocka</surname><given-names>J</given-names></name><name name-style="western"><surname>Nepovimova</surname><given-names>E</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><name name-style="western"><surname>Kuca</surname><given-names>K</given-names></name></person-group><article-title>Digoxin: pharmacology and toxicology-A review</article-title><source>Environ. Toxicol. Pharm.</source><year>2020</year><volume>79</volume><fpage>103400</fpage><pub-id pub-id-type="doi">10.1016/j.etap.2020.103400</pub-id><pub-id pub-id-type="pmid">32464466</pub-id></element-citation></ref><ref id="CR314"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haiser</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta</article-title><source>Science</source><year>2013</year><volume>341</volume><fpage>295</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1126/science.1235872</pub-id><pub-id pub-id-type="pmid">23869020</pub-id><pub-id pub-id-type="pmcid">PMC3736355</pub-id></element-citation></ref><ref id="CR315"><label>315.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>JR</given-names></name><name name-style="western"><surname>Butler</surname><given-names>VP</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Neu</surname><given-names>HC</given-names></name><name name-style="western"><surname>Lindenbaum</surname><given-names>J</given-names></name></person-group><article-title>Digoxin-inactivating bacteria: identification in human gut flora</article-title><source>Science</source><year>1983</year><volume>220</volume><fpage>325</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1126/science.6836275</pub-id><pub-id pub-id-type="pmid">6836275</pub-id></element-citation></ref><ref id="CR316"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Eggerthella lenta bloodstream infections: two cases and review of the literature</article-title><source>Future Microbiol.</source><year>2020</year><volume>15</volume><fpage>981</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.2217/fmb-2019-0338</pub-id><pub-id pub-id-type="pmid">32815419</pub-id></element-citation></ref><ref id="CR317"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kageyama</surname><given-names>A</given-names></name><name name-style="western"><surname>Benno</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakase</surname><given-names>T</given-names></name></person-group><article-title>Phylogenetic evidence for the transfer of Eubacterium lentum to the genus Eggerthella as Eggerthella lenta gen. nov., comb. nov</article-title><source>Int J. Syst. Bacteriol.</source><year>1999</year><volume>49</volume><fpage>1725</fpage><lpage>1732</lpage><pub-id pub-id-type="doi">10.1099/00207713-49-4-1725</pub-id><pub-id pub-id-type="pmid">10555354</pub-id></element-citation></ref><ref id="CR318"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haiser</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Seim</surname><given-names>KL</given-names></name><name name-style="western"><surname>Balskus</surname><given-names>EP</given-names></name><name name-style="western"><surname>Turnbaugh</surname><given-names>PJ</given-names></name></person-group><article-title>Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics</article-title><source>Gut Microbes</source><year>2014</year><volume>5</volume><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.4161/gmic.27915</pub-id><pub-id pub-id-type="pmid">24637603</pub-id><pub-id pub-id-type="pmcid">PMC4063850</pub-id></element-citation></ref><ref id="CR319"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Diet rapidly and reproducibly alters the human gut microbiome</article-title><source>Nature</source><year>2014</year><volume>505</volume><fpage>559</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/nature12820</pub-id><pub-id pub-id-type="pmid">24336217</pub-id><pub-id pub-id-type="pmcid">PMC3957428</pub-id></element-citation></ref><ref id="CR320"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evered</surname><given-names>MD</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>MM</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>MA</given-names></name></person-group><article-title>Captopril given intracerebroventricularly, subcutaneously or by gavage inhibits angiotensin-converting enzyme activity in the rat brain</article-title><source>Eur. J. Pharm.</source><year>1980</year><volume>68</volume><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(80)90419-7</pub-id><pub-id pub-id-type="pmid">6258934</pub-id></element-citation></ref><ref id="CR321"><label>321.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antunes</surname><given-names>AM</given-names></name><name name-style="western"><surname>Guerrante</surname><given-names>RD</given-names></name><name name-style="western"><surname>Avila</surname><given-names>JP</given-names></name><name name-style="western"><surname>Lins Mendes</surname><given-names>FM</given-names></name><name name-style="western"><surname>Fierro</surname><given-names>IM</given-names></name></person-group><article-title>Case study of patents related to captopril, Squibb&#8217;s first blockbuster</article-title><source>Expert Opin. Ther. Pat.</source><year>2016</year><volume>26</volume><fpage>1449</fpage><lpage>1457</lpage><pub-id pub-id-type="doi">10.1080/13543776.2016.1227321</pub-id><pub-id pub-id-type="pmid">27573807</pub-id></element-citation></ref><ref id="CR322"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berecek</surname><given-names>KH</given-names></name><name name-style="western"><surname>Reaves</surname><given-names>P</given-names></name><name name-style="western"><surname>Raizada</surname><given-names>M</given-names></name></person-group><article-title>Effects of early perturbation of the renin-angiotensin system on cardiovascular remodeling in spontaneously hypertensive rats</article-title><source>Vasc. Pharm.</source><year>2005</year><volume>42</volume><fpage>93</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.vph.2005.01.010</pub-id><pub-id pub-id-type="pmid">15792926</pub-id></element-citation></ref><ref id="CR323"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>JN</given-names></name><name name-style="western"><surname>Berecek</surname><given-names>KH</given-names></name></person-group><article-title>Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril</article-title><source>Hypertension</source><year>1993</year><volume>22</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.22.2.139</pub-id><pub-id pub-id-type="pmid">8340149</pub-id></element-citation></ref><ref id="CR324"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>DG</given-names></name><name name-style="western"><surname>Berecek</surname><given-names>KH</given-names></name></person-group><article-title>Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY)</article-title><source>Clin. Exp. Hypertens.</source><year>1996</year><volume>18</volume><fpage>201</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.3109/10641969609081765</pub-id><pub-id pub-id-type="pmid">8869001</pub-id></element-citation></ref><ref id="CR325"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Lam</surname><given-names>TYC</given-names></name><name name-style="western"><surname>Shum</surname><given-names>TF</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>TY</given-names></name><name name-style="western"><surname>Chiou</surname><given-names>J</given-names></name></person-group><article-title>Hypotensive effect of captopril on deoxycorticosterone acetate-salt-induced hypertensive rat is associated with gut microbiota alteration</article-title><source>Hypertens. Res.</source><year>2022</year><volume>45</volume><fpage>270</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1038/s41440-021-00796-x</pub-id><pub-id pub-id-type="pmid">34857899</pub-id><pub-id pub-id-type="pmcid">PMC8766282</pub-id></element-citation></ref><ref id="CR326"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><etal/></person-group><article-title>Sustained captopril-induced reduction in blood pressure is associated with alterations in gut-brain axis in the spontaneously hypertensive rat</article-title><source>J. Am. Heart Assoc.</source><year>2019</year><volume>8</volume><fpage>e010721</fpage><pub-id pub-id-type="doi">10.1161/JAHA.118.010721</pub-id><pub-id pub-id-type="pmid">30755073</pub-id><pub-id pub-id-type="pmcid">PMC6405665</pub-id></element-citation></ref><ref id="CR327"><label>327.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Richards</surname><given-names>EM</given-names></name><name name-style="western"><surname>Pepine</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Raizada</surname><given-names>MK</given-names></name></person-group><article-title>The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease</article-title><source>Nat. Rev. Nephrol.</source><year>2018</year><volume>14</volume><fpage>442</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1038/s41581-018-0018-2</pub-id><pub-id pub-id-type="pmid">29760448</pub-id><pub-id pub-id-type="pmcid">PMC6385605</pub-id></element-citation></ref><ref id="CR328"><label>328.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santisteban</surname><given-names>MM</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Pepine</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Raizada</surname><given-names>MK</given-names></name></person-group><article-title>Brain-gut-bone marrow axis: implications for hypertension and related therapeutics</article-title><source>Circ. Res.</source><year>2016</year><volume>118</volume><fpage>1327</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.307709</pub-id><pub-id pub-id-type="pmid">27081113</pub-id><pub-id pub-id-type="pmcid">PMC4834860</pub-id></element-citation></ref><ref id="CR329"><label>329.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>HB</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Richards</surname><given-names>EM</given-names></name><name name-style="western"><surname>Pepine</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Raizada</surname><given-names>MK</given-names></name></person-group><article-title>Maternal treatment with captopril persistently alters gut-brain communication and attenuates hypertension of male offspring</article-title><source>Hypertension</source><year>2020</year><volume>75</volume><fpage>1315</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.14736</pub-id><pub-id pub-id-type="pmid">32200676</pub-id><pub-id pub-id-type="pmcid">PMC7145738</pub-id></element-citation></ref><ref id="CR330"><label>330.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Aranda</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>V</given-names></name><name name-style="western"><surname>Raizada</surname><given-names>MK</given-names></name><name name-style="western"><surname>Pepine</surname><given-names>CJ</given-names></name></person-group><article-title>Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension&#8212;a case report</article-title><source>Int J. Cardiol.</source><year>2015</year><volume>201</volume><fpage>157</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2015.07.078</pub-id><pub-id pub-id-type="pmid">26301638</pub-id><pub-id pub-id-type="pmcid">PMC4711349</pub-id></element-citation></ref><ref id="CR331"><label>331.</label><mixed-citation publication-type="other">Angiotensin-Converting Enzyme Inhibitors. in <italic toggle="yes">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</italic> (Bethesda, 2012).</mixed-citation></ref><ref id="CR332"><label>332.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>BL</given-names></name><name name-style="western"><surname>Pan</surname><given-names>DQ</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>KL</given-names></name><name name-style="western"><surname>Lou</surname><given-names>YY</given-names></name><name name-style="western"><surname>Shi</surname><given-names>JH</given-names></name></person-group><article-title>Multi-spectroscopic approaches and molecular simulation research of the intermolecular interaction between the angiotensin-converting enzyme inhibitor (ACE inhibitor) benazepril and bovine serum albumin (BSA)</article-title><source>Spectrochim. Acta A Mol. Biomol. Spectrosc.</source><year>2019</year><volume>212</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.saa.2018.12.040</pub-id><pub-id pub-id-type="pmid">30594849</pub-id></element-citation></ref><ref id="CR333"><label>333.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>FF</given-names></name><etal/></person-group><article-title>Efficacy and safety of benazepril for advanced chronic renal insufficiency</article-title><source>N. Engl. J. Med.</source><year>2006</year><volume>354</volume><fpage>131</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa053107</pub-id><pub-id pub-id-type="pmid">16407508</pub-id></element-citation></ref><ref id="CR334"><label>334.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senthong</surname><given-names>V</given-names></name><etal/></person-group><article-title>Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort</article-title><source>J. Am. Heart Assoc.</source><year>2016</year><volume>5</volume><fpage>e002816</fpage><pub-id pub-id-type="doi">10.1161/JAHA.115.002816</pub-id><pub-id pub-id-type="pmid">27287696</pub-id><pub-id pub-id-type="pmcid">PMC4937244</pub-id></element-citation></ref><ref id="CR335"><label>335.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>XS</given-names></name><etal/></person-group><article-title>Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors</article-title><source>Eur. Heart J.</source><year>2017</year><volume>38</volume><fpage>814</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">28077467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehw582</pub-id><pub-id pub-id-type="pmcid">PMC5837488</pub-id></element-citation></ref><ref id="CR336"><label>336.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Increased trimethylamine N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus</article-title><source>Clin. Chem.</source><year>2017</year><volume>63</volume><fpage>297</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2016.263640</pub-id><pub-id pub-id-type="pmid">27864387</pub-id><pub-id pub-id-type="pmcid">PMC5659115</pub-id></element-citation></ref><ref id="CR337"><label>337.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konop</surname><given-names>M</given-names></name><etal/></person-group><article-title>Enalapril decreases rat plasma concentration of TMAO, a gut bacteria-derived cardiovascular marker</article-title><source>Biomarkers</source><year>2018</year><volume>23</volume><fpage>380</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1080/1354750X.2018.1432689</pub-id><pub-id pub-id-type="pmid">29363331</pub-id></element-citation></ref><ref id="CR338"><label>338.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romano</surname><given-names>KA</given-names></name><name name-style="western"><surname>Vivas</surname><given-names>EI</given-names></name><name name-style="western"><surname>Amador-Noguez</surname><given-names>D</given-names></name><name name-style="western"><surname>Rey</surname><given-names>FE</given-names></name></person-group><article-title>Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide</article-title><source>mBio</source><year>2015</year><volume>6</volume><fpage>e02481</fpage><pub-id pub-id-type="doi">10.1128/mBio.02481-14</pub-id><pub-id pub-id-type="pmid">25784704</pub-id><pub-id pub-id-type="pmcid">PMC4453578</pub-id></element-citation></ref><ref id="CR339"><label>339.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craciun</surname><given-names>S</given-names></name><name name-style="western"><surname>Balskus</surname><given-names>EP</given-names></name></person-group><article-title>Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>21307</fpage><lpage>21312</lpage><pub-id pub-id-type="doi">10.1073/pnas.1215689109</pub-id><pub-id pub-id-type="pmid">23151509</pub-id><pub-id pub-id-type="pmcid">PMC3535645</pub-id></element-citation></ref><ref id="CR340"><label>340.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nowinski</surname><given-names>A</given-names></name><name name-style="western"><surname>Ufnal</surname><given-names>M</given-names></name></person-group><article-title>Trimethylamine N-oxide: a harmful, protective or diagnostic marker in lifestyle diseases?</article-title><source>Nutrition</source><year>2018</year><volume>46</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2017.08.001</pub-id><pub-id pub-id-type="pmid">29290360</pub-id></element-citation></ref><ref id="CR341"><label>341.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaworska</surname><given-names>K</given-names></name><etal/></person-group><article-title>Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>e0189310</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0189310</pub-id><pub-id pub-id-type="pmid">29236735</pub-id><pub-id pub-id-type="pmcid">PMC5728578</pub-id></element-citation></ref><ref id="CR342"><label>342.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>X</given-names></name><name name-style="western"><surname>Yun</surname><given-names>C</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>J</given-names></name></person-group><article-title>The impact of the gut microbiota on the reproductive and metabolic endocrine system</article-title><source>Gut Microbes</source><year>2021</year><volume>13</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1080/19490976.2021.1894070</pub-id><pub-id pub-id-type="pmid">33722164</pub-id><pub-id pub-id-type="pmcid">PMC7971312</pub-id></element-citation></ref><ref id="CR343"><label>343.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornejo-Pareja</surname><given-names>I</given-names></name><name name-style="western"><surname>Munoz-Garach</surname><given-names>A</given-names></name><name name-style="western"><surname>Clemente-Postigo</surname><given-names>M</given-names></name><name name-style="western"><surname>Tinahones</surname><given-names>FJ</given-names></name></person-group><article-title>Importance of gut microbiota in obesity</article-title><source>Eur. J. Clin. Nutr.</source><year>2019</year><volume>72</volume><fpage>26</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1038/s41430-018-0306-8</pub-id><pub-id pub-id-type="pmid">30487562</pub-id></element-citation></ref><ref id="CR344"><label>344.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pascale</surname><given-names>A</given-names></name><etal/></person-group><article-title>Microbiota and metabolic diseases</article-title><source>Endocrine</source><year>2018</year><volume>61</volume><fpage>357</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1007/s12020-018-1605-5</pub-id><pub-id pub-id-type="pmid">29721802</pub-id></element-citation></ref><ref id="CR345"><label>345.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuman</surname><given-names>H</given-names></name><name name-style="western"><surname>Debelius</surname><given-names>JW</given-names></name><name name-style="western"><surname>Knight</surname><given-names>R</given-names></name><name name-style="western"><surname>Koren</surname><given-names>O</given-names></name></person-group><article-title>Microbial endocrinology: the interplay between the microbiota and the endocrine system</article-title><source>FEMS Microbiol. Rev.</source><year>2015</year><volume>39</volume><fpage>509</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1093/femsre/fuu010</pub-id><pub-id pub-id-type="pmid">25701044</pub-id></element-citation></ref><ref id="CR346"><label>346.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis</article-title><source>Cardiovasc Diabetol.</source><year>2019</year><volume>18</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1186/s12933-019-0900-7</pub-id><pub-id pub-id-type="pmid">31362743</pub-id><pub-id pub-id-type="pmcid">PMC6668189</pub-id></element-citation></ref><ref id="CR347"><label>347.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LaMoia</surname><given-names>TE</given-names></name><name name-style="western"><surname>Shulman</surname><given-names>GI</given-names></name></person-group><article-title>Cellular and molecular mechanisms of metformin action</article-title><source>Endocr. Rev.</source><year>2021</year><volume>42</volume><fpage>77</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1210/endrev/bnaa023</pub-id><pub-id pub-id-type="pmid">32897388</pub-id><pub-id pub-id-type="pmcid">PMC7846086</pub-id></element-citation></ref><ref id="CR348"><label>348.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giusti</surname><given-names>L</given-names></name><etal/></person-group><article-title>The protective action of metformin against pro-inflammatory cytokine-induced human islet cell damage and the mechanisms involved</article-title><source>Cells</source><year>2022</year><volume>11</volume><fpage>2465</fpage><pub-id pub-id-type="doi">10.3390/cells11152465</pub-id><pub-id pub-id-type="pmid">35954309</pub-id><pub-id pub-id-type="pmcid">PMC9368307</pub-id></element-citation></ref><ref id="CR349"><label>349.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sundelin</surname><given-names>E</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>JB</given-names></name><name name-style="western"><surname>Jakobsen</surname><given-names>S</given-names></name><name name-style="western"><surname>Gormsen</surname><given-names>LC</given-names></name><name name-style="western"><surname>Jessen</surname><given-names>N</given-names></name></person-group><article-title>Metformin biodistribution: a key to mechanisms of action?</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2020</year><volume>105</volume><fpage>dgaa332</fpage><pub-id pub-id-type="doi">10.1210/clinem/dgaa332</pub-id><pub-id pub-id-type="pmid">32480406</pub-id></element-citation></ref><ref id="CR350"><label>350.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minamii</surname><given-names>T</given-names></name><name name-style="western"><surname>Nogami</surname><given-names>M</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>W</given-names></name></person-group><article-title>Mechanisms of metformin action: in and out of the gut</article-title><source>J. Diabetes Investig.</source><year>2018</year><volume>9</volume><fpage>701</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1111/jdi.12864</pub-id><pub-id pub-id-type="pmid">29777629</pub-id><pub-id pub-id-type="pmcid">PMC6031513</pub-id></element-citation></ref><ref id="CR351"><label>351.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rena</surname><given-names>G</given-names></name><name name-style="western"><surname>Hardie</surname><given-names>DG</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>ER</given-names></name></person-group><article-title>The mechanisms of action of metformin</article-title><source>Diabetologia</source><year>2017</year><volume>60</volume><fpage>1577</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1007/s00125-017-4342-z</pub-id><pub-id pub-id-type="pmid">28776086</pub-id><pub-id pub-id-type="pmcid">PMC5552828</pub-id></element-citation></ref><ref id="CR352"><label>352.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foretz</surname><given-names>M</given-names></name><name name-style="western"><surname>Guigas</surname><given-names>B</given-names></name><name name-style="western"><surname>Viollet</surname><given-names>B</given-names></name></person-group><article-title>Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus</article-title><source>Nat. Rev. Endocrinol.</source><year>2019</year><volume>15</volume><fpage>569</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41574-019-0242-2</pub-id><pub-id pub-id-type="pmid">31439934</pub-id></element-citation></ref><ref id="CR353"><label>353.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>850</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1038/nm.4345</pub-id><pub-id pub-id-type="pmid">28530702</pub-id></element-citation></ref><ref id="CR354"><label>354.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><etal/></person-group><article-title>Gut microbiota and intestinal FXR mediate the clinical benefits of metformin</article-title><source>Nat. Med.</source><year>2018</year><volume>24</volume><fpage>1919</fpage><lpage>1929</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0222-4</pub-id><pub-id pub-id-type="pmid">30397356</pub-id><pub-id pub-id-type="pmcid">PMC6479226</pub-id></element-citation></ref><ref id="CR355"><label>355.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryrup</surname><given-names>T</given-names></name><etal/></person-group><article-title>Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study</article-title><source>Diabetologia</source><year>2019</year><volume>62</volume><fpage>1024</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1007/s00125-019-4848-7</pub-id><pub-id pub-id-type="pmid">30904939</pub-id><pub-id pub-id-type="pmcid">PMC6509092</pub-id></element-citation></ref><ref id="CR356"><label>356.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollak</surname><given-names>M</given-names></name></person-group><article-title>The effects of metformin on gut microbiota and the immune system as research frontiers</article-title><source>Diabetologia</source><year>2017</year><volume>60</volume><fpage>1662</fpage><lpage>1667</lpage><pub-id pub-id-type="doi">10.1007/s00125-017-4352-x</pub-id><pub-id pub-id-type="pmid">28770326</pub-id></element-citation></ref><ref id="CR357"><label>357.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duca</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats</article-title><source>Nat. Med.</source><year>2015</year><volume>21</volume><fpage>506</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/nm.3787</pub-id><pub-id pub-id-type="pmid">25849133</pub-id><pub-id pub-id-type="pmcid">PMC6104807</pub-id></element-citation></ref><ref id="CR358"><label>358.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management</article-title><source>Cardiovasc. Diabetol.</source><year>2019</year><volume>18</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.1186/s12933-019-0860-y</pub-id><pub-id pub-id-type="pmid">31029144</pub-id><pub-id pub-id-type="pmcid">PMC6486984</pub-id></element-citation></ref><ref id="CR359"><label>359.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalile</surname><given-names>B</given-names></name><name name-style="western"><surname>Van Oudenhove</surname><given-names>L</given-names></name><name name-style="western"><surname>Vervliet</surname><given-names>B</given-names></name><name name-style="western"><surname>Verbeke</surname><given-names>K</given-names></name></person-group><article-title>The role of short-chain fatty acids in microbiota-gut-brain communication</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2019</year><volume>16</volume><fpage>461</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1038/s41575-019-0157-3</pub-id><pub-id pub-id-type="pmid">31123355</pub-id></element-citation></ref><ref id="CR360"><label>360.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>N</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>M</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>A</given-names></name></person-group><article-title>Recent advances of alpha-glucosidase inhibitors: a comprehensive review</article-title><source>Curr. Top. Med. Chem.</source><year>2022</year><volume>22</volume><fpage>2069</fpage><lpage>2086</lpage><pub-id pub-id-type="doi">10.2174/1568026622666220831092855</pub-id><pub-id pub-id-type="pmid">36045528</pub-id></element-citation></ref><ref id="CR361"><label>361.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhameja</surname><given-names>M</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>P</given-names></name></person-group><article-title>Synthetic heterocyclic candidates as promising alpha-glucosidase inhibitors: an overview</article-title><source>Eur. J. Med. Chem.</source><year>2019</year><volume>176</volume><fpage>343</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.04.025</pub-id><pub-id pub-id-type="pmid">31112894</pub-id></element-citation></ref><ref id="CR362"><label>362.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial</article-title><source>Diabetes Ther.</source><year>2017</year><volume>8</volume><fpage>293</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1007/s13300-017-0226-y</pub-id><pub-id pub-id-type="pmid">28130771</pub-id><pub-id pub-id-type="pmcid">PMC5380489</pub-id></element-citation></ref><ref id="CR363"><label>363.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunkhorst</surname><given-names>C</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>C</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>E</given-names></name></person-group><article-title>Acarbose, a pseudooligosaccharide, is transported but not metabolized by the maltose-maltodextrin system of Escherichia coli</article-title><source>J. Bacteriol.</source><year>1999</year><volume>181</volume><fpage>2612</fpage><lpage>2619</lpage><pub-id pub-id-type="doi">10.1128/JB.181.8.2612-2619.1999</pub-id><pub-id pub-id-type="pmid">10198028</pub-id><pub-id pub-id-type="pmcid">PMC93690</pub-id></element-citation></ref><ref id="CR364"><label>364.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>H</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>PR</given-names></name></person-group><article-title>Effect of Dahi containing Lactococcus lactis on the progression of diabetes induced by a high-fructose diet in rats</article-title><source>Biosci. Biotechnol. Biochem.</source><year>2006</year><volume>70</volume><fpage>1255</fpage><lpage>1258</lpage><pub-id pub-id-type="doi">10.1271/bbb.70.1255</pub-id><pub-id pub-id-type="pmid">16717431</pub-id></element-citation></ref><ref id="CR365"><label>365.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>H</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>PR</given-names></name></person-group><article-title>Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats</article-title><source>Nutrition</source><year>2007</year><volume>23</volume><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2006.09.002</pub-id><pub-id pub-id-type="pmid">17084593</pub-id></element-citation></ref><ref id="CR366"><label>366.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaushal</surname><given-names>D</given-names></name><name name-style="western"><surname>Kansal</surname><given-names>VK</given-names></name></person-group><article-title>Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum improves phagocytic potential of macrophages in aged mice</article-title><source>J. Food Sci. Technol.</source><year>2014</year><volume>51</volume><fpage>1147</fpage><lpage>1153</lpage><pub-id pub-id-type="doi">10.1007/s13197-012-0637-8</pub-id><pub-id pub-id-type="pmid">24876648</pub-id><pub-id pub-id-type="pmcid">PMC4033742</pub-id></element-citation></ref><ref id="CR367"><label>367.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>B</given-names></name><etal/></person-group><article-title>Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus</article-title><source>J. Diabetes</source><year>2015</year><volume>7</volume><fpage>729</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1111/1753-0407.12232</pub-id><pub-id pub-id-type="pmid">25327485</pub-id></element-citation></ref><ref id="CR368"><label>368.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maruhama</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effects of a glucoside-hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, fecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients</article-title><source>Tohoku J. Exp. Med.</source><year>1980</year><volume>132</volume><fpage>453</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1620/tjem.132.453</pub-id><pub-id pub-id-type="pmid">7256727</pub-id></element-citation></ref><ref id="CR369"><label>369.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kishida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okubo</surname><given-names>H</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>H</given-names></name><name name-style="western"><surname>Oki</surname><given-names>K</given-names></name><name name-style="western"><surname>Yoneda</surname><given-names>M</given-names></name></person-group><article-title>Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model</article-title><source>J. Gastroenterol.</source><year>2017</year><volume>52</volume><fpage>1180</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1007/s00535-017-1331-4</pub-id><pub-id pub-id-type="pmid">28349245</pub-id><pub-id pub-id-type="pmcid">PMC5666045</pub-id></element-citation></ref><ref id="CR370"><label>370.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drucker</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Nauck</surname><given-names>MA</given-names></name></person-group><article-title>The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>1696</fpage><lpage>1705</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)69705-5</pub-id><pub-id pub-id-type="pmid">17098089</pub-id></element-citation></ref><ref id="CR371"><label>371.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meier</surname><given-names>JJ</given-names></name></person-group><article-title>GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus</article-title><source>Nat. Rev. Endocrinol.</source><year>2012</year><volume>8</volume><fpage>728</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2012.140</pub-id><pub-id pub-id-type="pmid">22945360</pub-id></element-citation></ref><ref id="CR372"><label>372.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>Mechanisms of action and therapeutic application of glucagon-like peptide-1</article-title><source>Cell Metab.</source><year>2018</year><volume>27</volume><fpage>740</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.03.001</pub-id><pub-id pub-id-type="pmid">29617641</pub-id></element-citation></ref><ref id="CR373"><label>373.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baggio</surname><given-names>LL</given-names></name><name name-style="western"><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight</article-title><source>J. Clin. Invest.</source><year>2014</year><volume>124</volume><fpage>4223</fpage><lpage>4226</lpage><pub-id pub-id-type="doi">10.1172/JCI78371</pub-id><pub-id pub-id-type="pmid">25202976</pub-id><pub-id pub-id-type="pmcid">PMC4191040</pub-id></element-citation></ref><ref id="CR374"><label>374.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tolhurst</surname><given-names>G</given-names></name><etal/></person-group><article-title>Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2</article-title><source>Diabetes</source><year>2012</year><volume>61</volume><fpage>364</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.2337/db11-1019</pub-id><pub-id pub-id-type="pmid">22190648</pub-id><pub-id pub-id-type="pmcid">PMC3266401</pub-id></element-citation></ref><ref id="CR375"><label>375.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>I</given-names></name><etal/></person-group><article-title>The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43</article-title><source>Nat. Commun.</source><year>2013</year><volume>4</volume><fpage>1829</fpage><pub-id pub-id-type="doi">10.1038/ncomms2852</pub-id><pub-id pub-id-type="pmid">23652017</pub-id><pub-id pub-id-type="pmcid">PMC3674247</pub-id></element-citation></ref><ref id="CR376"><label>376.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vettorazzi</surname><given-names>JF</given-names></name><etal/></person-group><article-title>The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells</article-title><source>Metabolism</source><year>2016</year><volume>65</volume><fpage>54</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2015.10.021</pub-id><pub-id pub-id-type="pmid">26892516</pub-id></element-citation></ref><ref id="CR377"><label>377.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aoki</surname><given-names>R</given-names></name><etal/></person-group><article-title>A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>43522</fpage><pub-id pub-id-type="doi">10.1038/srep43522</pub-id><pub-id pub-id-type="pmid">28252037</pub-id><pub-id pub-id-type="pmcid">PMC5333160</pub-id></element-citation></ref><ref id="CR378"><label>378.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yan</surname><given-names>X</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B</given-names></name></person-group><article-title>Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>33251</fpage><pub-id pub-id-type="doi">10.1038/srep33251</pub-id><pub-id pub-id-type="pmid">27633081</pub-id><pub-id pub-id-type="pmcid">PMC5025740</pub-id></element-citation></ref><ref id="CR379"><label>379.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Featured article: structure moderation of gut microbiota in liraglutide-treated diabetic male rats</article-title><source>Exp. Biol. Med. (Maywood)</source><year>2018</year><volume>243</volume><fpage>34</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1177/1535370217743765</pub-id><pub-id pub-id-type="pmid">29171288</pub-id><pub-id pub-id-type="pmcid">PMC5788162</pub-id></element-citation></ref><ref id="CR380"><label>380.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><etal/></person-group><article-title>A glucagon-like peptide-1 receptor agonist lowers weight by modulating the structure of gut microbiota</article-title><source>Front. Endocrinol. (Lausanne)</source><year>2018</year><volume>9</volume><fpage>233</fpage><pub-id pub-id-type="doi">10.3389/fendo.2018.00233</pub-id><pub-id pub-id-type="pmid">29867765</pub-id><pub-id pub-id-type="pmcid">PMC5966539</pub-id></element-citation></ref><ref id="CR381"><label>381.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charpentier</surname><given-names>J</given-names></name><etal/></person-group><article-title>Liraglutide targets the gut microbiota and the intestinal immune system to regulate insulin secretion</article-title><source>Acta Diabetol.</source><year>2021</year><volume>58</volume><fpage>881</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1007/s00592-020-01657-8</pub-id><pub-id pub-id-type="pmid">33723651</pub-id></element-citation></ref><ref id="CR382"><label>382.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus</article-title><source>PeerJ</source><year>2021</year><volume>9</volume><fpage>e11128</fpage><pub-id pub-id-type="doi">10.7717/peerj.11128</pub-id><pub-id pub-id-type="pmid">33850659</pub-id><pub-id pub-id-type="pmcid">PMC8019531</pub-id></element-citation></ref><ref id="CR383"><label>383.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>X</given-names></name><etal/></person-group><article-title>Identification of therapeutic effect of glucagon-like peptide 1 in the treatment of STZ-induced diabetes mellitus in rats by restoring the balance of intestinal flora</article-title><source>J. Cell Biochem.</source><year>2018</year><volume>119</volume><fpage>10067</fpage><lpage>10074</lpage><pub-id pub-id-type="doi">10.1002/jcb.27343</pub-id><pub-id pub-id-type="pmid">30129059</pub-id></element-citation></ref><ref id="CR384"><label>384.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Handelsman</surname><given-names>Y</given-names></name><etal/></person-group><article-title>American association of clinical endocrinologists and american college of endocrinology&#8212;clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015</article-title><source>Endocr. Pract.</source><year>2015</year><volume>21</volume><fpage>1</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.4158/EP15672.GLSUPPL</pub-id><pub-id pub-id-type="pmid">25869408</pub-id><pub-id pub-id-type="pmcid">PMC4959114</pub-id></element-citation></ref><ref id="CR385"><label>385.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olivares</surname><given-names>M</given-names></name><etal/></person-group><article-title>The potential role of the dipeptidyl peptidase-4-like activity from the gut microbiota on the host health</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>1900</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.01900</pub-id><pub-id pub-id-type="pmid">30186247</pub-id><pub-id pub-id-type="pmcid">PMC6113382</pub-id></element-citation></ref><ref id="CR386"><label>386.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis</article-title><source>EBioMedicine</source><year>2019</year><volume>44</volume><fpage>665</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2019.03.057</pub-id><pub-id pub-id-type="pmid">30922964</pub-id><pub-id pub-id-type="pmcid">PMC6603491</pub-id></element-citation></ref><ref id="CR387"><label>387.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>X</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Microflora disturbance during progression of glucose intolerance and effect of sitagliptin: an animal study</article-title><source>J. Diabetes Res.</source><year>2016</year><volume>2016</volume><fpage>2093171</fpage><pub-id pub-id-type="doi">10.1155/2016/2093171</pub-id><pub-id pub-id-type="pmid">27631013</pub-id><pub-id pub-id-type="pmcid">PMC5007364</pub-id></element-citation></ref><ref id="CR388"><label>388.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>e0184735</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0184735</pub-id><pub-id pub-id-type="pmid">29036231</pub-id><pub-id pub-id-type="pmcid">PMC5643055</pub-id></element-citation></ref><ref id="CR389"><label>389.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Host-microbiota interaction-mediated resistance to inflammatory bowel disease in pigs</article-title><source>Microbiome</source><year>2022</year><volume>10</volume><fpage>115</fpage><pub-id pub-id-type="doi">10.1186/s40168-022-01303-1</pub-id><pub-id pub-id-type="pmid">35907917</pub-id><pub-id pub-id-type="pmcid">PMC9338544</pub-id></element-citation></ref><ref id="CR390"><label>390.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alshehri</surname><given-names>D</given-names></name><etal/></person-group><article-title>Dysbiosis of gut microbiota in inflammatory bowel disease: current therapies and potential for microbiota-modulating therapeutic approaches</article-title><source>Bosn. J. Basic Med. Sci.</source><year>2021</year><volume>21</volume><fpage>270</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">33052081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17305/bjbms.2020.5016</pub-id><pub-id pub-id-type="pmcid">PMC8112554</pub-id></element-citation></ref><ref id="CR391"><label>391.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nilsson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study</article-title><source>Am. J. Gastroenterol</source><year>1995</year><volume>90</volume><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">7872274</pub-id></element-citation></ref><ref id="CR392"><label>392.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name></person-group><article-title>Gut microbiota-mediated drug-antibiotic interactions</article-title><source>Drug Metab. Dispos.</source><year>2015</year><volume>43</volume><fpage>1581</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1124/dmd.115.063867</pub-id><pub-id pub-id-type="pmid">25926432</pub-id></element-citation></ref><ref id="CR393"><label>393.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azad Khan</surname><given-names>AK</given-names></name><name name-style="western"><surname>Guthrie</surname><given-names>G</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>HH</given-names></name><name name-style="western"><surname>Truelove</surname><given-names>SC</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>DH</given-names></name></person-group><article-title>Tissue and bacterial splitting of sulphasalazine</article-title><source>Clin. Sci. (Lond.)</source><year>1983</year><volume>64</volume><fpage>349</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1042/cs0640349</pub-id><pub-id pub-id-type="pmid">6129936</pub-id></element-citation></ref><ref id="CR394"><label>394.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Orlovich</surname><given-names>DA</given-names></name><name name-style="western"><surname>Fawcett</surname><given-names>JP</given-names></name></person-group><article-title>The influence of probiotic treatment on sulfasalazine metabolism in rat</article-title><source>Xenobiotica</source><year>2012</year><volume>42</volume><fpage>791</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.3109/00498254.2012.660508</pub-id><pub-id pub-id-type="pmid">22348441</pub-id></element-citation></ref><ref id="CR395"><label>395.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crouwel</surname><given-names>F</given-names></name><name name-style="western"><surname>Buiter</surname><given-names>HJC</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>NK</given-names></name></person-group><article-title>Gut microbiota-driven drug metabolism in inflammatory bowel disease</article-title><source>J. Crohns Colitis</source><year>2020</year><volume>15</volume><fpage>307</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjaa143</pub-id><pub-id pub-id-type="pmid">32652007</pub-id><pub-id pub-id-type="pmcid">PMC7904070</pub-id></element-citation></ref><ref id="CR396"><label>396.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savarino</surname><given-names>V</given-names></name><etal/></person-group><article-title>The appropriate use of proton-pump inhibitors</article-title><source>Minerva Med</source><year>2018</year><volume>109</volume><fpage>386</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.23736/S0026-4806.18.05705-1</pub-id><pub-id pub-id-type="pmid">29856192</pub-id></element-citation></ref><ref id="CR397"><label>397.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>DY</given-names></name><name name-style="western"><surname>Tansel</surname><given-names>A</given-names></name></person-group><article-title>Interchangeable use of proton pump inhibitors based on relative potency</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2018</year><volume>16</volume><fpage>800</fpage><lpage>808.e7</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2017.09.033</pub-id><pub-id pub-id-type="pmid">28964908</pub-id><pub-id pub-id-type="pmcid">PMC6913203</pub-id></element-citation></ref><ref id="CR398"><label>398.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinto-Sanchez</surname><given-names>MI</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bercik</surname><given-names>P</given-names></name><name name-style="western"><surname>Moayyedi</surname><given-names>P</given-names></name></person-group><article-title>Proton pump inhibitors for functional dyspepsia</article-title><source>Cochrane Database Syst. Rev.</source><year>2017</year><volume>3</volume><fpage>CD011194</fpage><pub-id pub-id-type="pmid">28271513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD011194.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6464600</pub-id></element-citation></ref><ref id="CR399"><label>399.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forgacs</surname><given-names>I</given-names></name><name name-style="western"><surname>Loganayagam</surname><given-names>A</given-names></name></person-group><article-title>Overprescribing proton pump inhibitors</article-title><source>BMJ</source><year>2008</year><volume>336</volume><fpage>2</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1136/bmj.39406.449456.BE</pub-id><pub-id pub-id-type="pmid">18174564</pub-id><pub-id pub-id-type="pmcid">PMC2174763</pub-id></element-citation></ref><ref id="CR400"><label>400.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akram</surname><given-names>F</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lim</surname><given-names>V</given-names></name><name name-style="western"><surname>Huggan</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Merchant</surname><given-names>RA</given-names></name></person-group><article-title>Proton pump inhibitors: are we still prescribing them without valid indications?</article-title><source>Australas. Med. J.</source><year>2014</year><volume>7</volume><fpage>465</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.4066/AMJ.2014.2093</pub-id><pub-id pub-id-type="pmid">25550719</pub-id><pub-id pub-id-type="pmcid">PMC4259212</pub-id></element-citation></ref><ref id="CR401"><label>401.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eid</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists</article-title><source>Intern Med.</source><year>2010</year><volume>49</volume><fpage>2561</fpage><lpage>2568</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.49.4064</pub-id><pub-id pub-id-type="pmid">21139293</pub-id></element-citation></ref><ref id="CR402"><label>402.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonder</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>The influence of a short-term gluten-free diet on the human gut microbiome</article-title><source>Genome Med.</source><year>2016</year><volume>8</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/s13073-016-0295-y</pub-id><pub-id pub-id-type="pmid">27102333</pub-id><pub-id pub-id-type="pmcid">PMC4841035</pub-id></element-citation></ref><ref id="CR403"><label>403.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Proton pump inhibitors alter the composition of the gut microbiota</article-title><source>Gut</source><year>2016</year><volume>65</volume><fpage>749</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2015-310861</pub-id><pub-id pub-id-type="pmid">26719299</pub-id><pub-id pub-id-type="pmcid">PMC4853574</pub-id></element-citation></ref><ref id="CR404"><label>404.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imhann</surname><given-names>F</given-names></name><etal/></person-group><article-title>Proton pump inhibitors affect the gut microbiome</article-title><source>Gut</source><year>2016</year><volume>65</volume><fpage>740</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2015-310376</pub-id><pub-id pub-id-type="pmid">26657899</pub-id><pub-id pub-id-type="pmcid">PMC4853569</pub-id></element-citation></ref><ref id="CR405"><label>405.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freedberg</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial</article-title><source>Gastroenterology</source><year>2015</year><volume>149</volume><fpage>883</fpage><lpage>885.e9</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.06.043</pub-id><pub-id pub-id-type="pmid">26164495</pub-id><pub-id pub-id-type="pmcid">PMC4584196</pub-id></element-citation></ref><ref id="CR406"><label>406.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maier</surname><given-names>L</given-names></name><etal/></person-group><article-title>Extensive impact of non-antibiotic drugs on human gut bacteria</article-title><source>Nature</source><year>2018</year><volume>555</volume><fpage>623</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1038/nature25979</pub-id><pub-id pub-id-type="pmid">29555994</pub-id><pub-id pub-id-type="pmcid">PMC6108420</pub-id></element-citation></ref><ref id="CR407"><label>407.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buffie</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile</article-title><source>Nature</source><year>2015</year><volume>517</volume><fpage>205</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1038/nature13828</pub-id><pub-id pub-id-type="pmid">25337874</pub-id><pub-id pub-id-type="pmcid">PMC4354891</pub-id></element-citation></ref><ref id="CR408"><label>408.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buffie</surname><given-names>CG</given-names></name><name name-style="western"><surname>Pamer</surname><given-names>EG</given-names></name></person-group><article-title>Microbiota-mediated colonization resistance against intestinal pathogens</article-title><source>Nat. Rev. Immunol.</source><year>2013</year><volume>13</volume><fpage>790</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1038/nri3535</pub-id><pub-id pub-id-type="pmid">24096337</pub-id><pub-id pub-id-type="pmcid">PMC4194195</pub-id></element-citation></ref><ref id="CR409"><label>409.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonard</surname><given-names>J</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>JK</given-names></name><name name-style="western"><surname>Moayyedi</surname><given-names>P</given-names></name></person-group><article-title>Systematic review of the risk of enteric infection in patients taking acid suppression</article-title><source>Am. J. Gastroenterol.</source><year>2007</year><volume>102</volume><fpage>2047</fpage><lpage>2056</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2007.01275.x</pub-id><pub-id pub-id-type="pmid">17509031</pub-id></element-citation></ref><ref id="CR410"><label>410.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baur</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis</article-title><source>Lancet Infect. Dis.</source><year>2017</year><volume>17</volume><fpage>990</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30325-0</pub-id><pub-id pub-id-type="pmid">28629876</pub-id></element-citation></ref><ref id="CR411"><label>411.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis</article-title><source>Am. J. Gastroenterol.</source><year>2018</year><volume>113</volume><fpage>1177</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1038/s41395-018-0085-9</pub-id><pub-id pub-id-type="pmid">29872220</pub-id></element-citation></ref><ref id="CR412"><label>412.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stark</surname><given-names>CM</given-names></name><name name-style="western"><surname>Susi</surname><given-names>A</given-names></name><name name-style="western"><surname>Emerick</surname><given-names>J</given-names></name><name name-style="western"><surname>Nylund</surname><given-names>CM</given-names></name></person-group><article-title>Antibiotic and acid-suppression medications during early childhood are associated with obesity</article-title><source>Gut</source><year>2019</year><volume>68</volume><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2017-314971</pub-id><pub-id pub-id-type="pmid">30377188</pub-id></element-citation></ref><ref id="CR413"><label>413.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harirforoosh</surname><given-names>S</given-names></name><name name-style="western"><surname>Asghar</surname><given-names>W</given-names></name><name name-style="western"><surname>Jamali</surname><given-names>F</given-names></name></person-group><article-title>Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications</article-title><source>J. Pharm. Pharm. Sci.</source><year>2013</year><volume>16</volume><fpage>821</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.18433/J3VW2F</pub-id><pub-id pub-id-type="pmid">24393558</pub-id></element-citation></ref><ref id="CR414"><label>414.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sostres</surname><given-names>C</given-names></name><name name-style="western"><surname>Gargallo</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Lanas</surname><given-names>A</given-names></name></person-group><article-title>Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage</article-title><source>Arthritis Res. Ther.</source><year>2013</year><volume>15</volume><fpage>S3</fpage><pub-id pub-id-type="doi">10.1186/ar4175</pub-id><pub-id pub-id-type="pmid">24267289</pub-id><pub-id pub-id-type="pmcid">PMC3890944</pub-id></element-citation></ref><ref id="CR415"><label>415.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higuchi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Present status and strategy of NSAIDs-induced small bowel injury</article-title><source>J. Gastroenterol.</source><year>2009</year><volume>44</volume><fpage>879</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1007/s00535-009-0102-2</pub-id><pub-id pub-id-type="pmid">19568687</pub-id></element-citation></ref><ref id="CR416"><label>416.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petruzzelli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts</article-title><source>Clin. Biochem.</source><year>2007</year><volume>40</volume><fpage>503</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2007.01.015</pub-id><pub-id pub-id-type="pmid">17321514</pub-id></element-citation></ref><ref id="CR417"><label>417.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boelsterli</surname><given-names>UA</given-names></name><name name-style="western"><surname>Redinbo</surname><given-names>MR</given-names></name><name name-style="western"><surname>Saitta</surname><given-names>KS</given-names></name></person-group><article-title>Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies</article-title><source>Toxicol. Sci.</source><year>2013</year><volume>131</volume><fpage>654</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfs310</pub-id><pub-id pub-id-type="pmid">23091168</pub-id><pub-id pub-id-type="pmcid">PMC3551426</pub-id></element-citation></ref><ref id="CR418"><label>418.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yauw</surname><given-names>STK</given-names></name><etal/></person-group><article-title>Microbial glucuronidase inhibition reduces severity of diclofenac-induced anastomotic leak in rats</article-title><source>Surg. Infect. (Larchmt.)</source><year>2018</year><volume>19</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1089/sur.2017.245</pub-id><pub-id pub-id-type="pmid">29624485</pub-id><pub-id pub-id-type="pmcid">PMC5961743</pub-id></element-citation></ref><ref id="CR419"><label>419.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dashnyam</surname><given-names>P</given-names></name><etal/></person-group><article-title>beta-Glucuronidases of opportunistic bacteria are the major contributors to xenobiotic-induced toxicity in the gut</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>16372</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-34678-z</pub-id><pub-id pub-id-type="pmid">30401818</pub-id><pub-id pub-id-type="pmcid">PMC6219552</pub-id></element-citation></ref><ref id="CR420"><label>420.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ervin</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Targeting regorafenib-induced toxicity through inhibition of gut microbial beta-glucuronidases</article-title><source>ACS Chem. Biol.</source><year>2019</year><volume>14</volume><fpage>2737</fpage><lpage>2744</lpage><pub-id pub-id-type="doi">10.1021/acschembio.9b00663</pub-id><pub-id pub-id-type="pmid">31663730</pub-id><pub-id pub-id-type="pmcid">PMC7254866</pub-id></element-citation></ref><ref id="CR421"><label>421.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>VK</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name></person-group><article-title>New insights on bioactivities and biosynthesis of flavonoid glycosides</article-title><source>Trends Food Sci. Technol.</source><year>2018</year><volume>79</volume><fpage>116</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.tifs.2018.07.006</pub-id></element-citation></ref><ref id="CR422"><label>422.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falony</surname><given-names>G</given-names></name><etal/></person-group><article-title>Population-level analysis of gut microbiome variation</article-title><source>Science</source><year>2016</year><volume>352</volume><fpage>560</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1126/science.aad3503</pub-id><pub-id pub-id-type="pmid">27126039</pub-id></element-citation></ref><ref id="CR423"><label>423.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinan</surname><given-names>TG</given-names></name><name name-style="western"><surname>Cryan</surname><given-names>JF</given-names></name></person-group><article-title>The microbiome-gut-brain axis in health and disease</article-title><source>Gastroenterol. Clin. North Am.</source><year>2017</year><volume>46</volume><fpage>77</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.gtc.2016.09.007</pub-id><pub-id pub-id-type="pmid">28164854</pub-id></element-citation></ref><ref id="CR424"><label>424.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LeWitt</surname><given-names>PA</given-names></name></person-group><article-title>Levodopa therapy for Parkinson&#8217;s disease: pharmacokinetics and pharmacodynamics</article-title><source>Mov. Disord.</source><year>2015</year><volume>30</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1002/mds.26082</pub-id><pub-id pub-id-type="pmid">25449210</pub-id></element-citation></ref><ref id="CR425"><label>425.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marsot</surname><given-names>A</given-names></name><name name-style="western"><surname>Guilhaumou</surname><given-names>R</given-names></name><name name-style="western"><surname>Azulay</surname><given-names>JP</given-names></name><name name-style="western"><surname>Blin</surname><given-names>O</given-names></name></person-group><article-title>Levodopa in Parkinson&#8217;s disease: a review of population pharmacokinetics/pharmacodynamics analysis</article-title><source>J. Pharm. Pharm. Sci.</source><year>2017</year><volume>20</volume><fpage>226</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.18433/J30H04</pub-id><pub-id pub-id-type="pmid">28719359</pub-id></element-citation></ref><ref id="CR426"><label>426.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Kessel</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson&#8217;s disease</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>310</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-08294-y</pub-id><pub-id pub-id-type="pmid">30659181</pub-id><pub-id pub-id-type="pmcid">PMC6338741</pub-id></element-citation></ref><ref id="CR427"><label>427.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maini Rekdal</surname><given-names>V</given-names></name><name name-style="western"><surname>Bess</surname><given-names>EN</given-names></name><name name-style="western"><surname>Bisanz</surname><given-names>JE</given-names></name><name name-style="western"><surname>Turnbaugh</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Balskus</surname><given-names>EP</given-names></name></person-group><article-title>Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism</article-title><source>Science</source><year>2019</year><volume>364</volume><fpage>eaau6323</fpage><pub-id pub-id-type="doi">10.1126/science.aau6323</pub-id><pub-id pub-id-type="pmid">31196984</pub-id><pub-id pub-id-type="pmcid">PMC7745125</pub-id></element-citation></ref><ref id="CR428"><label>428.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musil</surname><given-names>V</given-names></name><name name-style="western"><surname>Blankova</surname><given-names>A</given-names></name><name name-style="western"><surname>Baca</surname><given-names>V</given-names></name></person-group><article-title>A plea for an extension of the anatomical nomenclature: the locomotor system</article-title><source>Bosn. J. Basic Med. Sci.</source><year>2018</year><volume>18</volume><fpage>117</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">29144891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17305/bjbms.2017.2276</pub-id><pub-id pub-id-type="pmcid">PMC5988530</pub-id></element-citation></ref><ref id="CR429"><label>429.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peretti</surname><given-names>S</given-names></name><etal/></person-group><article-title>The Yin-Yang pharmacomicrobiomics on treatment response in inflammatory arthritides: a narrative review</article-title><source>Genes (Basel)</source><year>2022</year><volume>14</volume><fpage>89</fpage><pub-id pub-id-type="doi">10.3390/genes14010089</pub-id><pub-id pub-id-type="pmid">36672830</pub-id><pub-id pub-id-type="pmcid">PMC9859330</pub-id></element-citation></ref><ref id="CR430"><label>430.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Drug repurposing by siderophore conjugation: synthesis and biological evaluation of siderophore-methotrexate conjugates as antibiotics</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2022</year><volume>61</volume><fpage>e202204139</fpage><pub-id pub-id-type="doi">10.1002/anie.202204139</pub-id><pub-id pub-id-type="pmid">35802518</pub-id></element-citation></ref><ref id="CR431"><label>431.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romao</surname><given-names>VC</given-names></name><name name-style="western"><surname>Lima</surname><given-names>A</given-names></name><name name-style="western"><surname>Bernardes</surname><given-names>M</given-names></name><name name-style="western"><surname>Canhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>JE</given-names></name></person-group><article-title>Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?</article-title><source>Immunol. Res.</source><year>2014</year><volume>60</volume><fpage>289</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1007/s12026-014-8564-6</pub-id><pub-id pub-id-type="pmid">25391609</pub-id></element-citation></ref><ref id="CR432"><label>432.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos-Romero</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mechanistically different effects of fat and sugar on insulin resistance, hypertension, and gut microbiota in rats</article-title><source>Am. J. Physiol. Endocrinol. Metab.</source><year>2018</year><volume>314</volume><fpage>E552</fpage><lpage>E563</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00323.2017</pub-id><pub-id pub-id-type="pmid">29351480</pub-id></element-citation></ref><ref id="CR433"><label>433.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Peters</surname><given-names>DH</given-names></name></person-group><article-title>Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus</article-title><source>Drugs</source><year>1995</year><volume>49</volume><fpage>721</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.2165/00003495-199549050-00007</pub-id><pub-id pub-id-type="pmid">7601013</pub-id></element-citation></ref><ref id="CR434"><label>434.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><etal/></person-group><article-title>Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut microbiota</article-title><source>EBioMedicine</source><year>2018</year><volume>33</volume><fpage>122</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.06.029</pub-id><pub-id pub-id-type="pmid">30049384</pub-id><pub-id pub-id-type="pmcid">PMC6085585</pub-id></element-citation></ref><ref id="CR435"><label>435.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayers</surname><given-names>E</given-names></name><name name-style="western"><surname>MacGregor</surname><given-names>A</given-names></name><name name-style="western"><surname>Carding</surname><given-names>SR</given-names></name></person-group><article-title>Drug-microbiota interactions and treatment response: relevance to rheumatoid arthritis</article-title><source>AIMS Microbiol.</source><year>2018</year><volume>4</volume><fpage>642</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.3934/microbiol.2018.4.642</pub-id><pub-id pub-id-type="pmid">31294239</pub-id><pub-id pub-id-type="pmcid">PMC6613334</pub-id></element-citation></ref><ref id="CR436"><label>436.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment</article-title><source>Nat. Med.</source><year>2015</year><volume>21</volume><fpage>895</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1038/nm.3914</pub-id><pub-id pub-id-type="pmid">26214836</pub-id></element-citation></ref><ref id="CR437"><label>437.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodman</surname><given-names>SM</given-names></name><name name-style="western"><surname>Cronstein</surname><given-names>BN</given-names></name><name name-style="western"><surname>Bykerk</surname><given-names>VP</given-names></name></person-group><article-title>Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review</article-title><source>Clin. Exp. Rheumatol.</source><year>2015</year><volume>33</volume><fpage>272</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">25536122</pub-id><pub-id pub-id-type="pmcid">PMC4406815</pub-id></element-citation></ref><ref id="CR438"><label>438.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halilova</surname><given-names>KI</given-names></name><etal/></person-group><article-title>Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?</article-title><source>Int. J. Rheumatol.</source><year>2012</year><volume>2012</volume><fpage>978396</fpage><pub-id pub-id-type="doi">10.1155/2012/978396</pub-id><pub-id pub-id-type="pmid">22844292</pub-id><pub-id pub-id-type="pmcid">PMC3400362</pub-id></element-citation></ref><ref id="CR439"><label>439.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angelis-Stoforidis</surname><given-names>P</given-names></name><name name-style="western"><surname>Vajda</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Christophidis</surname><given-names>N</given-names></name></person-group><article-title>Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis</article-title><source>Clin. Exp. Rheumatol.</source><year>1999</year><volume>17</volume><fpage>313</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">10410264</pub-id></element-citation></ref><ref id="CR440"><label>440.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dervieux</surname><given-names>T</given-names></name><etal/></person-group><article-title>Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis</article-title><source>Arthritis Rheum.</source><year>2004</year><volume>50</volume><fpage>2766</fpage><lpage>2774</lpage><pub-id pub-id-type="doi">10.1002/art.20460</pub-id><pub-id pub-id-type="pmid">15457444</pub-id></element-citation></ref><ref id="CR441"><label>441.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemens</surname><given-names>JQ</given-names></name></person-group><article-title>Infection and inflammation of the genitourinary tract</article-title><source>J. Urol.</source><year>2022</year><volume>208</volume><fpage>455</fpage><pub-id pub-id-type="doi">10.1097/JU.0000000000002742</pub-id><pub-id pub-id-type="pmid">35583402</pub-id></element-citation></ref><ref id="CR442"><label>442.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>E</given-names></name><name name-style="western"><surname>Buie</surname><given-names>J</given-names></name><name name-style="western"><surname>Camacho</surname><given-names>J</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>de Riese</surname><given-names>WTW</given-names></name></person-group><article-title>Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers</article-title><source>Res. Rep. Urol.</source><year>2022</year><volume>14</volume><fpage>87</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">35386270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/RRU.S303215</pub-id><pub-id pub-id-type="pmcid">PMC8977476</pub-id></element-citation></ref><ref id="CR443"><label>443.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terrisse</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e004191</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-004191</pub-id><pub-id pub-id-type="pmid">35296557</pub-id><pub-id pub-id-type="pmcid">PMC8928383</pub-id></element-citation></ref><ref id="CR444"><label>444.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daisley</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>4822</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-18649-5</pub-id><pub-id pub-id-type="pmid">32973149</pub-id><pub-id pub-id-type="pmcid">PMC7515896</pub-id></element-citation></ref><ref id="CR445"><label>445.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sfanos</surname><given-names>KS</given-names></name><name name-style="western"><surname>Yegnasubramanian</surname><given-names>S</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>WG</given-names></name><name name-style="western"><surname>De Marzo</surname><given-names>AM</given-names></name></person-group><article-title>The inflammatory microenvironment and microbiome in prostate cancer development</article-title><source>Nat. Rev. Urol.</source><year>2018</year><volume>15</volume><fpage>11</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2017.167</pub-id><pub-id pub-id-type="pmid">29089606</pub-id></element-citation></ref><ref id="CR446"><label>446.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCulloch</surname><given-names>JA</given-names></name><name name-style="western"><surname>Trinchieri</surname><given-names>G</given-names></name></person-group><article-title>Gut bacteria enable prostate cancer growth</article-title><source>Science</source><year>2021</year><volume>374</volume><fpage>154</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1126/science.abl7070</pub-id><pub-id pub-id-type="pmid">34618567</pub-id></element-citation></ref><ref id="CR447"><label>447.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickson</surname><given-names>RP</given-names></name><name name-style="western"><surname>Erb-Downward</surname><given-names>JR</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Huffnagle</surname><given-names>GB</given-names></name></person-group><article-title>The microbiome and the respiratory tract</article-title><source>Annu Rev. Physiol.</source><year>2016</year><volume>78</volume><fpage>481</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-021115-105238</pub-id><pub-id pub-id-type="pmid">26527186</pub-id><pub-id pub-id-type="pmcid">PMC4751994</pub-id></element-citation></ref><ref id="CR448"><label>448.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unger</surname><given-names>SA</given-names></name><name name-style="western"><surname>Bogaert</surname><given-names>D</given-names></name></person-group><article-title>The respiratory microbiome and respiratory infections</article-title><source>J. Infect.</source><year>2017</year><volume>74</volume><fpage>S84</fpage><lpage>S88</lpage><pub-id pub-id-type="doi">10.1016/S0163-4453(17)30196-2</pub-id><pub-id pub-id-type="pmid">28646967</pub-id></element-citation></ref><ref id="CR449"><label>449.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Man</surname><given-names>WH</given-names></name><name name-style="western"><surname>de Steenhuijsen Piters</surname><given-names>WA</given-names></name><name name-style="western"><surname>Bogaert</surname><given-names>D</given-names></name></person-group><article-title>The microbiota of the respiratory tract: gatekeeper to respiratory health</article-title><source>Nat. Rev. Microbiol.</source><year>2017</year><volume>15</volume><fpage>259</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2017.14</pub-id><pub-id pub-id-type="pmid">28316330</pub-id><pub-id pub-id-type="pmcid">PMC7097736</pub-id></element-citation></ref><ref id="CR450"><label>450.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mi</surname><given-names>J</given-names></name><etal/></person-group><article-title>The research progress in immunotherapy of tuberculosis</article-title><source>Front. Cell Infect. Microbiol.</source><year>2021</year><volume>11</volume><fpage>763591</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2021.763591</pub-id><pub-id pub-id-type="pmid">34869066</pub-id><pub-id pub-id-type="pmcid">PMC8634162</pub-id></element-citation></ref><ref id="CR451"><label>451.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bermingham</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Practical management of suspected hypersensitivity reactions to anti-tuberculosis drugs</article-title><source>Clin. Exp. Allergy</source><year>2022</year><volume>52</volume><fpage>375</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1111/cea.14084</pub-id><pub-id pub-id-type="pmid">34939251</pub-id></element-citation></ref><ref id="CR452"><label>452.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Namasivayam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy</article-title><source>Microbiome</source><year>2017</year><volume>5</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1186/s40168-017-0286-2</pub-id><pub-id pub-id-type="pmid">28683818</pub-id><pub-id pub-id-type="pmcid">PMC5501520</pub-id></element-citation></ref><ref id="CR453"><label>453.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naidoo</surname><given-names>CC</given-names></name><etal/></person-group><article-title>The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda</article-title><source>Lancet Respir. Med.</source><year>2019</year><volume>7</volume><fpage>892</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(18)30501-0</pub-id><pub-id pub-id-type="pmid">30910543</pub-id></element-citation></ref><ref id="CR454"><label>454.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wipperman</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>10767</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-10346-6</pub-id><pub-id pub-id-type="pmid">28883399</pub-id><pub-id pub-id-type="pmcid">PMC5589918</pub-id></element-citation></ref><ref id="CR455"><label>455.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Outer membrane vesicles of a human commensal mediate immune regulation and disease protection</article-title><source>Cell Host Microbe</source><year>2012</year><volume>12</volume><fpage>509</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2012.08.004</pub-id><pub-id pub-id-type="pmid">22999859</pub-id><pub-id pub-id-type="pmcid">PMC3895402</pub-id></element-citation></ref><ref id="CR456"><label>456.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsen</surname><given-names>JM</given-names></name></person-group><article-title>The immune response to Prevotella bacteria in chronic inflammatory disease</article-title><source>Immunology</source><year>2017</year><volume>151</volume><fpage>363</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1111/imm.12760</pub-id><pub-id pub-id-type="pmid">28542929</pub-id><pub-id pub-id-type="pmcid">PMC5506432</pub-id></element-citation></ref><ref id="CR457"><label>457.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>JM</given-names></name></person-group><article-title>Immunomodulatory mechanisms of lactobacilli</article-title><source>Micro. Cell Fact.</source><year>2011</year><volume>10</volume><fpage>S17</fpage><pub-id pub-id-type="doi">10.1186/1475-2859-10-S1-S17</pub-id><pub-id pub-id-type="pmcid">PMC3231924</pub-id><pub-id pub-id-type="pmid">21995674</pub-id></element-citation></ref><ref id="CR458"><label>458.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scriba</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Differential recognition of mycobacterium tuberculosis-specific epitopes as a function of tuberculosis disease history</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2017</year><volume>196</volume><fpage>772</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1164/rccm.201706-1208OC</pub-id><pub-id pub-id-type="pmid">28759253</pub-id><pub-id pub-id-type="pmcid">PMC5620682</pub-id></element-citation></ref><ref id="CR459"><label>459.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawn</surname><given-names>TR</given-names></name><name name-style="western"><surname>Matheson</surname><given-names>AI</given-names></name><name name-style="western"><surname>Maley</surname><given-names>SN</given-names></name><name name-style="western"><surname>Vandal</surname><given-names>O</given-names></name></person-group><article-title>Host-directed therapeutics for tuberculosis: can we harness the host?</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2013</year><volume>77</volume><fpage>608</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00032-13</pub-id><pub-id pub-id-type="pmid">24296574</pub-id><pub-id pub-id-type="pmcid">PMC3973381</pub-id></element-citation></ref><ref id="CR460"><label>460.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caballero-Flores</surname><given-names>G</given-names></name><name name-style="western"><surname>Pickard</surname><given-names>JM</given-names></name><name name-style="western"><surname>Nunez</surname><given-names>G</given-names></name></person-group><article-title>Microbiota-mediated colonization resistance: mechanisms and regulation</article-title><source>Nat. Rev. Microbiol.</source><year>2023</year><volume>21</volume><fpage>347</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00833-7</pub-id><pub-id pub-id-type="pmid">36539611</pub-id><pub-id pub-id-type="pmcid">PMC10249723</pub-id></element-citation></ref><ref id="CR461"><label>461.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>X</given-names></name><etal/></person-group><article-title>The interactions between gut microbiota and bioactive ingredients of traditional Chinese medicines: a review</article-title><source>Pharm. Res.</source><year>2020</year><volume>157</volume><fpage>104824</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104824</pub-id><pub-id pub-id-type="pmid">32344049</pub-id></element-citation></ref><ref id="CR462"><label>462.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayase</surname><given-names>E</given-names></name><name name-style="western"><surname>Jenq</surname><given-names>RR</given-names></name></person-group><article-title>Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer</article-title><source>Genome Med.</source><year>2021</year><volume>13</volume><fpage>107</fpage><pub-id pub-id-type="doi">10.1186/s13073-021-00923-w</pub-id><pub-id pub-id-type="pmid">34162429</pub-id><pub-id pub-id-type="pmcid">PMC8220726</pub-id></element-citation></ref><ref id="CR463"><label>463.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Role of gut microbiota in travel-related acquisition of extended spectrum beta-lactamase-producing Enterobacteriaceae</article-title><source>J. Travel Med.</source><year>2021</year><volume>28</volume><fpage>taab022</fpage><pub-id pub-id-type="doi">10.1093/jtm/taab022</pub-id><pub-id pub-id-type="pmid">33615366</pub-id></element-citation></ref><ref id="CR464"><label>464.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Gut microbiota-derived ursodeoxycholic acid from neonatal dairy calves improves intestinal homeostasis and colitis to attenuate extended-spectrum beta-lactamase-producing enteroaggregative Escherichia coli infection</article-title><source>Microbiome</source><year>2022</year><volume>10</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.1186/s40168-022-01269-0</pub-id><pub-id pub-id-type="pmid">35643532</pub-id><pub-id pub-id-type="pmcid">PMC9142728</pub-id></element-citation></ref><ref id="CR465"><label>465.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smet</surname><given-names>A</given-names></name><etal/></person-group><article-title>Broad-spectrum beta-lactamases among Enterobacteriaceae of animal origin: molecular aspects, mobility and impact on public health</article-title><source>FEMS Microbiol. Rev.</source><year>2010</year><volume>34</volume><fpage>295</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2009.00198.x</pub-id><pub-id pub-id-type="pmid">20030731</pub-id></element-citation></ref><ref id="CR466"><label>466.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piewngam</surname><given-names>P</given-names></name><etal/></person-group><article-title>Composition of the intestinal microbiota in extended-spectrum beta-lactamase-producing Enterobacteriaceae carriers and non-carriers in Thailand</article-title><source>Int J. Antimicrob. Agents</source><year>2019</year><volume>53</volume><fpage>435</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.12.006</pub-id><pub-id pub-id-type="pmid">30578963</pub-id><pub-id pub-id-type="pmcid">PMC6700749</pub-id></element-citation></ref><ref id="CR467"><label>467.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCulloch</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>545</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01698-2</pub-id><pub-id pub-id-type="pmid">35228752</pub-id><pub-id pub-id-type="pmcid">PMC10246505</pub-id></element-citation></ref><ref id="CR468"><label>468.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munier</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Comparative dynamics of the emergence of fluoroquinolone resistance in staphylococci from the nasal microbiota of patients treated with fluoroquinolones according to their environment</article-title><source>Int J. Antimicrob. Agents</source><year>2015</year><volume>46</volume><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2015.09.004</pub-id><pub-id pub-id-type="pmid">26508586</pub-id></element-citation></ref><ref id="CR469"><label>469.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Lastours</surname><given-names>V</given-names></name><name name-style="western"><surname>Fantin</surname><given-names>B</given-names></name></person-group><article-title>Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance</article-title><source>Future Microbiol.</source><year>2015</year><volume>10</volume><fpage>1241</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.2217/fmb.15.40</pub-id><pub-id pub-id-type="pmid">26119580</pub-id></element-citation></ref><ref id="CR470"><label>470.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klunemann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Bioaccumulation of therapeutic drugs by human gut bacteria</article-title><source>Nature</source><year>2021</year><volume>597</volume><fpage>533</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03891-8</pub-id><pub-id pub-id-type="pmid">34497420</pub-id><pub-id pub-id-type="pmcid">PMC7614428</pub-id></element-citation></ref><ref id="CR471"><label>471.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abt</surname><given-names>MC</given-names></name><name name-style="western"><surname>McKenney</surname><given-names>PT</given-names></name><name name-style="western"><surname>Pamer</surname><given-names>EG</given-names></name></person-group><article-title>Clostridium difficile colitis: pathogenesis and host defence</article-title><source>Nat. Rev. Microbiol.</source><year>2016</year><volume>14</volume><fpage>609</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.108</pub-id><pub-id pub-id-type="pmid">27573580</pub-id><pub-id pub-id-type="pmcid">PMC5109054</pub-id></element-citation></ref><ref id="CR472"><label>472.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Grady</surname><given-names>K</given-names></name><name name-style="western"><surname>Knight</surname><given-names>DR</given-names></name><name name-style="western"><surname>Riley</surname><given-names>TV</given-names></name></person-group><article-title>Antimicrobial resistance in Clostridioides difficile</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2021</year><volume>40</volume><fpage>2459</fpage><lpage>2478</lpage><pub-id pub-id-type="doi">10.1007/s10096-021-04311-5</pub-id><pub-id pub-id-type="pmid">34427801</pub-id></element-citation></ref><ref id="CR473"><label>473.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gil</surname><given-names>F</given-names></name><name name-style="western"><surname>Paredes-Sabja</surname><given-names>D</given-names></name></person-group><article-title>Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections</article-title><source>Future Microbiol.</source><year>2016</year><volume>11</volume><fpage>1179</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.2217/fmb-2016-0064</pub-id><pub-id pub-id-type="pmid">27546386</pub-id></element-citation></ref><ref id="CR474"><label>474.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L</given-names></name></person-group><article-title>Gut microbiota-mediated immunomodulation in tumor</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2021</year><volume>40</volume><fpage>221</fpage><pub-id pub-id-type="doi">10.1186/s13046-021-01983-x</pub-id><pub-id pub-id-type="pmid">34217349</pub-id><pub-id pub-id-type="pmcid">PMC8254267</pub-id></element-citation></ref><ref id="CR475"><label>475.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simpson</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>2344</fpage><lpage>2352</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01965-2</pub-id><pub-id pub-id-type="pmid">36138151</pub-id></element-citation></ref><ref id="CR476"><label>476.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>WY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CY</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>The role of gut microbiota in cancer treatment: friend or foe?</article-title><source>Gut</source><year>2020</year><volume>69</volume><fpage>1867</fpage><lpage>1876</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-321153</pub-id><pub-id pub-id-type="pmid">32759302</pub-id><pub-id pub-id-type="pmcid">PMC7497589</pub-id></element-citation></ref><ref id="CR477"><label>477.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Guo</surname><given-names>G</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Gut microbiome in modulating immune checkpoint inhibitors</article-title><source>EBioMedicine</source><year>2022</year><volume>82</volume><fpage>104163</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104163</pub-id><pub-id pub-id-type="pmid">35841869</pub-id><pub-id pub-id-type="pmcid">PMC9297075</pub-id></element-citation></ref><ref id="CR478"><label>478.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies</article-title><source>J. Hematol. Oncol.</source><year>2022</year><volume>15</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/s13045-022-01273-9</pub-id><pub-id pub-id-type="pmid">35488243</pub-id><pub-id pub-id-type="pmcid">PMC9052532</pub-id></element-citation></ref><ref id="CR479"><label>479.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paone</surname><given-names>P</given-names></name><name name-style="western"><surname>Cani</surname><given-names>PD</given-names></name></person-group><article-title>Mucus barrier, mucins and gut microbiota: the expected slimy partners?</article-title><source>Gut</source><year>2020</year><volume>69</volume><fpage>2232</fpage><lpage>2243</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-322260</pub-id><pub-id pub-id-type="pmid">32917747</pub-id><pub-id pub-id-type="pmcid">PMC7677487</pub-id></element-citation></ref><ref id="CR480"><label>480.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takiishi</surname><given-names>T</given-names></name><name name-style="western"><surname>Fenero</surname><given-names>CIM</given-names></name><name name-style="western"><surname>Camara</surname><given-names>NOS</given-names></name></person-group><article-title>Intestinal barrier and gut microbiota: shaping our immune responses throughout life</article-title><source>Tissue Barriers</source><year>2017</year><volume>5</volume><fpage>e1373208</fpage><pub-id pub-id-type="doi">10.1080/21688370.2017.1373208</pub-id><pub-id pub-id-type="pmid">28956703</pub-id><pub-id pub-id-type="pmcid">PMC5788425</pub-id></element-citation></ref><ref id="CR481"><label>481.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ianiro</surname><given-names>G</given-names></name><name name-style="western"><surname>Tilg</surname><given-names>H</given-names></name><name name-style="western"><surname>Gasbarrini</surname><given-names>A</given-names></name></person-group><article-title>Antibiotics as deep modulators of gut microbiota: between good and evil</article-title><source>Gut</source><year>2016</year><volume>65</volume><fpage>1906</fpage><lpage>1915</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2016-312297</pub-id><pub-id pub-id-type="pmid">27531828</pub-id></element-citation></ref><ref id="CR482"><label>482.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becattini</surname><given-names>S</given-names></name><name name-style="western"><surname>Taur</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pamer</surname><given-names>EG</given-names></name></person-group><article-title>Antibiotic-induced changes in the intestinal microbiota and disease</article-title><source>Trends Mol. Med.</source><year>2016</year><volume>22</volume><fpage>458</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2016.04.003</pub-id><pub-id pub-id-type="pmid">27178527</pub-id><pub-id pub-id-type="pmcid">PMC4885777</pub-id></element-citation></ref><ref id="CR483"><label>483.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akbarali</surname><given-names>HI</given-names></name><name name-style="western"><surname>Dewey</surname><given-names>WL</given-names></name></person-group><article-title>Gastrointestinal motility, dysbiosis and opioid-induced tolerance: is there a link?</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2019</year><volume>16</volume><fpage>323</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1038/s41575-019-0150-x</pub-id><pub-id pub-id-type="pmid">31024090</pub-id><pub-id pub-id-type="pmcid">PMC7045338</pub-id></element-citation></ref><ref id="CR484"><label>484.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurz</surname><given-names>A</given-names></name><name name-style="western"><surname>Sessler</surname><given-names>DI</given-names></name></person-group><article-title>Opioid-induced bowel dysfunction: pathophysiology and potential new therapies</article-title><source>Drugs</source><year>2003</year><volume>63</volume><fpage>649</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.2165/00003495-200363070-00003</pub-id><pub-id pub-id-type="pmid">12656645</pub-id></element-citation></ref><ref id="CR485"><label>485.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mora</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection</article-title><source>Am. J. Med. Sci.</source><year>2012</year><volume>343</volume><fpage>277</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1097/MAJ.0b013e31822f42eb</pub-id><pub-id pub-id-type="pmid">21934595</pub-id></element-citation></ref><ref id="CR486"><label>486.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>YP</given-names></name><etal/></person-group><article-title>Gut microbiota interactions with antitumor immunity in colorectal cancer: from understanding to application</article-title><source>Biomed. Pharmacother.</source><year>2023</year><volume>165</volume><fpage>115040</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2023.115040</pub-id><pub-id pub-id-type="pmid">37364479</pub-id></element-citation></ref><ref id="CR487"><label>487.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pezo</surname><given-names>RC</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M</given-names></name><name name-style="western"><surname>Martin</surname><given-names>A</given-names></name></person-group><article-title>Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities</article-title><source>Ther. Adv. Gastroenterol.</source><year>2019</year><volume>12</volume><fpage>1756284819870911</fpage><pub-id pub-id-type="doi">10.1177/1756284819870911</pub-id><pub-id pub-id-type="pmcid">PMC6747860</pub-id><pub-id pub-id-type="pmid">31555343</pub-id></element-citation></ref><ref id="CR488"><label>488.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Aspirin ameliorates atherosclerotic immuno-inflammation through regulating the Treg/Th17 axis and CD39-CD73 adenosine signaling via remodeling the gut microbiota in ApoE(-/-) mice</article-title><source>Int. Immunopharmacol.</source><year>2023</year><volume>120</volume><fpage>110296</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2023.110296</pub-id><pub-id pub-id-type="pmid">37187127</pub-id></element-citation></ref><ref id="CR489"><label>489.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolodziejczyk</surname><given-names>AA</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>D</given-names></name><name name-style="western"><surname>Elinav</surname><given-names>E</given-names></name></person-group><article-title>Diet-microbiota interactions and personalized nutrition</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>742</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0256-8</pub-id><pub-id pub-id-type="pmid">31541197</pub-id></element-citation></ref><ref id="CR490"><label>490.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zmora</surname><given-names>N</given-names></name><name name-style="western"><surname>Suez</surname><given-names>J</given-names></name><name name-style="western"><surname>Elinav</surname><given-names>E</given-names></name></person-group><article-title>You are what you eat: diet, health and the gut microbiota</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2019</year><volume>16</volume><fpage>35</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/s41575-018-0061-2</pub-id><pub-id pub-id-type="pmid">30262901</pub-id></element-citation></ref><ref id="CR491"><label>491.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>ME</given-names></name><name name-style="western"><surname>Merenstein</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Reid</surname><given-names>G</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>GR</given-names></name><name name-style="western"><surname>Rastall</surname><given-names>RA</given-names></name></person-group><article-title>Probiotics and prebiotics in intestinal health and disease: from biology to the clinic</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2019</year><volume>16</volume><fpage>605</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1038/s41575-019-0173-3</pub-id><pub-id pub-id-type="pmid">31296969</pub-id></element-citation></ref><ref id="CR492"><label>492.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>H</given-names></name><etal/></person-group><article-title>Artificial intelligence approaches to human-microbiome protein-protein interactions</article-title><source>Curr. Opin. Struct. Biol.</source><year>2022</year><volume>73</volume><fpage>102328</fpage><pub-id pub-id-type="doi">10.1016/j.sbi.2022.102328</pub-id><pub-id pub-id-type="pmid">35152186</pub-id></element-citation></ref><ref id="CR493"><label>493.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cammarota</surname><given-names>G</given-names></name><etal/></person-group><article-title>Gut microbiome, big data and machine learning to promote precision medicine for cancer</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2020</year><volume>17</volume><fpage>635</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1038/s41575-020-0327-3</pub-id><pub-id pub-id-type="pmid">32647386</pub-id></element-citation></ref><ref id="CR494"><label>494.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vitetta</surname><given-names>L</given-names></name><name name-style="western"><surname>Coulson</surname><given-names>S</given-names></name><name name-style="western"><surname>Linnane</surname><given-names>AW</given-names></name><name name-style="western"><surname>Butt</surname><given-names>H</given-names></name></person-group><article-title>The gastrointestinal microbiome and musculoskeletal diseases: a beneficial role for probiotics and prebiotics</article-title><source>Pathogens</source><year>2013</year><volume>2</volume><fpage>606</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.3390/pathogens2040606</pub-id><pub-id pub-id-type="pmid">25437335</pub-id><pub-id pub-id-type="pmcid">PMC4235701</pub-id></element-citation></ref><ref id="CR495"><label>495.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bermudez-Brito</surname><given-names>M</given-names></name><name name-style="western"><surname>Plaza-Diaz</surname><given-names>J</given-names></name><name name-style="western"><surname>Munoz-Quezada</surname><given-names>S</given-names></name><name name-style="western"><surname>Gomez-Llorente</surname><given-names>C</given-names></name><name name-style="western"><surname>Gil</surname><given-names>A</given-names></name></person-group><article-title>Probiotic mechanisms of action</article-title><source>Ann. Nutr. Metab.</source><year>2012</year><volume>61</volume><fpage>160</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1159/000342079</pub-id><pub-id pub-id-type="pmid">23037511</pub-id></element-citation></ref><ref id="CR496"><label>496.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Allen-Vercoe</surname><given-names>E</given-names></name><name name-style="western"><surname>Petrof</surname><given-names>EO</given-names></name></person-group><article-title>Fecal microbiota transplantation: in perspective</article-title><source>Ther. Adv. Gastroenterol.</source><year>2016</year><volume>9</volume><fpage>229</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1177/1756283X15607414</pub-id><pub-id pub-id-type="pmcid">PMC4749851</pub-id><pub-id pub-id-type="pmid">26929784</pub-id></element-citation></ref><ref id="CR497"><label>497.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ser</surname><given-names>HL</given-names></name><name name-style="western"><surname>Letchumanan</surname><given-names>V</given-names></name><name name-style="western"><surname>Goh</surname><given-names>BH</given-names></name><name name-style="western"><surname>Wong</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>LH</given-names></name></person-group><article-title>The use of fecal microbiome transplant in treating human diseases: too early for poop?</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><fpage>519836</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2021.519836</pub-id><pub-id pub-id-type="pmid">34054740</pub-id><pub-id pub-id-type="pmcid">PMC8155486</pub-id></element-citation></ref><ref id="CR498"><label>498.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khoruts</surname><given-names>A</given-names></name></person-group><article-title>Fecal microbiota transplantation-early steps on a long journey ahead</article-title><source>Gut Microbes</source><year>2017</year><volume>8</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1080/19490976.2017.1316447</pub-id><pub-id pub-id-type="pmid">28394706</pub-id><pub-id pub-id-type="pmcid">PMC5479406</pub-id></element-citation></ref><ref id="CR499"><label>499.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Nood</surname><given-names>E</given-names></name><name name-style="western"><surname>Speelman</surname><given-names>P</given-names></name><name name-style="western"><surname>Nieuwdorp</surname><given-names>M</given-names></name><name name-style="western"><surname>Keller</surname><given-names>J</given-names></name></person-group><article-title>Fecal microbiota transplantation: facts and controversies</article-title><source>Curr. Opin. Gastroenterol.</source><year>2014</year><volume>30</volume><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1097/MOG.0000000000000024</pub-id><pub-id pub-id-type="pmid">24241245</pub-id></element-citation></ref><ref id="CR500"><label>500.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borody</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>J</given-names></name></person-group><article-title>Fecal microbiota transplantation: techniques, applications, and issues</article-title><source>Gastroenterol. Clin. North Am.</source><year>2012</year><volume>41</volume><fpage>781</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1016/j.gtc.2012.08.008</pub-id><pub-id pub-id-type="pmid">23101687</pub-id></element-citation></ref><ref id="CR501"><label>501.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells</article-title><source>Eur. J. Pharm.</source><year>2018</year><volume>831</volume><fpage>52</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2018.05.003</pub-id><pub-id pub-id-type="pmid">29750914</pub-id></element-citation></ref><ref id="CR502"><label>502.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>DM</given-names></name><name name-style="western"><surname>Koskella</surname><given-names>B</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HC</given-names></name></person-group><article-title>Phage therapy: an alternative to antibiotics in the age of multi-drug resistance</article-title><source>World J. Gastrointest. Pharm. Ther.</source><year>2017</year><volume>8</volume><fpage>162</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.4292/wjgpt.v8.i3.162</pub-id><pub-id pub-id-type="pmcid">PMC5547374</pub-id><pub-id pub-id-type="pmid">28828194</pub-id></element-citation></ref><ref id="CR503"><label>503.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourdin</surname><given-names>G</given-names></name><etal/></person-group><article-title>Coverage of diarrhoea-associated Escherichia coli isolates from different origins with two types of phage cocktails</article-title><source>Micro. Biotechnol.</source><year>2014</year><volume>7</volume><fpage>165</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1111/1751-7915.12113</pub-id><pub-id pub-id-type="pmcid">PMC3937720</pub-id><pub-id pub-id-type="pmid">24528873</pub-id></element-citation></ref><ref id="CR504"><label>504.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ackermann</surname><given-names>HW</given-names></name></person-group><article-title>The first phage electron micrographs</article-title><source>Bacteriophage</source><year>2011</year><volume>1</volume><fpage>225</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.4161/bact.1.4.17280</pub-id><pub-id pub-id-type="pmid">23050215</pub-id><pub-id pub-id-type="pmcid">PMC3448108</pub-id></element-citation></ref><ref id="CR505"><label>505.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rakhuba</surname><given-names>DV</given-names></name><name name-style="western"><surname>Kolomiets</surname><given-names>EI</given-names></name><name name-style="western"><surname>Dey</surname><given-names>ES</given-names></name><name name-style="western"><surname>Novik</surname><given-names>GI</given-names></name></person-group><article-title>Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell</article-title><source>Pol. J. Microbiol.</source><year>2010</year><volume>59</volume><fpage>145</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.33073/pjm-2010-023</pub-id><pub-id pub-id-type="pmid">21033576</pub-id></element-citation></ref><ref id="CR506"><label>506.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motlagh</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bhattacharjee</surname><given-names>AS</given-names></name><name name-style="western"><surname>Goel</surname><given-names>R</given-names></name></person-group><article-title>Biofilm control with natural and genetically-modified phages</article-title><source>World J. Microbiol Biotechnol.</source><year>2016</year><volume>32</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1007/s11274-016-2009-4</pub-id><pub-id pub-id-type="pmid">26931607</pub-id></element-citation></ref><ref id="CR507"><label>507.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramachandran</surname><given-names>G</given-names></name><name name-style="western"><surname>Bikard</surname><given-names>D</given-names></name></person-group><article-title>Editing the microbiome the CRISPR way</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2019</year><volume>374</volume><fpage>20180103</fpage><pub-id pub-id-type="doi">10.1098/rstb.2018.0103</pub-id><pub-id pub-id-type="pmid">30905295</pub-id><pub-id pub-id-type="pmcid">PMC6452265</pub-id></element-citation></ref><ref id="CR508"><label>508.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reyes</surname><given-names>A</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><name name-style="western"><surname>McNulty</surname><given-names>NP</given-names></name><name name-style="western"><surname>Rohwer</surname><given-names>FL</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>Gnotobiotic mouse model of phage-bacterial host dynamics in the human gut</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>20236</fpage><lpage>20241</lpage><pub-id pub-id-type="doi">10.1073/pnas.1319470110</pub-id><pub-id pub-id-type="pmid">24259713</pub-id><pub-id pub-id-type="pmcid">PMC3864308</pub-id></element-citation></ref><ref id="CR509"><label>509.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lusiak-Szelachowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Weber-Dabrowska</surname><given-names>B</given-names></name><name name-style="western"><surname>Jonczyk-Matysiak</surname><given-names>E</given-names></name><name name-style="western"><surname>Wojciechowska</surname><given-names>R</given-names></name><name name-style="western"><surname>Gorski</surname><given-names>A</given-names></name></person-group><article-title>Bacteriophages in the gastrointestinal tract and their implications</article-title><source>Gut Pathog.</source><year>2017</year><volume>9</volume><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/s13099-017-0196-7</pub-id><pub-id pub-id-type="pmid">28811841</pub-id><pub-id pub-id-type="pmcid">PMC5553654</pub-id></element-citation></ref><ref id="CR510"><label>510.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Divya Ganeshan</surname><given-names>S</given-names></name><name name-style="western"><surname>Hosseinidoust</surname><given-names>Z</given-names></name></person-group><article-title>Phage therapy with a focus on the human microbiota</article-title><source>Antibiotics (Basel)</source><year>2019</year><volume>8</volume><fpage>131</fpage><pub-id pub-id-type="doi">10.3390/antibiotics8030131</pub-id><pub-id pub-id-type="pmid">31461990</pub-id><pub-id pub-id-type="pmcid">PMC6783874</pub-id></element-citation></ref><ref id="CR511"><label>511.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma</article-title><source>Gut</source><year>2019</year><volume>68</volume><fpage>1014</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2017-315084</pub-id><pub-id pub-id-type="pmid">30045880</pub-id><pub-id pub-id-type="pmcid">PMC6580753</pub-id></element-citation></ref><ref id="CR512"><label>512.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis</article-title><source>Gut</source><year>2019</year><volume>68</volume><fpage>1624</fpage><lpage>1632</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2019-318556</pub-id><pub-id pub-id-type="pmid">31092590</pub-id><pub-id pub-id-type="pmcid">PMC6709773</pub-id></element-citation></ref><ref id="CR513"><label>513.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Human microbiome is a diagnostic biomarker in hepatocellular carcinoma</article-title><source>Hepatobiliary Pancreat. Dis. Int.</source><year>2020</year><volume>19</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.hbpd.2020.01.003</pub-id><pub-id pub-id-type="pmid">32037278</pub-id></element-citation></ref><ref id="CR514"><label>514.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuntz</surname><given-names>TM</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>JA</given-names></name></person-group><article-title>Introducing the microbiome into precision medicine</article-title><source>Trends Pharm. Sci.</source><year>2017</year><volume>38</volume><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2016.10.001</pub-id><pub-id pub-id-type="pmid">27814885</pub-id></element-citation></ref><ref id="CR515"><label>515.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizkallah</surname><given-names>MR</given-names></name><name name-style="western"><surname>Saad</surname><given-names>R</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>RK</given-names></name></person-group><article-title>The Human Microbiome Project, personalized medicine and the birth of phar macomicrobiomics</article-title><source>Curr. Pharm. Pers. Med.</source><year>2010</year><volume>8</volume><fpage>182</fpage><lpage>193</lpage></element-citation></ref></ref-list></back></article></pmc-articleset>